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ABSTRACT 
 
Background 
Oxidative stress has been implicated in the etiology of skeletal muscle insulin 
resistance in type 2 diabetes (T2D).  Therapies that target skeletal muscle oxidative 
stress might therefore promote improvements in insulin action at this pivotal site of 
dysfunction in people with T2D. High dose antioxidant vitamin C supplementation has 
been shown in some previous studies to improve whole body glucose disposal and 
glucose control in people with T2D.  However, mechanisms of action through which 
vitamin C improves insulin action have not been well elucidated in vivo.  Furthermore, 
there is a paucity of data reporting on the bioavailability of high dose oral vitamin C 
in human skeletal muscle. Thus, there is a need to investigate the effects of high dose 
oral vitamin C supplementation on its transport into, and augmentation of levels in, 
skeletal muscle, as a basis to its potential antioxidant actions in skeletal muscle.  
The aims of this thesis were therefore to firstly investigate the effects of chronic high 
dose vitamin C supplementation on skeletal muscle levels of vitamin C, protein 
expression of the vitamin C transporter sodium-dependent vitamin C transporter-2 
(SVCT2), and oxidative stress in people with T2D. A further key aim was to generate 
data on the clinical efficacy of vitamin C supplementation as a means of improving 
skeletal muscle insulin sensitivity in people with T2D.  It was hypothesized that in 
people with T2D long-term supplementation with high dose vitamin C 
supplementation would (a) increase skeletal muscle vitamin C concentration; (b) 
reduce SVCT2 protein abundance; (c) decrease markers of skeletal muscle oxidative 
stress; and (d) improve insulin-stimulated skeletal muscle glucose uptake.   
Abstract 
XXII 
 
 
Methods 
Study in people with T2D: Males (n=12) and females (n=1) with T2D (aged 57.9 ± 2.5 
y [mean ± SEM] with BMI: 30.5 ± 0.8 kg/m2) commenced a randomized, placebo-
controlled cross-over clinical trial involving four months of twice daily 
supplementation with vitamin C (VC; 2 x 500 mg ascorbic acid/day) or placebo (PLA). 
Participants demonstrated stable metabolic control (HbA1c: 7.6 ± 0.2 %) prior to the 
trial and were on oral anti-hyperglycaemic medications including Metformin, 
Sulfonureas and/or DPP-4 inhibitors. Insulin sensitivity was assessed using a 
hyperinsulinaemic, euglycaemic clamp coupled with infusion of a stable glucose 
tracer (6, 6-D2 glucose). Participants underwent muscle and blood sampling at pre- 
and post- supplementation timepoints. 
Study in healthy individuals: Healthy males (n=8, aged 25.9 ± 2.3 y) completed a 
randomized placebo-controlled, cross-over trial involving supplementation with 
ascorbic acid (2 x 500 mg/day) or placebo over 42 days. Participants underwent 
muscle and blood sampling on days 0, 1, 7 and 42 during each treatment. 
Skeletal muscle biopsies were measured for concentrations of vitamin C, SVCT2 
protein expression and oxidative stress/redox markers that included 2', 7'-
dichlorofluorescin (DCFH) oxidation and superoxide dismutase (SOD) activity. In the 
study in people with T2D, additional oxidative stress markers that included the ratio 
of reduced glutathione to oxidized glutathione disulphide (GSH/GSSG) and F2-
Isoprostanes; as well as nitric oxide synthase (NOS) and dehydroascorbic acid (DHA) 
were also investigated in skeletal muscle samples.  
 
Abstract 
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Results 
Study in people with T2D: Seven participants (6 males, 1 female, aged 59.4 ± 3.5 y) 
completed the trial in full compliance. VC supplementation significantly increased 
skeletal muscle total and reduced ascorbic acid content (VC: 22.3 ± 1.4 to 29.9 ± 1.9 
μg/g vs. PLA: 23.1 ± 1.3 to 24.2 ± 1.1 μg/g, p=0.017 and VC: 6.5 ± 0.9 to 10.7 ± 1.4 
μg/g vs. PLA: 6.0 ± 0.7 to 6.3 ± 1.1 μg/g, p=0.017, respectively).  Insulin-stimulated 
rate of glucose disappearance (Δ Rd) also improved significantly following VC (VC: 3.5 
± 4.1 to 14.0 ± 3.8 μmol/kg FFM/min vs. PLA: 5.7 ± 3.1 to 8.9 ± 3.2 μmol/kg FFM/min, 
p=0.009).  Furthermore, VC supplementation reduced insulin-stimulated muscle 
DCFH oxidation (VC: 31.7 % decrease [mean per cent change from baseline] vs. PLA: 
16.2 % increase, p=0.012). Neither basal measures of oxidative stress nor DHA 
concentration in skeletal muscle were significantly altered by supplementation. 
Contrary to the original hypothesis, VC supplementation increased protein 
abundance of SVCT2 (VC: 120.4 % increase vs. PLA: 11.0 % increase, p=0.008) in 
skeletal muscle. VC also increased protein abundance of eNOS (VC: 71.3 % increase 
vs. PLA: 12.6 % decrease, p=0.022), but decreased total SOD activity relative to 
placebo (VC: 10.1 % decrease vs. PLA: 11.6 % increase, p=0.006) in skeletal muscle. 
VC had no significant effect on total NOS activity, HbA1c or endogenous glucose 
production.  
Study in healthy individuals: VC supplementation significantly increased skeletal 
muscle VC concentration after 7 days, which was maintained at 42 days (VC: 30.2 ± 
2.4 to 38.8 ± 3.6 μg/g versus PLA: 30.9 ± 2.7 to 29.3 ± 1.8 μg/g, p=0.001). VC 
supplementation significantly increased skeletal muscle SVCT2 protein expression 
(main treatment effect p=0.006); although it did not alter levels of oxidative stress or 
redox markers in skeletal muscle. 
Abstract 
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Conclusion 
In summary, chronic high dose VC supplementation significantly increased skeletal 
muscle vitamin C concentration and SVCT2 protein expression in both healthy 
individuals and people with T2D. Furthermore, chronic high dose vitamin C 
supplementation improved levels of insulin-stimulated glucose disposal and oxidative 
stress in skeletal muscle of people with T2D. A higher vitamin C concentration and 
lower levels of reactive species in skeletal muscle after supplementation implicate 
enhanced antioxidant scavenging by vitamin C in the improved skeletal muscle insulin 
sensitivity. Results of this thesis provide novel insights into effects of vitamin C 
supplementation in healthy and diabetic skeletal muscle in vivo. Moreover, findings 
of this thesis provide evidence for the clinical efficacy and safety of regular, high dose 
vitamin C supplementation as a potential adjunct therapy to improve skeletal muscle 
insulin resistance in people with T2D.  
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1.0. LITERATURE REVIEW 
 
1.1. Type 2 diabetes 
1.1.1. Epidemiology and background 
  
The prevalence of diabetes has reached epidemic proportions worldwide (1), with 
estimates of global prevalence in adults predicted to increase from 382 million people 
in 2013 to 592 million people in 2035 (1). Of those individuals affected with diabetes, 
approximately 90-95 % have Type 2 diabetes (T2D) (2). T2D is associated with obesity 
(3) and is a major risk factor for coronary heart disease and stroke (4). People with 
T2D are also at an increased risk of blindness, kidney failure and limb amputation due 
to microvascular complications including retinopathy, nephropathy and 
neuropathies (4). The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) 
reported that 7.4 % percent of Australian adults had known or newly diagnosed 
diabetes. Moreover, an additional 16.4 % of study participants were found to have 
impaired glucose metabolism as characterized by impaired fasting glucose or 
impaired glucose tolerance (5).  
T2D and impaired glucose metabolism are diagnosed based on abnormally elevated 
blood glucose levels (Figure 1.1). A frank diagnosis of diabetes is made when a 
random plasma glucose level of ≥11.1 mmol/l or a fasting glucose level of ≥7 mmol/l 
accompanies obvious symptoms such as thirst or polyuria (6). Diagnosis of diabetes 
can also be confirmed via an oral 2h glucose tolerance test (OGTT) procedure (6). 
Hyperglycaemia in T2D is a result of insulin resistance in normally insulin-sensitive 
peripheral tissues (e.g. skeletal muscle, adipose tissue) combined with insufficient 
insulin secretion from pancreatic β-cells (6) and an impaired capacity of glucose to 
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regulate its own uptake and production (7). Additionally, insulin resistance in the liver 
can promote an abnormal production of glucose, further contributing to 
hyperglycaemia postprandially (8) and postabsorptively in poorly controlled type 2 
diabetes (9).  
 
 
Figure 1.1. Diagnosis of diabetes and impaired glucose metabolism 
Diabetes is diagnosed when obvious symptoms exist in addition to a fasting plasma 
glucose (FPG) of ≥7 mmol/l or a random plasma glucose (RPG) of ≥11.1 mmol/l.  If 
initial screening indicates a FPG between 5.5-6.9 mmol/l, an oral glucose tolerance 
test (OGTT) should be followed up to test for diabetes (glucose ≥11.1 mmol/l).  If the 
diagnosis is impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), testing 
for diabetes using OGTT should be repeated annually (from (6)). 
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Insulin resistance in tissues could be evident several decades before the clinical 
manifestation of T2D (10). During the pre-diabetic stage, insulin-secreting pancreatic 
β-cells can compensate for the insulin resistance by increasing the production and 
secretion of insulin, thus enabling maintenance of glucose homeostasis (11). 
However, persistent hyperinsulinaemia eventually leads to β-cell failure, impaired 
insulin secretion, and clinical diabetes (11).  
Causes of T2D are not completely understood (3). T2D is widely believed to be a multi-
factorial disease with genetic and environmental determinants (3). Concordance in 
monozygotic twins has been reported to be between 69-90 % in cross-sectional and 
prospective studies (12). Although genetic predisposition plays an important role in 
the etiology and manifestation of T2D, environmental factors might be required for 
the disease to become overt in genetically susceptible individuals (13). Large 
observational studies, metabolic studies and clinical trials strongly implicate poor 
diet, obesity and physical inactivity as contributing factors in the growing diabetes 
epidemic (2). 
 
1.1.2. Treatment approaches for glucose control in T2D 
 
Improving blood glucose control is the cornerstone of treatment in T2D in order to 
prevent the development and progression of complications and to improve quality of 
life (14). National evidence guidelines for treatment typically indicate a progression 
from lifestyle modifications (i.e. weight loss, exercise & diet control) to increasing 
pharmacological options based on individual circumstances (14) (Figure 1.2).  
Although weight loss and exercise regimens are modestly effective for weight loss 
and glucose control in T2D (15), they are limited by long-term adherence to programs 
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by patients (16).  Commonly Metformin (an insulin sensitizer) and/or a sulfonylurea 
(an insulin secretagogue) are indicated as initial pharmacological treatments in T2D 
(14); however other individualized strategies incorporating other drugs with different 
mechanisms of action are often adopted.  
 
 
Figure 1.2. An algorithm of treatment for improved glucose control in T2D 
Treatment of impaired glucose control in T2D often progresses from lifestyle 
modifications to Metformin treatment to more advanced individualized 
pharmacological approaches  (from (14)). 
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The use of pharmacological treatments in T2D has been associated with undesirable 
side effects including oedema and weight gain from use of thiazolodinediones, insulin 
and sulfonylureas (17, 18), hypoglycaemia from use of insulin and sulfonylureas (17); 
and gastrointestinal discomfort from use of GLP-1 agonists and acarbose (19, 20). 
Moreover use of some thiazolodinediones has been linked to an increased risk of 
cardiovascular disease, morbidity, heart failure and bone fractures in people with T2D 
(21-23). Considering the aforementioned side effects of current diabetes treatments, 
the pursuit of effective new treatment therapies with minimal side effects and a solid 
scientific basis is warranted. 
 
1.1.3. Summary and significance #1 
  
T2D is a major chronic disease with an incidence growing substantially in Australia 
and worldwide. Underlying its disease incidence is a strong genetic susceptibility 
coupled with modern environmental drivers of poor diet and physical inactivity. 
Treatments aimed at improving glucose control in people with T2D typically 
progress from lifestyle modifications to individualized pharmacological strategies.  
However traditional approaches involving lifestyle modifications and 
pharmacological treatments are limited by poor compliance and widespread side 
effects, respectively. This highlights the need for new effective therapies possessing 
sound scientific bases and safety profiles for use in the treatment of T2D. 
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1.2. Insulin resistance  
1.2.1. The importance of skeletal muscle 
 
Insulin resistance can be defined clinically as “the inability of a known quantity of 
exogenous or endogenous insulin to increase glucose uptake and utilization in an 
individual as much as it does in a normal population” (24). Skeletal muscle is 
quantitatively the most important tissue in peripheral insulin resistance, accounting 
for approximately 75-85 % of whole-body insulin-stimulated glucose disposal during 
a hyperinsulinaemic, euglycaemic clamp (25-27). In T2D, impairments in skeletal 
muscle glucose disposal account for approximately 80 % of the defective insulin 
mediated whole-body glucose disposal in vivo (28) (Figure 1.3).  
 
 
Figure 1.3. Defect of skeletal muscle glucose uptake in T2D 
Estimated contribution of skeletal muscle (shaded area of column) to whole body 
glucose disposal in controls (left) versus people with T2D (right) after physiological 
hyperinsulinaemia (From (28))  
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1.2.2. Insulin signaling in skeletal muscle glucose metabolism 
 
Following the consumption of a carbohydrate-containing meal or exogenous glucose 
infusion, an increased blood glucose level signals the pancreas to increase insulin 
production, thus facilitating an increased delivery of insulin to peripheral tissues. In 
skeletal muscle cells, insulin binds to its receptor on the cell membrane, subsequently 
stimulating pathways of glucose transport, glucose oxidation and glycogen synthesis 
(Figure 1.4).  
The binding of insulin to its receptor leads to a cascade of intracellular 
phosphorylation reactions on key tyrosine residues of signalling components. The 
phosphorylated insulin receptor recruits and phosphorylates insulin receptor 
substrate-1 (IRS-1), which in turn interacts with and activates the signalling molecule 
phosphatidylinositol -3- kinase (PI3-K) (29, 30). PI3-K catalyses the formation of 
phosphatidylinositol 3, 4, 5-triphosphate (PIP3) in the cell membrane, which acts as 
an allosteric regulator of phosphoinositide-dependent kinase 1 (PDK1) (31).  PDK1 is 
required for the phosphorylation and activation of Akt, a phosphoinositide-
dependent serine/threonine kinase pivotal in several of insulin’s actions (31). 
Specifically, Akt is activated by phosphorylation at Thr308 by PDK1 and at Ser473 (31) 
by mTOR (Mammalian target of Rapmycin) complexed with RICTOR (32). Akt 
phosphorylates and inhibits glycogen synthase kinase 3 (GSK3) which results in 
activation of glycogen synthase (GS) and glycogen synthesis (33). GS can also be 
activated allosterically by glucose-6-phosphate (G-6-P) as a result of a “feed-forward” 
response to increased glucose transport (34). More recently, it has been proposed 
that a PI3K-dependent muscle-specific protein phosphatase (PP1G.GM) can directly 
dephosphorylate and activate GS in response to insulin (33, 35, 36) (Figure 1.4).  
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Insulin-mediated translocation of glucose transporter GLUT4 to the plasma 
membrane facilitates increased glucose transport into muscle, although pathways 
underlying this mechanism are complex and relatively poorly understood (37). Akt-
dependent glucose uptake might be linked to the phosphorylation of the 160 kDa 
protein, AS160 (38). AS160 has several candidate Akt phosphorylation sites and a GAP 
domain selective for small GTP-binding Rab proteins which, when active, are required 
for GLUT4 translocation to occur (38). It has been proposed that under insulin-
stimulated conditions, phosphorylation of AS160 renders the GAP domain inactive 
and relieves the inhibitory basal effect of AS160 on Rab proteins, consequently 
resulting in trafficking of GLUT4 to the cell membrane and glucose transport into 
muscle (37, 38). In addition, activation of PIP3 downstream effector atypical protein 
kinase C (aPKC) is also believed to be important in insulin-mediated glucose transport; 
although mechanisms of its involvement are unclear (39).  
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Figure 1.4. Skeletal muscle insulin-stimulated glucose transport and glycogen 
synthesis 
The phosphorylated insulin receptor (IR) recruits and phosphorylates IRS-1, which in 
turn interacts with and activates the signalling molecule PI3-K. PI3-K catalyses the 
formation of PIP3 in the cell membrane, regulating the activity of PDK1.  PDK1 is 
required in the phosphorylation and activation of Akt, which promotes inhibition of 
GSK3, activation of GS, and glycogen synthesis. GS can also be activated allosterically 
by G-6-P and possibly via a muscle-specific PI3-K dependent phosphatase. Insulin-
mediated glucose transport via GLUT4 might be linked to phosphorylation of AS160 
and activation of aPKC. Thicker arrows represent better defined pathways than 
thinner lines (adapted in part from (40)). 
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1.2.3. Impairments in skeletal muscle insulin signalling in T2D 
 
Impaired skeletal muscle insulin-mediated glucose transport and glycogen synthesis 
are hallmark defects in T2D (33). Studies involving nuclear magnetic resonance have 
demonstrated that impaired glycogen synthesis in people with T2D is rate-limited by 
dysfunctional glucose transport into skeletal muscle (41). However, specific 
impairments within the insulin-signalling cascade underlying impaired glucose 
transport defects are not clear. Total basal GLUT4 protein levels do not appear to be 
altered in skeletal muscle of people with T2D (42-44); although insulin-mediated 
plasma membrane levels of GLUT-4 are reduced due to impaired membrane 
trafficking and translocation of GLUT4 (45-47). Impairments in insulin-mediated 
levels of activation, protein expression and/or gene expression pertaining to proximal 
insulin-signalling components such as IRS-1 and PI3-K have been reported in skeletal 
muscle of people with T2D (39, 48-50). While people with T2D appear to have 
impaired activation of aPKC (39, 51), impaired expression and/or activation of other 
key downstream components such as Akt are equivocal (33, 39, 49, 51-53). In 
addition, impaired glycogen synthesis in T2D has been associated with reduced 
activation of GS in some studies (54-58). Overall these findings suggest that the 
identity of the pivotal dysfunctional site(s) of the insulin signalling cascade in diabetic 
skeletal muscle glucose metabolism is uncertain. 
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1.2.4. Mechanisms of skeletal muscle insulin resistance in T2D 
 
Increased lipid availability 
 
Chronically elevated lipid levels might be a key underlying factor in skeletal muscle 
insulin resistance associated with T2D. Insulin resistance and T2D are associated with 
increased levels of circulating free fatty acids (FFA), intracellular long-chain acyl CoA 
esters and intramyocellular lipid (IMCL) stores (59-63). Moreover, increased IMCL 
levels in obesity and T2D were associated with increased transport of long chain fatty 
acids into skeletal muscle (62). The latter finding was observed despite an unaltered 
fat oxidation rate in these individuals, suggesting enhanced intramyocellular fat 
storage.  
Chronic high fat feeding is known to cause skeletal muscle insulin resistance in 
experimental rodents (64). In addition, elevating levels of FFA via lipid infusion during 
hyperinsulinaemic, euglycaemic clamps induces insulin resistance in skeletal muscle 
of healthy people in as little as 3-6h (65, 66). In contrast, six months of calorie 
restriction with or without exercise was shown to decrease IMCL levels and increase 
insulin sensitivity in an overweight population (67). 
Although increased levels of IMCL have been found in skeletal muscle of individuals 
with insulin resistance and T2D, increased IMCL levels have also been reported in 
highly trained endurance athletes who are highly insulin sensitive (68-70). Moreover, 
skeletal muscle oxidative capacity and mitochondrial function were found to be 
better predictors of insulin sensitivity than IMCL level in population groups ranging 
from well-trained athletes to individuals with T2D (71, 72). Thus, factors other than 
IMCL level might be important in promoting lipid-induced insulin resistance.  
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The accumulation of lipid intermediates including ceramide and diacylglycerol (DAG) 
has been found to be associated with impaired skeletal muscle insulin signalling (59, 
73) and insulin-stimulated glucose uptake (65). This inhibition of insulin signalling 
might occur via lipid intermediate-induced activation of protein kinase C (PKC) and 
PKC-θ, which can impair insulin signalling via serine/threonine phosphorylation of the 
insulin receptor and IRS-1 (65, 73). In addition, dietary fat-induced reactive oxygen 
species (ROS) production has been shown to activate the stress-sensitive molecules 
mitogen activated protein kinases (MAPK) (74), c-jun N-terminal kinase (JNK) (75), IkB 
kinase subunit β (IKK-β), NF-kappa B (NF-kB) transcription factor and PKC (76) in 
adiopcytes and skeletal muscle. In particular, JNK can phosphorylate IRS-1 at serine 
residues, thus attenuating key metabolic pathways of the insulin signalling cascade 
in liver, adipose tissue and skeletal muscle (77). 
 
Mitochondrial dysfunction 
 
Mitochondrial biogenesis is a regulatory program involving inter-genomic control of 
mitochondrial turnover, functional content and number required for maintenance of 
various homeostatic demands (78). In skeletal muscle this involves intergenomic 
regulation by peroxisome proliferator-activated receptor coactivator 1 (PGC1α), 
nuclear respiratory factors 1 & 2 (NRF-1, NRF-2) and the mitochondrial transcription 
factor A. These molecular regulators facilitate the coordinate regulation of genes 
coding for complexes within the electron transport chain (78).  
Mitochondrial dysfunction resulting from decreased mitochondrial biogenesis might 
impair normal lipid oxidation in skeletal muscle due to decreased mitochondrial 
content and functional capacity (79). With impaired lipid oxidation, dietary fat is 
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repartitioned away from oxidation to storage (62), and the production of toxic lipid 
intermediates is increased (80). The accumulation of ectopic IMCL and/or lipid 
intermediates such as DAG and ceramide might then increase activation of signalling 
molecules such as PKC and JNK, which can phosphorylate and inactivate important 
insulin signalling components and promote insulin resistance (78).  
Genes regulating mitochondrial biogenesis including PGC1α and NRF-1; as well as 
uncoupling protein -3 (UCP-3; involved in protection of mitochondria from oxidative 
stress (81)) have been found to be downregulated in skeletal muscle of people with 
T2D (82-84). Moreover, treatment with the insulin sensitizer Rosligitazone or exercise 
training increases expression of these genes in association with improved insulin 
sensitivity in people with T2D (83, 85, 86). Insulin-stimulated ATP synthesis has also 
been found to be impaired in people with T2D (87, 88). Furthermore, gene and 
proteomic analyses in skeletal muscle of people with T2D revealed reduced 
expression levels of proteins involved in ATP synthesis and electron transport (82, 89, 
90). Diminished in vivo mitochondrial function (using 31P-Magnetic resonance 
spectroscopy) and ex vivo mitochondrial respiration (using high-resolution 
respirometry) was also found in skeletal muscle of individuals with T2D (91-93). 
Despite these findings of mitochondrial dysfunction, other studies have failed to 
report any alterations in mitochondrial content and/or function in people with T2D 
when compared to insulin-sensitive individuals (94-96). One possible confounding 
factor of studies is a failure to control for physical activity status of groups (97). It is 
well known that aerobic exercise training enhances mitochondrial biogenesis in 
skeletal muscle (98). Moreover, much evidence suggests that this adaptability is not 
impaired in individuals with T2D when matched for physical fitness, age and BMI (91, 
92, 97, 99). Thus, due to the possibility of a reduced physical activity status of people 
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in T2D (100), it remains equivocal if mitochondrial biogenesis is intrinsically reduced 
in skeletal muscle in people with T2D. Furthermore, the likelihood of impaired lipid 
oxidatation arising from mitochondrial dysfunction has been challenged on grounds 
that the magnitude of reduced mitochondrial content reported in T2D (≈ 30 %) is not 
sufficient to impair fat oxidation, given the capacity of muscle to oxidize substrate far 
in excess of resting energy demands (101). 
The role of mitochondrial dysfunction as a cause or effect in the pathophysiology of 
insulin resistance in skeletal muscle is a contentious issue. It was suggested in a recent 
review (78) that although genetic predisposition can promote an early manifestation 
of mitochondrial dysfunction in the course of insulin resistance, most evidence 
appears to indicate that mitochondrial dysfunction is a subsequent effect of early 
perturbations of insulin resistance such as nutrient excess, physical inactivity or 
increased ROS production (78, 102) (Figure 1.5).  
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Figure 1.5. Proposed role of the mitochondria in the development of insulin 
resistance 
This schematic shows primary mitochondrial defects to the left of the hatched line in 
the center of the cell and the development of mitochondrial deficits in response to 
environmental cues and aging to the right of the hatched line. In primary disruption 
in the mitochondrial metabolic capacity, fat oxidation is diminished, fat intermediates 
accumulate and DAG, which appears to be the primary intermediate that then 
activates protein kinase C isoforms. These in turn phosphorylate and inactivate 
numerous kinase substrates in the insulin signaling pathway. The reduced insulin 
sensitivity exacerbates the metabolic perturbations by reducing glucose uptake and 
possibly by further down-regulation of the mitochondrial biogenesis program. The 
etiologies of primary mitochondrial defects are labeled 1–3. The etiologies of 
secondary disruption of mitochondrial dysfunction are labeled 4–7. High-fat diet can 
promote mitochondrial biogenesis; alternatively nutrient overload, which may include 
both glucose and fats, enhances both lipid intermediates that facilitate oxidative 
damage and impair insulin signaling. Furthermore, the nutrient overload presents 
excess reducing equivalents to the ETC that can result in increased ROS generation. 
The oxidative damage, in turn, disrupts the mitochondrial oxidative capacity, which 
then recapitulates the phenotype of primary mitochondrial deficits promoting insulin 
resistance (from (78)). 
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1.2.5. Summary and significance #2  
 
Impaired insulin signalling in skeletal muscle is associated with insulin resistance in 
people with T2D. While impaired insulin-stimulated glucose transport and glycogen 
synthesis are key defects in skeletal muscle insulin resistance, it is unclear which (if 
any) specific insulin signalling component is pivotal in skeletal muscle insulin 
resistance in T2D. Furthermore, while increased lipid availability and mitochondrial 
dysfunction are associated with insulin resistance in skeletal muscle, their causative 
role in insulin resistance in T2D is equivocal.  
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1.3.  Reactive oxygen species  
1.3.1. Background to ROS 
 
Reactive oxygen species (ROS; Table 1.1) are highly reactive chemical byproducts of 
metabolism and cellular processes in the body. ROS are produced at multiple cellular 
sites including in the mitochondria during oxidative phosphorylation (103), in the 
endoplasmic reticulum in response to protein folding stresses (104), in membrane-
bound NADPH oxidases (105), through xanthine oxidase (XO) activation (106) and via 
phospholipase A2-dependent processes (107).  
 
Table 1.1. Main reactive oxygen species 
Name Formula 
Reactive Oxygen Species  
Singlet Oxygen 1O2 
Superoxide Radical ·O2- 
Hydroxyl Radical ·OH 
Hydrogen Peroxide H2O2 
Peroxide Radical (lipid peroxide) ROO· 
Aloxyl Radical RO· 
Hypochlorous acid HOCl 
(adapted from (10)) 
 
In basal conditions, ROS produced in mitochondria constitute a major source of 
cellular ROS (103). During oxidative phosphorylation, reducing equivalents (NADH, 
FADH2) formed during energy metabolism provide electrons to be transferred along 
a series of electron carriers within the mitochondrial respiratory chain. The transfer 
of electrons generates increased membrane potential, increased oxygen 
consumption and ultimately the conversion of ADP to ATP (108). However, the 
process is not perfect and a small percentage (≈0.15%) of electrons leak from 
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respiratory chain complexes (I & III), resulting in production of ROS including 
superoxide (·O2-) (109). ·O2- is modestly reactive and can oxidize several biomolecules, 
notably dehydratases containing [4Fe-4s] clusters such as aconitase in the citric acid 
cycle (110) (Figure 1.6). ·O2- can also be converted into another reactive species, 
peroxynitrite (ONOO-), which is highly reactive to DNA, proteins and lipids (111). 
However, ·O2- is relatively short-lived and is converted into the more stable hydrogen 
peroxide (H2O2) by endogenous antioxidant enzymes including manganese 
superoxide dismutase (MnSOD) and copper/zinc superoxide dismutase (Cu/ZnSOD). 
H2O2 in turn can oxidize several biomolecules including protein kinases and 
phosphatases (112) and protein thiols (113). H2O2 is decomposed to oxygen and 
water by cellular antioxidant enzymes including catalase, glutathione peroxidise 
(GPx) and thioredoxin peroxidase. However, in the presence of free metals such as 
iron and copper, H2O2 can be converted into the highly reactive hydroxyl radical (·OH) 
(111).  
Interestingly, ROS have been implicated as both physiologically beneficial and 
pathologically harmful in the body. ROS have been shown to act as important 
intracellular signalling molecules for insulin signalling transduction in healthy tissues 
(114, 115). Additionally, exercise is known to increase levels of ROS in skeletal muscle 
and other tissues (116). ROS produced during exercise, which is primarily of non-
mitochondrial origin (117), are also thought to play key roles in skeletal muscle 
adaptations associated with exercise training (118).  
In contrast to this physiologically beneficial ROS, a chronic over-production of ROS 
systemically and in skeletal muscle promotes oxidative stress and might contribute 
to the pathogenesis of T2D (102, 119), cancer cachexia (120), and sarcopenia (121).  
Excess ROS produced during metabolic and cellular processes can oxidatively damage 
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macromolecules including DNA, lipids and proteins, modify cellular redox status, and 
alter cellular functions (10). Furthermore, by acting as signalling molecules (64), 
excess ROS might act as important causative secondary messengers in the impaired 
insulin signalling pathways associated with insulin resistance in T2D (108).  
 
 
Figure 1.6. The cellular origins of ROS, their targets, and antioxidant systems 
ETC, electron transfer chain; ER, endoplasmic reticulum; NADP(H), nicotinamide 
adenine dinucleotide phosphate; MnSOD, manganese superoxide dismutase; 
Cu/ZnSOD, copper/zinc superoxide dismutase; GPx, glutathione peroxidase; Prx, 
peroxiredoxin; Trx, thioredoxin (from (111)). 
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1.3.2. ROS: the good and the bad in skeletal muscle insulin sensitivity 
 
Different experimental models have linked excess ROS production with the 
development of skeletal muscle insulin resistance.  These models include (a) excess 
ROS production by mitochondria in experimental murine models of excess nutrient 
intake and T2D (64, 102, 122, 123); (b) excess ROS production by NADPH oxidases 
due to overactivity of the renin-angiotensin system and increased Angiotensin II 
levels (124); and more recently (c) excess ROS production by XO in experimental 
diabetes models (125).  
In particular, the relationship between increased mitochondrial ROS and skeletal 
muscle insulin resistance has been well established in vitro and in vivo (64, 119, 122, 
126). In humans it was demonstrated that both acute and chronic high fat dietary 
intakes can increase mitochondrial H2O2 production and oxidative stress in skeletal 
muscle of healthy, insulin-sensitive individuals (64). Moreover, obese, insulin-
resistant humans have increased skeletal muscle mitochondrial H2O2 emission 
compared with lean insulin-sensitive individuals (64, 127). Hoehn et al. (126) 
demonstrated an increased mitochondrial ·O2- production in palmitate-treated L6-
mytobes in vitro and in high fat-fed experimental mice in vivo. Furthermore, 
approaches aimed at the selective quenching of mitochondrial ·O2- including the 
genetic overexpression of MnSOD or supplementation with the mitochondrial ·O2- 
targeted antioxidant Mn(III)–tetrakis (4-benzoic acid) porphyrin were shown to 
improve or prevent skeletal muscle insulin resistance in the high fat fed mice (126). 
In addition, Anderson et al. (64) employed the use of both a small antioxidant peptide 
(SS31) targeted to the mitochondrial inner membrane and the genetic 
overexpression of mitochondrial-targeted human catalase (MCAT) in experimental 
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rats and mice respectively, fed high fat diets. All treatments resulted in a reduction 
of mitochondrial H2O2 emission by >50%. Moreover, chronic intake of SS31 or genetic 
over-expression of MCAT prevented the onset of high-fat-diet-induced insulin 
resistance in skeletal muscle in the experimental animals (64). Together, these and 
other studies (119) implicate excess mitochondrial ROS as both a causative factor in 
skeletal muscle insulin resistance and a key target for antioxidant-based prevention 
and treatment strategies. 
In contrast to these findings, two recent studies (122, 123) found no benefit of 
mitochondrial-targeted antioxidant treatments in C57BL/6 mice for improving 
skeletal muscle insulin resistance despite marked reductions in mitochondrial ROS 
and improvements in skeletal muscle oxidative stress levels. These findings thus raise 
the possibility that targeting elevated mitochondrial ROS levels associated with 
skeletal muscle insulin resistance might not in fact be a fruitful treatment approach 
for improving insulin sensitivity in disease states (such as T2D) characterized by 
skeletal muscle insulin resistance.  
Pathways through which ROS might impair insulin signalling have not been well 
defined, but ROS have been shown to activate stress-sensitive molecules including 
MAPK (74) and JNK (75). As previously discussed, JNK can phosphorylate the IRS 
subunit of the insulin signalling cascade at serine residues, thus attenuating key 
metabolic pathways of the insulin signalling cascade (77). Moreover, antioxidant 
supplementation in rats was shown to inhibit high-fat diet-induced activation of JNK 
and IRS-1 serine phosphorylation in skeletal muscle, thus preventing a reduction in 
insulin sensitivity (128). Mechanisms through which ROS activate JNK in tissues are 
unclear (129). However, it has been shown that ROS can activate JNK via oxidation 
and inactivation of specific JNK-inactivating phosphatases (129). Furthermore, it has 
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been shown that TNFα-induced mitochondrial ROS can activate JNK through 
activation of the apoptosis signal-regulating kinase (ASK-1) in human hepatoma cells 
(130).  
In contrast to potentially harmful excess mitochondrial ROS production, the 
generation of ROS from non-mitochondrial sources has been shown to be important 
in relation to healthy insulin signalling in insulin sensitive tissues (105, 131). In 
particular, H2O2 production by plasma membrane bound NADPH oxidases has been 
shown to increase in response to insulin stimulation both in adipocytes and myotubes 
in vitro (105, 131). A recent study also implicated XO as a key ROS generator in 
response to insulin stimulation in skeletal muscle (106). Increased insulin-stimulated 
H2O2 in skeletal muscle might occur via a PI3-K and/or PKC induced calcium release 
mechanism of action in vitro (131). Moreover, H2O2 has been shown to oxidatively 
modify and inactivate key protein tyrosine phosphatases (PTEN & PTP1B) in 
adipocytes and myotubes, thus resulting in enhanced insulin signalling (105, 131).  
Although this physiological H2O2 appears to be primarily of NADPH oxidase (105, 131) 
or XO (106) origin, it was demonstrated that levels of H2O2, PI3-K/Akt pathway 
activation and insulin sensitivity were increased in skeletal muscle of high-fat-fed 
transgenic mice lacking the antioxidant enzyme GPx (GPx-/-) (115). Moreover, 
treatment of GPx-/- mice with the antioxidant n-acetyl cysteine increased insulin 
resistance in skeletal muscle (115). GPx is expressed both in the mitochondria and 
cytosol (132), thus implying the possible involvement of mitochondrial ROS in 
maintenance of normal insulin sensitivity also. The seemingly paradoxical role of 
excess ROS in physiological versus pathological states in skeletal muscle could be a 
function of magnitude, duration and/or cellular origin of ROS produced (106).  
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1.3.3. Linking mitochondrial ROS to mitochondrial dysfunction in T2D 
 
Excess mitochondrial ROS production in diabetic and nutrient overloaded insulin-
resistant animal models has been linked to mitochondrial dysfunction in skeletal 
muscle (102, 122). Moreover, treatments with general or mitochondrial-specific 
antioxidants were shown to normalize altered mitochondrial content (as 
characterized by altered citrate synthase activity) in high-fat, insulin resistant 
C57BL/6 mice (102, 122, 123). In humans, mitochondria isolated from obese, insulin 
resistant individuals was found to possess decreased content (as characterized by 
reduced total protein and citrate synthase activity levels) compared with 
mitochondria from lean, insulin-sensitive individuals, despite a capacity for increased 
ROS production (127). It has been proposed that increased ROS-induced damage to 
mitochondrial DNA, lipids and proteins could impair mitochondrial biogenesis and 
mitochondrial DNA replication (102). In particular, damage to mitochondrial DNA 
could impair genes and proteins linked with energy metabolism (104). In turn, 
reduced mitochondrial content and altered lipid oxidation (133) could promote 
ectopic lipid deposition and propagation of a lipid-/lipid intermediate- induced 
decrease in skeletal muscle insulin sensitivity (134, 135). Presently the relationships 
between insulin resistance, excess mitochondrial ROS and mitochondrial dysfunction 
and their temporal order in the pathophysiology of skeletal muscle insulin resistance 
is uncertain (78, 122) and remain highly controversial (for more information readers 
are referred to recent arguments by Holloszy (136) and Goodpaster (135)). 
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1.3.4. Do people with T2D have increased levels of ROS in skeletal muscle? 
 
Studies that have directly measured ROS production in human T2D skeletal muscle 
have been scant, limited methodologically by ex vivo measurement techniques, and 
have produced uncertain findings (97, 137, 138). Abdul-Ghani et al. (137) reported 
no difference in overall mitochondrial ROS production in skeletal muscle of people 
with T2D versus healthy controls, although the individuals with T2D had an increased 
mitochondrial H2O2 generation per unit of ATP production. Given that ATP production 
is driven by cellular energy demand in vivo, these findings suggest an increased in 
vivo ROS production in skeletal muscle of people with T2D (137). Another study (97) 
reported a tendency for increased mitochondrial ROS production in individuals with 
T2D when compared with control participants matched for age, BMI, physical fitness 
and mitochondrial content. In contrast to these studies, Minet & Gaster (138) found 
reduced absolute mitochondrial H2O2 production in primary myotubes from 
individuals with T2D and no difference in the ratio of mitochondrial H2O2 production 
per unit of ATP production when compared to control participants. However, as 
discussed by the authors, different findings in the latter in vitro study compared to 
the previous studies could relate to the absence of in vivo metabolic conditions 
relevant to ROS production in T2D (138). Overall, these studies might also be limited 
by the accuracy of assays used to assess ROS production from isolated mitochondria. 
In particular, commonly used redox-sensitive probes such as Amplex Red (10-acetyl-
3,7-dihydroxyphenoxazine) could be cross-reactive with lipid hydroperoxides and/or 
other redox-related metabolites (108, 139) and are prone to artifactual ROS 
formation (140). Thus a degree of caution is required in the interpretation of these 
findings (108).  
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In addition to direct measurements of ROS production, indirect oxidative stress 
measurements reflective of excess ROS including protein carbonyls and 8-hydroxy-
2’-deoxyguanosine were shown to be increased in skeletal muscle of people with T2D 
when compared to non-diabetics (141, 142). In contrast to these findings, Brinkmann 
et al. (143) reported reduced levels of F2-Isoprostanes in skeletal muscle of people 
with T2D when compared with age and BMI-matched controls.   With respect to the 
latter finding, the authors speculated that decreased muscle F2-Isoprostanes in the 
people with T2D might have arisen as a compensatory response to insulin resistance; 
such that total mitochondrial activity and thus mitochondrial ROS formation were 
reduced (143). 
Oxidative stress is defined broadly as a suprathreshold imbalance between the 
production and scavenging of ROS by the body’s antioxidant defence network, 
favouring ROS production (64). Thus, a limitation of using these oxidative stress 
markers as indicators of ROS production is that decreased antioxidant levels could 
theoretically promote oxidative stress without a concomitant increase in ROS 
production.  Studies investigating levels of antioxidant enzymes in skeletal muscle of 
people with T2D have produced mixed findings when compared to the levels of 
insulin sensitive controls. Protein levels of MnSOD were found to be reduced in 
skeletal muscle of individuals with T2D in some studies (141, 144) but not others 
(143). On the other hand, Brinkmann et al. (143) reported increased levels of 
peroxiredoxins (PRDX2 & PRDX6) but unaltered levels of GPx in skeletal muscle of 
people with T2D using immunohistochemical methods. Exercise training can alter 
levels of antioxidant enzymes (145). Therefore a lack of control for physical activity 
levels could complicate findings of antioxidant enzyme levels in people with T2D. 
Collectively, these findings suggest that, compared with healthy controls, the skeletal 
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muscle antioxidant status in people with T2D is unclear and further studies are 
required that closely match age, body mass and physical activity levels.  
A lack of comprehensive data on the oxidative stress milieu in skeletal muscle of 
people with T2D coupled with the absence of currently available accurate in vivo 
measurement techniques for the probing of ROS (108) makes it difficult to establish 
a clear conclusion on alterations in levels of ROS in skeletal muscle of people with 
T2D.   
Finally, a proposed integrated model linking mechanisms of skeletal muscle insulin 
resistance is presented in Figure 1.7. Here, ROS are implicated as important signalling 
factors in establishing skeletal muscle insulin resistance. Excess ROS production also 
links increased lipid availability with mitochondrial dysfunction associated with 
skeletal muscle insulin resistance. Lastly, according to this model antioxidant 
treatment can target both insulin resistance and mitochondrial dysfunction in 
skeletal muscle associated with T2D (64, 102, 126). 
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Figure 1.7. Vicious cycle linking lipid excess, insulin resistance and mitochondrial 
dysfunction in T2D 
A proposed pivotal role of ROS in mediating these deleterious changes is highlighted, 
along with potential protection by antioxidants. Broken lines indicate uncertainty.  
Under conditions of high fat intake, obesity and in T2D, increased levels of IMCL and 
lipid intermediates in skeletal muscle promote impairments in insulin signalling and 
insulin-stimulated glucose disposal via activation of PKCs. Increased lipid availability 
such as through high fat intake also promotes increased electron transport flux and 
elevated mitochondrial ROS production, which impairs normal insulin signalling and 
promotes insulin resistance in skeletal muscle via JNK and p38 MAPK-signalling. 
Increased ROS in turn causes oxidative damage to the mitochondria, resulting in 
reduced mitochondrial oxidative capacity and mitochondrial dysfunction. Such a state 
can promote ectopic lipid storage due to either an overburden on mitochondrial β-
oxidation or impaired mitochondrial lipid oxidation, thus worsening existing insulin 
resistance. These effects however might be ameliorated by treatment with 
antioxidants (adapted in part from (79)). 
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1.3.5. Summary and significance #3  
 
At present only limited data exists on ROS levels, markers of oxidative stress and 
levels of antioxidants in skeletal muscle of people with T2D. Data in rodent models 
implicate oxidative stress in the causation of skeletal muscle insulin resistance; with 
antioxidant therapy reversing this defect. Studies looking at the potential 
ameliorative effects of antioxidant therapies on skeletal muscle ROS and oxidative 
stress in people with T2D are required. Moreover, studies investigating the 
association between changes in oxidative stress and improvements in insulin 
sensitivity in skeletal muscle following antioxidant therapy might offer some 
mechanistic insights into the importance of oxidative stress and its targeted 
therapy in people with T2D. 
Finally, although mechanisms underlying insulin resistance in skeletal muscle 
remain contentious; increased ROS appears to play an important signalling role in 
mediating insulin resistance as well as linking increased lipid availability with 
mitochondrial dysfunction in insulin resistance. 
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1.4.  Dietary antioxidants for prevention and treatment of T2D 
1.4.1. Observational studies 
 
Dietary intake of antioxidant vitamins has been associated with a reduced risk of 
developing T2D (146-150). Moreover, a recent meta-analysis of nine cohort studies 
of antioxidant intake and diabetes risk reported a pooled relative risk of 0.87 (95 %CI 
0.79, 0.98) for the highest antioxidant intake versus the lowest intake (151). Despite 
such findings, these studies are limited by their observational designs, and may have 
been prone to confounding bias by residual dietary and/or lifestyle factors (152). 
Furthermore, the majority of these studies related prospective diabetes incidence to 
baseline dietary intake or baseline antioxidant levels, which was estimated decades 
before incidence was assessed. Changes in dietary antioxidant intake of individuals 
over this time might not have been accurately accounted for, thus potentially 
increasing exposure misclassification (153).  
 
1.4.2. Large randomized controlled trials 
 
In contrast to observational studies, evidence from large, long-term randomized 
controlled trials evaluating the effectiveness of antioxidant supplementation in 
primary or secondary disease prevention has not been supportive of benefits (152, 
154-159). A recent meta-analysis of randomized controlled trials reported no 
protective effect of antioxidant supplementation on risk of all-cause mortality in 
primary and secondary prevention of various diseases (160). Moreover, after 
exclusion of “high-bias risk trials”, this meta-analysis reported an increased risk of all-
cause mortality after supplementation with vitamin E, vitamin A and beta-carotene 
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(160). However, few of the studies included in the meta-analysis were of clear 
relevance to the treatment of people with T2D. Large scale antioxidant 
supplementation randomized controlled trials (RCTs) have been limited by factors 
including reduction of supplementation compliance over time (152, 159), a high-risk 
study population bias (156, 157), use of poly-antioxidant supplementation regimens 
rather than single antioxidant regimens (thus introducing potential interactive 
effects), a lack of strict dietary antioxidant control, and use of  self-reported diabetes 
status (152, 156, 159). Moreover, assessment of oxidative stress was largely ignored 
in these studies. Thus it is unclear if dosage regimens used were effective enough to 
improve oxidative stress. Finally, most large scale studies appear to have lacked clear 
insight into the mode of action of the specific antioxidants used and their biological 
targets (161, 162), thus making interpretation of their findings difficult. 
 
1.4.3. Randomized controlled trials for the treatment of insulin resistance in T2D 
 
Studies of antioxidant vitamin supplementation in people with T2D have produced 
mixed results in terms of improving glycaemic control and insulin sensitivity. A recent 
meta-analysis of 14 intervention studies reported no effect of vitamin E or vitamin C 
supplementation in people with T2D on fasting glucose and fasting insulin levels 
(163). However a significant reduction in HbA1c following supplementation was 
reported (p=0.0021; mean difference, -0.571 %; 95 % CI -0.935, -0.207)(163). Notably, 
the number of studies selected for this meta-analysis was relatively small, and there 
was an absence of studies that used “gold-standard” glucose clamp methods to 
assess insulin sensitivity.   
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Findings from smaller well controlled studies that investigated effects of antioxidant 
treatments on insulin resistance in people with T2D and which used glucose clamp 
methods yielded more promising outcomes in terms of improving insulin resistance. 
In particular, oral or intravenous supplementation with alpha-lipoic acid (164-166), 
vitamin E (167), vitamin C (168, 169) and glutathione (170) was found to improve 
insulin sensitivity in people with T2D. Unfortunately a comparison between these 
studies is rather difficult based on their heterogeneous designs in relation to type, 
dose, duration and route of supplementation; as well as varying baseline participant 
characteristics. 
 
1.4.4. Summary and significance #4  
 
Despite consistent associations between dietary antioxidant intake and protection 
from T2D in observational studies, data from large randomized controlled trials is 
not generally supportive of benefits of antioxidant supplementation for disease 
prevention. However, many of these studies suffer from limitations such as 
inadequate compliance with supplementation, use of high risk population groups, 
and use of multi-compound antioxidants. Thus, concerns of internal validity of 
some of the larger studies are brought into question. Smaller, better controlled 
trials that have used “gold-standard” glucose clamp methods have produced more 
promising findings supporting antioxidants in the treatment of insulin resistance in 
T2D. However, it is difficult to arrive at a clear consensus of benefit given the small 
number and heterogeneity of trials. Future clinical studies should be designed with 
clear antioxidant-specific biological targets as outcomes as well as key clinical 
measurements.  
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1.5.  Vitamin C for the treatment of T2D 
1.5.1. Biochemistry and functions of vitamin C 
 
Vitamin C is a six-carbon compound that exists in two active forms: in its reduced 
ascorbic acid (AA) form or in its oxidized dehydroascorbic acid (DHA) form (Figure 
1.8). Vitamin C plays an important role in many biological reactions, and is an 
essential cofactor of numerous hydroxylation reactions (171). For instance, vitamin C 
acts as a cofactor for iron-dependent dioxygenases (e.g. prolyl & lysyl hydroxylases) 
which catalyze the hydroxylation of unfolded procollagen chains, leading to the 
formation of mature collagen (171-173). Among its other functions, vitamin C is also 
involved in the biosynthesis of catecholamines (174) and carnitine (175). Moreover, 
vitamin C is a potent water soluble antioxidant in cells and plasma, quenching ROS 
such as ·O2-, ▪OH and ROO▪ and reducing oxidative stress (176-182). Acting as an 
antioxidant, AA undergoes a single electron oxidation yielding the ascorbyl radical 
(Figure 1.8). At physiological pH the ascorbyl radical disproportionates either back to 
AA or it can donate another electron, forming DHA (183). The fate of DHA is either 
that of irreversible hydrolysis to diketogulonic acid or it can be reduced back to AA 
via enzymatic and non-enzymatic mechanisms (184) (Figure 1.9). Notably, 
glutathione and glutathione-dependent enzymes including glutaredoxins have been 
shown to be important in this recycling process (183, 185). NADPH-dependent DHA 
reductases including thioredoxin reductase are also involved in AA recycling (186). 
 
 
Literature Review 
33 
 
 
 
Figure 1.8. Conversion between the active forms of vitamin C 
Vitamin C in its reduced AA form can be oxidized to the ascorbyl radical, which in turn 
can be oxidized to DHA. Both the ascorbyl radical and DHA can be reduced back to AA 
(from (184)). 
 
Membrane Transport      Vit. E quinone 
          Loss             Loss 
CO2 +          
Pentose                  NADPH                     GSSG        AA     Vit E 
                   Radical 
          
                                                                                                      A-radical 
         
G-6-P                         NADP                     GSH        DHA   Vit E 
       Loss 
Glucose           Diketo-L-gulonic acid 
 
Figure 1.9. Cyclical redox reactions linked to the reduction of DHA to AA 
Glutathione (GSH), ascorbic acid (AA), and vitamin E (Vit. E). The oxidized forms of 
these compounds, respectively, are glutathione disulfide (GSSG), ascorbyl radical (A-
radical), dehydroascorbic acid (DHA), and vitamin E-radical (Vit. E radical). The 
reduction of GSSG requires NADPH as a cofactor (which is produced by cellular glucose 
metabolism) and is catalyzed by glutathione reductase (not shown). Also shown are 
several nodal sites where the oxidized forms of the compounds may be lost from the 
cycles: GSSG may exit from cells; DHA may be irreversibly degraded to diketo-L-
gulonic acid; and Vit. E radical may be converted to the relatively nonreactive Vit. E 
quinone. (adapted from (185)). 
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1.5.3. Vitamin C nutrition and supplementation 
 
Unlike most other mammals, humans are unable to produce vitamin C endogenously 
due to absence of the enzyme L-gulonolactone oxidase (187). Therefore sufficient 
dietary vitamin C must be consumed to prevent vitamin C deficiency and scurvy. 
Fruits and vegetables are generally good sources of vitamin C, collectively 
contributing the vast majority of dietary vitamin C intake in Australians (188). 
Nutrient reference values include a recommended dietary intake (RDI) of 45 mg/day 
for adult men and women, and a prudent upper limit of 1000 mg/day (189).  
The vitamin C RDI in healthy adults might not be sufficient in people with T2D 
however, as oxidative stress could promote decreased cellular vitamin C transport 
and/or increased turnover of vitamin C (190). In fact, oxidative stress associated with 
T2D might partly explain the decreased plasma and leukocyte levels of vitamin C 
observed in people with T2D (168, 191-194) despite their apparently similar dietary 
vitamin C intakes compared with non-diabetics (195, 196). 
High, supra-dietary doses of vitamin C (≥ 500 mg/day) are not associated with major 
adverse effects nor specific toxic endpoints (189). The most commonly reported mild 
adverse effects resulting from high dose oral vitamin C are gastrointestinal 
disturbances (189). Of potential concern is the formation of oxalate from AA that 
could crystallize in the urine, forming kidney stones in susceptible individuals (171). 
Some studies have reported modestly increased urinary oxalate with doses of 1-2 
g/day in both stone-forming individuals and non-stone-forming individuals (197-200), 
leading to suggested recommendations of <2 g/day (197, 198) in individuals who are 
known stone formers. However, most studies in humans with normal renal function 
have not reported substantially elevated levels of urinary oxalate following high dose 
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vitamin C (189, 201). Finally, while supplementation with fat soluble dietary 
antioxidants including vitamin E and beta-carotene has been associated with an 
increased risk of morbidity and mortality in randomized controlled trials (160, 202), 
such negative effects were not found for high dose vitamin C (160). Given its safety 
profile and its relative deficiency in people with T2D, vitamin C could potentially be 
an ideal antioxidant treatment for safely targeting oxidative stress and improving 
insulin sensitivity in people with T2D. 
 
1.5.4. Vitamin C supplementation trials in T2D: effects on insulin sensitivity, 
oxidative stress and glycaemic control 
 
Randomized controlled trials that have evaluated the impact of vitamin C 
supplementation on insulin sensitivity, oxidative stress and/or glycaemic control in 
people with T2D are summarized in Table 1.2. Studies are limited in number and are 
heterogeneous in relation to factors such as vitamin C dosage, dosage schedule, 
duration of supplementation, baseline characteristics of participants, and specific 
measurements undertaken.  
One notable study conducted was a placebo-controlled randomized trial in elderly 
people with T2D that involved four months of vitamin C supplementation (500mg 
twice daily) in a cross-over manner (169). The study reported significantly improved 
insulin-mediated whole body glucose disposal (WBGD) and non-oxidative glucose 
metabolism (NOGM; a semi quantitative estimation of glycogen synthesis rate) 
following supplementation. HbA1c, plasma cholesterol, triglycerides, fasting insulin 
and plasma levels of ·O2- were also found to be significantly improved following 
supplementation in this study.  
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From these summarized studies it appears that a threshold dose of 1 g vitamin C per 
day for ≥6 weeks might be required to elicit favourable outcomes in terms of 
improved insulin sensitivity, oxidative stress and/or glycaemic control in people with 
T2D (169, 181, 182, 203-211). With the exception of one study (211) no studies that 
employed supplementation regimens consisting of < 1 g vitamin C per day and/or 
durations of < 6 weeks found improvements in relation to systemic oxidative stress 
and/or glucose metabolism in people with T2D. It should be noted that some 
reviewed studies did not include a placebo group to evaluate longitudinal effects 
(207, 209, 210). Furthermore, while some studies in Table 1.2 evaluated markers of 
systemic oxidative stress (169, 181, 182, 204, 208, 212), with some studies finding 
improvements following supplementation (169, 181, 182); none of these studies 
investigated effects of vitamin C on levels of ROS or oxidative stress in skeletal 
muscle.  Improvements in insulin sensitivity were reported in one study (169), but 
only two studies (169, 205) used “gold-standard” glucose clamp methods (213) to 
assess insulin sensitivity in people with T2D. Finally, there are no data shown in Table 
1.2 for β-cell insulin secretory capacity of study participants. It remains possible that 
varying baseline insulin secretory capacities of participants and alterations in insulin 
secretory capacity in response to vitamin C supplementation potentially affected 
glycaemic control outcomes of the different studies.
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Table 1.2. Randomized trials investigating effects of vitamin C supplementation on insulin sensitivity, oxidative stress and glycaemic control in people 
with T2D 
Authors/ 
Study design 
Subjects Subject data*  Duration Main Measures Main Findings** Limitations Δ VC (μmol/l) 
Baseline, Post 
Ardekani & 
Shojaoddiny-
Ardekani 
(209) 
 
Parallel-group  
N=84 (T2D) 
(41 F, 43 M) 
(aged: 52.3 ± 9.62 
y) 
 
Groups: 
1). 500 mg 
VC/day: n=41 
2). 1 g VC/day: 
n=43   
DD: 7.62 ± 5.74 y 
HbA1c: 8.82 ± 1.3 % 
Drugs: No insulin, no 
other drugs specified 
BMI: N/A 
BP: N/A 
TC: 198.3 ± 38.1 mg/dl 
TG: 210.0 ± 65.1 mg/dl 
Glu: 169.3 ± 34.0 
mg/dl 
6 weeks 
treatment:  
500mg VC/ 
day (2 x 250 
mg) or  
1 g VC/day (4 x 
250 mg) 
Fasting blood 
glucose, TC, TG, 
LDL, HDL, HbA1c, 
Insulin 
1 g/day VC: ↓fasting 
glucose, ↓TG,↓ 
LDL-C, ↓HbA1c & 
↓Insulin  compared 
with baseline; no 
effects elicited with 
500 mg/day VC 
No placebo 
control group; 
not double-
blinded; did not 
assess vitamin C 
levels 
Not Assessed 
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Authors/ 
Study design 
Subjects Subject data*  Duration Main Measures Main Findings** Limitations Δ VC (μmol/l) 
Baseline, Post 
Bishop, 
Schorah & 
Wales (203) 
 
Double-blind, 
cross-over, 
placebo-
controlled 
N=50 [n=38 
(T2D); n=12 
(T1D)]  
(24 M, 26 W);  
 
Groups: 
1). VC/placebo 
n=25 (aged 51 
[19-76] y);  
2). Placebo/VC 
n=25 (aged 60 
[33-76] y)   
DD: N/A 
HbA1c: 9.6 ± 1.9 % 
Drugs: Metformin 
and/or sulfonylureas; 
anti-hypertensives  
BMI: N/A 
BP: N/A 
TC: 7.0 ± 1.2 mmol/l 
TG: 2.8 ± 1.5 mmol/l 
Glu: 7.5 ± 3.0 mmol/l 
2-months 
treatment 
with 
500mg/day 
Vitamin C & 2-
months 
placebo, no 
wash-out 
Fasting glucose, 
cholesterol, TG, 
HbA1c. Plasma & 
Leukocyte VC levels 
No effect of VC on 
any clinical measures 
Dose possibly 
too low; 
compliance not 
assessed; no 
wash-out period 
between 
treatment arms; 
included 
patients with 
complications & 
both T1D & T2D 
In plasma: 
VC group: 
41.6 ± 26.4, 
92.5 ± 29.2 
Placebo group: 
41.6 ± 26.4, 
44.6 ± 21.9 
In leukocytes: 
(μg/108 cells) 
VC group: 
27.6 ± 9.1, 
36.0 ± 8.7 
Placebo group: 
27.6 ± 9.1, 
31.4 ± 8.6 
Chen et al. 
(205) 
 
Double-blind, 
placebo-
controlled, 
parallel-group 
N=32 (T2D)  
(13 M, 19 F)  
 
Groups: 
1). Placebo n=17 
(aged 47 ± 3 y) 
2). VC: n=15 
(aged 49 ± 2 y) 
DD: 4.3 ±1.1 y 
HbA1c: 7.5 ± 0.3 % 
Drugs: anti-
hypertensives, anti-
diabetics (no insulin)  
BMI: 34.1 ± 1 
SBP: 140 ± 4 mmHg 
DBP: 77 ± 2mmHg 
TC: 202 ±11 mg/dl 
TG: 231 ± 31 mg/dl 
Glu: 156 ± 11 mg/dl 
4 weeks 
treatment 
with 800 mg 
vitamin C/day 
or placebo 
Plasma VC, fasting 
glucose, fasting 
insulin, forearm 
blood flow, insulin 
sensitivity (using 
isoglycaemic, 
hyperinsulinaemic 
clamp , QUICKI and 
HOMA) 
No effect of VC on 
insulin sensitivity or 
clinical measures 
Some potential 
compliance 
issues; short 
duration; dose 
possibly too low  
In plasma: 
VC group: 
23 ± 2, 
48 ± 6 
Placebo group: 
21 ± 3, 
19 ± 3 
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Authors/ 
Study design 
Subjects Subject data*  Duration Main Measures Main Findings** Limitations Δ VC (μmol/l) 
Baseline, Post 
Dakhale, 
Chaudhari & 
Shrivastava 
(211) 
Double-blind, 
placebo-
controlled, 
parallel group 
N=66 (T2D) (28M, 
38F);  
Groups: 
1). VC + 
metformin: n=33 
(aged 48.3±1.4 y); 
2). placebo + 
metformin: n=33 
(aged 45.9±1.4 y) 
DD: N/A 
HbA1c: 8.26 ±0.09 % 
Drugs: Metformin, no 
psychotropics 
BMI: N/A 
BP: N/A 
TC: N/A 
TG: N/A 
Glu: 8.7±0.2 mmol/l 
12 weeks 
treatment 
with: 500mg 
VC + 500mg 
Metformin 
(both 2 x /day) 
or placebo + 
Metformin 
(both 2 x /day) 
Fasting glucose, 
post-prandial 
glucose, HbA1c 
VC: ↓ fasting & post-
prandial glucose & 
↓HbA1c;  
Placebo:↓fasting & 
post-prandial 
glucose (but not 
Hba1c); all changes 
greater in VC group 
vs. placebo 
Metformin likely 
confounded 
findings; no 
measures of 
oxidative stress  
In plasma: 
VC group: 
14.8 ± 0.5, 
25.6 ± 0.6 
Placebo group: 
13.6 ± 0.3, 
15.3 ± 0.6 
 
Darko et al. 
(204) 
 
Double-blind, 
placebo-
controlled, 
parallel-group 
N=35 (T2D)  
(12 F, 23 M)  
 
Groups: 
1). placebo: n=17 
(aged 56.6 ± 1.2y) 
2). VC: n=18  
(aged 55.5 ± 1.8y)  
DD: 7.8 ±0.6 y 
HbA1c: 7.5 ± 0.3 % 
Drugs: Metformin, 
Sulfonylureas, anti-
hypertensives 
BMI: 27.9 ± 1.5 
SBP: 141 ± 5 mmHg 
DBP: 80 ± 2 mmHg 
TC: 5.8 ± 0.3 mmol/l 
TG: 2.1 mmol/l 
Glu: 10.9 ± 0.9 mmol/l 
3 weeks 
treatment 
with vitamin C 
(3 x 500 
mg/day) or 
placebo 
Blood pressure, 8-
epi-PGF2α 
(oxidative stress 
marker), 
endothelial 
function (digital 
volume pulse, 
forearm blood 
flow: FBF), TC, HDL-
C, fasting glucose, 
plasma VC 
No effect of VC on 
any clinical measures 
Duration of 
treatment 
possibly too 
short; only 
assessed one 
marker of 
oxidative stress; 
insulin 
sensitivity not 
assessed  
In plasma: 
VC group: 
58 ± 6, 
122 ± 10 
Placebo group: 
51 ± 5, 
53 ± 5 
  
 
40 
Authors/ 
Study design 
Subjects Subject data*  Duration Main Measures Main Findings** Limitations Δ VC (μmol/l) 
Baseline, Post 
Erikkson & 
Kohvakka 
(210)  
 
Double blind, 
cross-over 
N=56  
[n=29 (T1D)  n=27 
(T2D)] 
(aged 61 ± 2y) 
 
T2D subjects: 
DD: 10 ±1 y 
HbA1c: 9.3 ± 0.3 % 
Drugs: anti-
hyperglycaemics, 
insulin, others not 
specified  
BMI: 28.9 ± 0.8 
SBP: 149 ± 3 mmHg 
DBP: 87 ± 2mmHg 
TC: 6.2 ±0.2 mmol/l 
TG: 2.5± 0.2 mmol/l 
Glu: 10.1 ± 0.6 mmol/l 
90 days 
treatment 
with 
magnesium 
(600 mg/day) 
& 90 days with 
Vitamin C (1 g 
2x/day), with a 
4-week wash-
out period and 
a 90-day run-
in period 
Systolic/Diastolic 
BP, fasting 
glucose,HBA1c, TC, 
TG 
T2D subjects:  
VC: ↓fasting 
glucose, ↓HbA1c, 
↓TC & ↓TG; 
Magnesium 
supplementation 
had no effect 
No placebo 
control group; 
did not assess 
vitamin C levels 
Not assessed 
Evans et al. 
(181) 
 
Double blind, 
placebo-
controlled, 
parallel design 
N=20 (T2D)  
(17 M, 3 W)  
 
Groups: 
1). VC: n=10 
(aged 52.7 ± 6.9 
y)  
2). placebo: n=10 
(aged  53.6 ± 7.9 
y) 
 
DD: N/A 
HbA1c: 8.4 % 
Drugs: Metformin 
and/or Sulfonylureas 
BMI: 29.2 ± 4.8 
SBP: 151 ±11 mmHg 
DBP: 85 ± 10 mmHg 
TC: 5.4 ± 0.7 mmol/l 
TG: 2.1 ± 0.3 mmol/l 
Glu: 8.4 ± 0.7 mmol/l 
6 weeks with 
lispro (insulin) 
+ 1 g VC/day 
or 6-weeks 
with lispro + 
placebo 
HbA1c; Fasting and 
postprandial flow-
mediated dilation 
(FMD), TG, 
cholesterol, insulin, 
glucose; plasma 
free radicals using 
electron 
paramagnetic 
resonance (EPR) 
spectroscopy & 
lipid peroxidation 
(TBARS) 
VC: ↓ fasting & post 
prandial plasma free 
radicals & TBARS; No 
effect of VC on 
fasting glucose, 
cholesterol, insulin 
or HbA1c  
No control 
group without 
insulin; insulin 
treatment might 
have interacted 
with vitamin C; 
study possibly 
underpowered 
for biochemical 
indices 
Not assessed 
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Authors/ 
Study design 
Subjects Subject data*  Duration Main Measures Main Findings** Limitations Δ VC (μmol/l) 
Baseline, Post 
Mazloom et 
al. (182) 
 
Single blind, 
placebo-
controlled, 
parallel group 
N=30 (T2D)  
(22 W, 8 M)  
 
Groups: 
1). VC n=14 (aged 
47±8.93 y)  
2). placebo n=13 
(aged 46.61 ± 
7.58 y) 
DD: 4.57 ± 4.2 y 
HbA1c: N/A 
Drugs: Metformin 
and/or Sulfonylureas 
BMI: 26.94 ± 4.94 
SBP: N/A 
DBP: N/A 
TC: 189.4 ± 38.1 mg/dl 
TG: 174.8±110.4 mg/dl 
Glu: 131.1± 32.8 mg/dl 
6 weeks of 1 g 
VC/day or 
placebo 
Fasting and 
postprandial TG, 
cholesterol & 
plasma 
malondealdehyde 
(MDA; determined 
using TBARS) 
VC: ↓ fasting & 
postprandial plasma 
MDA; no effect of VC 
on other lipid 
measures 
Single blind 
only; baseline 
MDA higher in 
VC vs. placebo; 
study possibly 
underpowered 
for lipid 
measures 
Not Assessed 
McAuliffe et 
al. (214) 
 
Double-blind, 
placebo-
controlled, 
parallel group 
N=20 [n=18 
(T2D); n=2 (T1D) 
(15 M, 5 F);  
 
Groups: 
1). VC: n=10 
(aged 58±12 y)  
2). placebo n=10 
(aged 58 ± 12 y) 
DD: 12 ± 11 y 
HbA1c: 7.9 ±1.4 % 
Drugs: anti-diabetics & 
insulin 
BMI: 31.98 
SBP: 147 ± 17mm Hg 
DBP: 84 ± 9mm Hg 
TC: N/A 
TG: N/A 
Glu: N/A 
12 months of 
500 mg VC 
2x/day or 
placebo 
Albumin excretion 
rate (AER), HbA1c, 
TG, TC, HDL-C, SBP 
& DBP; plasma VC 
No effect of VC on 
glycaemic control or 
lipid measures 
Study possibly 
underpowered; 
half of subjects 
were taking 
insulin; included 
subjects with 
complications; 
baseline body-
weight higher in 
VC group 
In plasma: 
VC group: 
40.0 (approx.), 
84.3 ± 8.0 
Placebo group: 
N/A (no 
significant 
change from 
baseline) 
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Authors/ 
Study design 
Subjects Subject data*  Duration Main Measures Main Findings** Limitations Δ VC (μmol/l) 
Baseline, Post 
Mullan et al. 
(206) 
 
Double blind, 
placebo-
controlled, 
parallel design 
N=30 (T2D)  
(22 M, 8 W)  
 
Groups: 
1). placebo: n= 15 
(aged 57.9 ± 6.6 
y);  
2). VC: n=15 
(aged 61.0 ± 6.5 
y) 
 
DD: <10 y 
HbA1c: 8.1 ± 1.3 % 
Drugs: Anti-
hypertensives & Anti-
diabetics (no insulin) 
BMI: 28.6 ± 4.4 
SBP: 142 ±12.6 mmHg 
DBP: 83.9 ± 4.8 mmHg 
TC: 5.2 ± 0.8 mmol/l 
TG: 2.2 ±1.1 mmol/l 
Glu: 9.3 ± 2.2 mmol/l 
4-weeks 
treatment 
with 500 mg 
AA or placebo 
Hemodynamic 
measures: blood 
pressure, pulse 
wave analysis; 
biochemical 
measures: HbA1c, 
plasma glucose, 
plasma insulin, TC, 
HDL-C, LDL-C, TG; 
plasma VC 
No effect of VC on 
any biochemical 
measures  
Participation by 
hypertensive 
diabetics; dose 
possibly too 
low; duration 
possibly too 
short 
In plasma: 
VC group: 
43.3 ± 19.3, 
78.1 ± 19.5 
Placebo group: 
N/A (no 
significant 
change from 
baseline) 
Paolisso et al. 
(169) 
 
Double-blind, 
placebo-
controlled, 
cross-over 
N=40 (T2D)  
(19 M/21 F)  
(aged 72 ± 0.5 y) 
 
DD: 8.l ± 0.3 y 
Hba1c: 8.1 ± 0.4 % 
Drugs: Sulfonylureas 
BMI: 27.7 ± 0.3 
SBP: 155 ± 0.6 mmHg 
DBP: 84 ± 0.4 mmHg 
TC: 7.2 ± 0.3 mmol/l 
TG: 2.61±0.09 mmol/l 
Glu: 8.8 ± 0.4 mmol/l 
4 months 
treatment 
with 500 mg 
Vitamin C 
2x/day or 
placebo, with 
a 30-day 
wash-out  
Plasma VC, Fasting 
glucose, fasting 
insulin, cholesterol, 
TG, GSH, HbA1c, 
free radicals (O2), 
glucose 
metabolism 
↑GSH, ↓TC, ↓LDL-
C, ↓TG, ↓HbA1c, 
↓O2, ↓insulin, 
↑whole body 
glucose disposal,↑ 
non-oxidative 
glucose metabolism  
Clamp data only 
from half of 
subjects; did not 
assess hepatic 
glucose output; 
findings might 
only be relevant 
to elderly adults 
In plasma: 
VC group: 
41.2 ± 5.4,  
76.6 ± 3.7 
Placebo group: 
41.2 ± 5.4, 
43.4 ± 2.8 
  
 
43 
Authors/ 
Study design 
Subjects Subject data*  Duration Main Measures Main Findings** Limitations Δ VC (μmol/l) 
Baseline, Post 
Tessier et al. 
(212) 
 
Double-blind, 
placebo-
controlled, 
parallel group 
N= 36 (T2D)  
(28 W, 8 M)  
 
Groups: 
1) 500 mg 
VC/day: n=12 
(aged 72 ± 5 y);  
2) 1 g VC/day : 
n=12 (aged 71 ± 4 
y);  
3). placebo: n=12 
(aged 72 ± 4 y) 
DD: 10.2 ± 9.4 y 
HbA1c: 7.4 ±0.8 % 
Drugs: Metformin, 
Sulfonylureas, Insulin 
BMI: 29.5 ± 5.3 
SBP: N/A 
DBP: N/A 
TC: 4.63 ± 0.76 mmol/l 
TG: 2.43 ± 0.83 mmol/l 
Glu: 8.3± 2.9 mmol/l 
12 weeks of 
500 mg 
VC/day or 1 g 
VC/day or 
placebo 
Granulocyte levels 
of VC, vitamin E, 
GSH, GSSG, 
lipoprotein lipid 
peroxidation 
(TBARS) & 
lipoprotein particle 
oxidation; fasting 
glycaemic & lipid 
parameters 
1 g VC/day: ↑ 
cellular VC (vs. 
baseline) & ↑ 
vitamin E content of 
LDL; both 1g/day & 
500 mg/day: ↑ 
cellular GSH vs. 
placebo; no effect of 
VC on any other 
measures 
Might only be 
relevant to 
elderly people 
with T2D; study 
might have 
lacked power 
for some 
measures; 
GSH/GSSG ratio 
not assessed  
In granulocytes: 
(nmol/mg 
protein) 
1g VC group: 
1.45 ± 1.20, 
5.66 ± 2.00 
500 mg VC 
group: 
3.36 ± 1.99, 
5.39 ± 1.90 
Placebo group: 
2.42 ± 2.01, 
2.72 ± 1.88 
Tousoulis et 
al. (207) 
 
Single blind, 
controlled, 
parallel group 
N=41 (T2D)  
(22 M, 19 W)  
Groups: 
1). Atorvastatin-
treated: n=15 
(aged 58.1± 2.6 y) 
2). VC- treated: 
n=13 (59.1 ± 2.4 
y)  
3). Control: n=13 
(aged 60.9± 3.1 y) 
DD: 8.6 (0.9) y 
HbA1c: 6.29 (0.22) % 
Drugs: No insulin or 
statins 
BMI: 29.1 ± 1.1 
SBP: N/A 
DBP: N/A 
TC: 4.9 ± 0.2 mmol/l 
TG:1.7 (1.1-2.4) 
mmol/l 
Glu: 7.0 (6.2-8.7) 
mg/ml  
4 weeks of 
daily 10 mg 
Atorvastatin (a 
statin drug) or 
2 g vitamin C 
or control (no 
supplementati
on) 
Inflammation 
markers, 
hyperaemic 
forearm blood 
flow, vasodilatory 
response to post-
ischaemic 
hyperaemia, 
cholesterol, TG, 
fasting glucose 
No effect of VC on 
fasting glucose, TG & 
cholesterol 
No placebo 
control group; 
only single 
blind; possibly 
too short in 
duration; 
included 
smokers & 
hypertensives; 
no measures of 
oxidative stress 
Not assessed 
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Authors/ 
Study design 
Subjects Subject data*  Duration Main Measures Main Findings** Limitations Δ VC (μmol/l) 
Baseline, Post 
Upritchard, 
Sutherland & 
Mann (208) 
 
Placebo-
controlled, 
parallel-group 
N=52 (T2D) (32M, 
20 F);  
Groups: 
1). VC: n=12 
(aged 56±9 y);  
2). Vitamin E: 
n=12 (aged 56 ± 
14 y);  
3). Tomato Juice: 
n=15 (aged 63±8 
y);  
4). Placebo: n=13 
(aged 60 ± 6 y) 
DD: 1.9 ± 1.3 y 
HbA1c: 6.7 ± 1.0 
Drugs: oral anti-
diabetics; anti-
hypertensives; aspirin 
BMI: 30.7 ± 6.3 
SBP: 78 ± 27mm Hg 
DBP: 123 ± 40mm Hg 
TC: 5.96 ± 1.16 mmol/l 
TG: 1.75 ± 1.64 mmol/l 
Glu: 8.7 ± 1.5 mmol/l 
4-weeks 
treatment 
with: 500mg 
VC/day or 
800IU vitamin 
E/day or 
500ml tomato 
juice/day or 
placebo (all 
groups: a 4-
week placebo 
run-in period) 
LDL-oxidation (lag 
time), C-RP, TC, 
HDL-C, LDL-C, 
HbA1c, plasma 
glucose, sVCAM-1, 
ICAM-1, α-
tocopherol; plasma 
VC 
No effect of VC on 
any measures 
VC dose 
possibly too 
low; baseline TG 
lower in VC vs. 
other groups; 
ACE inhibitor 
drug biased in 
tomato juice 
group; study 
possibly 
underpowered; 
study not fully-
blinded 
In plasma: 
VC group: 
37.7 ± 12.4, 
64.7 ± 14.3 
Placebo group: 
27.3 ± 15.4, 
29.7 ± 21.1 
 
 
(*vitamin C treated subject data; ** relevant to insulin sensitivity, glycaemic control, fasting glucose, fasting insulin & oxidative stress; DD - Diabetes 
duration; SBP – systolic blood pressure; DBP – diastolic blood pressure; TC – total cholesterol; LDL-C – low density lipoprotein cholesterol; HDL-C – high 
density lipoprotein cholesterol; TG – triglycerides; BMI – body mass index (in kg/m2); HbA1c – glycosylated haemoglobin; GSH – glutathione; GSSG – 
oxidized glutathione; HOMA - homeostasis model assessment; QUICKI - quantitative insulin sensitivity check index; VC – vitamin C; sVCAM-1 – soluble 
vascular cellular adhesion molecule-1; Glu – Fasting glucose; C-RP – C-reactive Protein; ICAM-1 – intercellular adhesion molecule 1; ACE – angiotensin-
converting enzyme; TBARS – thiobarbituric acid reactive substances)
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1.5.5. Glucose clamp and glucose tracer methods for measurement of insulin 
sensitivity in people with T2D 
 
Glucose clamp procedures have been used comprehensively in the past to evaluate 
in vivo insulin sensitivity of people with T2D (215). The basic concept of the glucose 
clamp is to assess glucose metabolism at an integrated whole-body level when both 
insulin and glucose levels are kept constant (215).  In relation to the commonly used 
hyperinsulinaemic euglycaemic clamp, plasma glucose concentrations are clamped 
at euglycaemic levels (normal non-diabetic fasting levels) through the infusion of 
insulin and variable amounts of glucose. This procedure can be further coupled with 
the infusion of glucose tracers to estimate the relative contributions of endogenous 
glucose production (EGP) and peripheral glucose disposal to whole-body glucose 
metabolism. Glucose tracers share identical kinetic characteristics to glucose, but are 
distinguishable from glucose for purposes of measurement (216).  Several different 
types of tracer-based methodologies have been used in studies of people with T2D 
to evaluate peripheral glucose disposal and EGP (readers are referred to (216) for a 
comprehensive review).  
The hot glucose infusion (Hot-Ginf) tracer technique contrasts to the cold glucose 
infusion (Cold-Ginf) tracer technique previously used in some vitamin C trials 
involving people with T2D (168, 169) by the additional enrichment of the variably 
infused glucose used to “clamp” plasma glucose with a small calculated amount of 
glucose tracer. The addition of tracer to the glucose infusate enables the 
maintenance of a constant level of plasma tracer enrichment during the clamp 
procedure. Moreover, the Hot-Ginf method minimizes errors associated with tracer 
compartmental gradients that can occur during the glucose clamp (217). During the 
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hyperinsulinaemic, euglycaemic clamp, the infusion of non-labelled glucose (Cold-
Ginf method) rapidly dilutes plasma tracer levels. This dilution of plasma glucose 
tracer is not reflective of tracer kinetics in the slower mixing interstitial glucose pool, 
in which concentrations can remain elevated for some time (217).  Furthermore, 
plasma glucose tracer level measured might not reflect true glucose movements 
during Cold-Ginf. Since tracer moves down a concentration gradient, some tracer 
could move from the interstitial glucose pool back into the plasma pool during Cold-
Ginf (217). This is unlike the true movement of glucose, which is from the plasma pool 
into the interstitial pool and finally into cells (217).  
Studies utilizing the Cold-Ginf method to calculate WBGD and EGP often report 
unrealistic negative values for EGP which can be overcome by using the Hot-Ginf 
method (217). Moreover, the Cold-Ginf method overestimates EGP suppression and 
underestimates WBGD compared to the Hot-Ginf method. Given that EGP is defective 
in insulin-stimulated states in T2D (218), previous studies utilizing the Cold-Ginf 
tracer in people with T2D might have overestimated hepatic insulin sensitivity. 
Studies are therefore required that couple Hot-Ginf glucose tracer methods with the 
hyperinsulinaemic, euglycaemic clamp to more accurately assess effects of vitamin C 
therapy on WBGD and EGP in people with T2D.  
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1.5.6. Summary and significance #5  
 
Vitamin C supplementation could potentially be a safe antioxidant treatment 
strategy for reducing ROS levels and improving insulin sensitivity in people with 
T2D. Studies investigating effects of vitamin C supplementation on levels of insulin 
sensitivity, markers of oxidative stress and glycaemic control have produced mixed 
results in people with T2D. Negative findings might be a result of an inadequate 
dosage and/or duration of vitamin C supplementation employed in studies. To 
better investigate the efficacy of vitamin C supplementation in people with T2D, 
randomized controlled trials involving high dose (≥1 g/day) and long-term (≥ six 
weeks) vitamin C that also incorporate hyperinsulinaemic, euglycaemic clamps and 
Hot-Ginf glucose tracer methods are required.  
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1.6. Effects of vitamin C supplementation on vitamin C status in T2D 
1.6.1. Assessing vitamin C levels and vitamin C status 
 
At body saturation point it has been estimated that the total body pool of vitamin C 
is approximately 1500 mg (219, 220), with the majority found in liver and muscle by 
virtue of their relative mass (221).  The approximate concentrations of vitamin C in 
various tissues in humans are shown in Table 1.3. Tissue concentrations range from 
relatively high levels (>25 mg/100 g tissue) in adrenal glands, pituitary glands and eye 
lens to relatively low levels (<5 mg/100 g tissue) in skeletal muscle, testes and thyroid 
(221).  
 
Table 1.3. Approximate tissue distribution of ascorbic acid in adult humans 
Tissue Approximate concentration 
(mg/100 g tissue) 
Adrenal glands 30-40  
Pituitary gland 40-50 
Liver 10-16 
Spleen 10-15 
Lungs 7 
Kidneys 5-15 
Testes 3 
Thyroid 2 
Heart Muscle 5-15 
Skeletal Muscle 3-4 
Brain 13-15 
Pancreas 10-15 
Eye Lens 25-31 
Plasma 0.4-1.0 
Saliva 0.07-0.09 
 
(from (221)) 
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There are no reliable functional indices of vitamin C status (222). Thus, static 
measurements including serum, leukocyte and plasma vitamin C levels are commonly 
used to assess vitamin C adequacy in humans (222). Plasma concentrations of AA in 
healthy individuals typically range from 5-90 μmol/l (223). In the National Health and 
Nutrition Examination Survey (NHANES) II study, deficient vitamin C levels were 
defined as serum levels <11.3 μmol/l, “normal” levels of vitamin C were defined as 
serum levels >22.7 μmol/l, while “saturated” levels were defined as serum levels 
>56.8 μmol/l (224).  
In contrast to plasma and serum vitamin C levels, leukocyte vitamin C levels are 
considered more representative of tissue vitamin C levels (222). In healthy 
individuals, AA levels in circulating blood cells (leukocytes, monocytes and platelets) 
were found to be “saturated” after prolonged intakes of 100 mg-400 mg vitamin 
C/day (225, 226). Yamada et al. (227) reported similar levels of plasma AA in healthy 
controls, uncomplicated patients with T2D and in patients with complicated T2D.  
However in the same study leukocyte levels of AA were found to be lower in the 
people with uncomplicated T2D when compared with healthy controls; and lower still 
in the people with complicated T2D when compared to individuals with 
uncomplicated T2D (227).  
It is unclear what the best measure of vitamin C adequacy might be in people with 
T2D.  Compared to plasma levels, leukocyte levels are less sensitive to short-term 
fluctuations in dietary vitamin C intake (228) and drop less rapidly with advancing 
deficiency (229). On the other hand, establishing levels of vitamin C adequacy on 
leukocyte concentrations could be limited due to their low relative ascorbic acid 
holding capacity and lower intake saturation threshold compared to plasma (225, 
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226, 230). Moreover, leukocyte vitamin C level has an unclear relationship with 
ascorbic acid deficiency and predicted saturation of some tissues (231-233). 
Based on modelling, skeletal muscle accounts for approximately 65 % of the body’s 
vitamin C stores (219, 220, 234). Moreover, a recent study in healthy individuals with 
low baseline vitamin C levels demonstrated a stronger correlation of skeletal muscle 
vitamin C content with both dietary vitamin C intake and plasma vitamin C levels 
when compared with leukocyte vitamin C content during repletion (233). Thus, 
skeletal muscle vitamin C concentration could potentially serve as a better marker of 
total body vitamin C content than either leukocyte or plasma vitamin C alone.  
Skeletal muscle concentrations of vitamin C have not yet been investigated in people 
with T2D. Skeletal muscle vitamin C concentrations in humans are often reported to 
be between 3-4 mg vitamin C/100 g wet weight tissue (221, 235, 236) as reported in 
human cadavers (234). In contrast, a more recent investigation in healthy humans 
found ascorbate levels to be ≈ 1.2 mg/100 g tissue after vitamin C repletion in 
previously vitamin-C deficient males (233). Differences in measurement and assay 
techniques for determination of vitamin C concentrations might complicate 
comparisons between these studies.  Schaus (234) measured levels of total vitamin C 
(AA + DHA) using a 2,4-dinitrophenylhydrazine-based colorimetric assay while Carr et 
al. (233) measured levels of ascorbic acid using high performance liquid 
chromatography (HPLC) with electrochemical detection.  Future research 
incorporating more consistent methodology for assessing vitamin C levels in skeletal 
muscle is required in order to establish an absolute concentration that might 
constitute an “adequate” level in skeletal muscle. 
 
 
Literature Review 
51 
 
1.6.2. Effects of vitamin C supplementation on vitamin C status in T2D 
 
Increasing vitamin C to very high levels in the blood via oral dosing is limited by the 
saturable processes of intestinal absorption (237, 238) and renal reabsorption of 
ascorbic acid (223, 239, 240). Separate studies in otherwise healthy men and women 
deplete in vitamin C collectively demonstrated that bioavailability of orally consumed 
vitamin C was reduced at intakes above 100-200 mg/day (225, 226). Moreover, 
plasma levels of vitamin C were found to peak at 400 mg/day in women (226) and 
1000 mg/day in men (225), with excretion of vitamin C in urine increasing markedly 
at doses of 500 mg or more.  
Quantification of body vitamin C levels before and after supplementation is 
important in randomized controlled trials that investigate effects of vitamin C so as 
to confirm that supplementation was effective at increasing vitamin C 
concentrations. From the studies presented in Table 1.2 (on page 37), it is clear that 
not all studies quantified body levels of vitamin C. Moreover, there does not appear 
to be any clear relationship between the relative or absolute reported increases in 
plasma or leukocyte levels of vitamin C from baseline and improvements in markers 
of oxidative stress, insulin sensitivity or glycaemic control in people with T2D (169, 
203-206, 208, 211). It should be noted however that comparisons between the 
studies outlined in Table 1.2 might be complicated by differences in baseline 
participant metabolic characteristics, baseline participant vitamin C levels and study 
designs employed.  
Skeletal muscle vitamin C concentrations of people with T2D have not yet been 
quantified following vitamin C supplementation. In healthy volunteers with 
apparently normal baseline plasma vitamin C levels, skeletal muscle vitamin C 
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concentration increased significantly by 41 % after seven days of supplementation 
with an antioxidant combination of 1500 mg vitamin C + 120 mg coenzyme Q + 345 
mg α-tocopherol (241). On the other hand, a recent bioavailability study in otherwise 
healthy males with low baseline ascorbate levels reported an increase in skeletal 
muscle ascorbate levels by ≈ 350 % over baseline following 42-days supplementation 
with only 53 or 212 mg of vitamin C (233). Baseline vitamin C levels might confound 
comparisons in these studies however. Participants in the study by Carr et al. (233) 
were marginally deficient in plasma vitamin C prior to supplementation while 
participants in the study of Hellston et al. (241) had an adequate mean plasma 
vitamin C concentration (242). The dose-response tissue vitamin C saturation curve 
is likely characterized by a steep portion (at low tissue vitamin C concentrations) and 
a flatter portion (at high tissue vitamin C concentrations) (225, 226). Therefore, it 
could be speculated that participants in the study by Carr et al. (233) were positioned 
on the steeper portion of the skeletal muscle dose-response curve while participants 
in the study by Hellston et al. (241) were on the flatter portion of this curve.  Thus, 
despite a lower vitamin C supplementation dose in the study by Carr et al. (233) 
compared with Hellston et al. (241), the relative increase in skeletal muscle vitamin 
C concentration was greater following supplementation. 
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 1.6.3. Summary and significance #6  
 
Plasma and/or leukocyte levels of vitamin C provide useful, but limited measures 
of body vitamin C content. Skeletal muscle vitamin C concentration might represent 
a potentially better indicator of body levels given that skeletal muscle contains the 
majority of the body’s vitamin C. However it is unclear from studies what 
concentration might constitute an “adequate” concentration of vitamin C in 
skeletal muscle. Measurement of vitamin C concentrations in skeletal muscle 
before and after vitamin C supplementation is important in antioxidant studies 
focussing on effects in skeletal muscle. Measurement of changes in vitamin C 
concentration following supplementation can provide confirmation that vitamin C 
supplementation is able to increase intramuscular vitamin C content so as to exert 
its antioxidant effects in muscle. 
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1.7. Skeletal muscle AA versus DHA levels in T2D 
1.7.1. Skeletal muscle levels of AA and DHA 
 
It is widely believed that DHA is present only at very low levels in plasma of healthy 
individuals (i.e. <2 % of total vitamin C) (223, 243). However, DHA levels as high as 
10-60 % of total plasma vitamin C has been reported in the literature in various 
population groups (244). In contrast to plasma, there is a paucity of data reporting 
on AA and DHA levels in human tissues. Like plasma it is widely believed that the 
majority of vitamin C in tissues is in the reduced AA form compared with the oxidized 
DHA form (221, 223, 243). However mixed data exists in animals, suggesting that the 
relative AA and DHA content of tissues might differ both within and between 
different species (245-248).  In guinea pigs, who like humans cannot synthesize 
ascorbic acid endogenously, the majority of vitamin C in the adrenal glands, brain, 
testis and liver after being fed a diet adequate in vitamin C was reported to be in the 
reduced, AA form; whereas the majority of vitamin C in the heart, spleen, thymus and 
skeletal muscle was in the oxidized DHA form (246, 247).  
Improper handling or treatment of samples prior to analysis has been suggested to 
result in increased oxidation of AA to DHA and diketogulonic acid, thus leading to 
artifactually increased DHA levels and a potential irreversible loss of vitamin C (243). 
Poor sample handling after collection includes a failure to minimize sample contact 
with oxygen, and a failure to freeze, acidify, and combine the sample with a metal-
chelating agent immediately after collection (243). Thus, a failure to minimize sample 
handling effects and artifactual AA oxidation might confound some of the findings 
reporting elevated DHA concentrations. 
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To our knowledge, levels of AA and DHA have not yet been investigated in skeletal 
muscle of people with T2D. Given that skeletal muscle is a key site of oxidative stress 
and insulin resistance in T2D, determining levels of both the reduced AA and oxidized 
DHA forms in muscle might be important in characterizing the oxidative stress mileu 
in people with T2D.  
 
1.7.2. Skeletal muscle DHA/AA: a marker of oxidative stress in T2D? 
 
Lower levels of AA and/or higher levels of DHA have been reported in plasma of 
people with T2D when compared with non-diabetic individuals (168, 191, 192, 194, 
249-251). One possible explanation for this discrepancy between healthy individuals 
and people with T2D is an increased oxidation of AA to DHA as a result of oxidative 
stress in people with T2D (223).  
Plasma DHA/AA has previously been regarded as a marker of oxidative stress in T2D 
(249, 252). An increased DHA/AA ratio in plasma was reported in people with T2D 
compared with non-diabetics (249, 252). Three weeks of vitamin C supplementation 
(500mg twice daily) increased plasma AA and reduced DHA/AA in people with T2D 
and in non-diabetics (249). However when supplementation continued for six weeks, 
the improved levels of AA and DHA/AA observed at three weeks had reverted back 
towards baseline levels in the people with T2D but not in the healthy participants 
(249). In relation to these findings, the authors suggested a disturbance in AA 
metabolism in the people with T2D (249). Compliance was not reported in the latter 
study however. Thus it remains possible that compliance with supplementation 
deteriorated over time in the people with T2D. Furthermore, other markers of 
oxidative stress and tissue DHA/AA levels were not assessed during this study. 
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Considering that plasma levels of vitamin C are sensitive to short-term dietary 
fluctuations, tissue levels of DHA/AA might represent a better marker of oxidative 
stress than plasma DHA/AA. In an experimental animal model of diabetes (253), 
significantly reduced levels of AA and increased levels of DHA were found in diabetic 
liver tissue compared with normal liver tissue. Increased tissue levels of DHA but 
reduced tissue levels of AA in diabetes are believed to be a result of increased cellular 
oxidation of AA to DHA (194) and/or due to impaired recycling of cellular DHA to AA 
(253). There is a current lack of data reporting on tissue DHA/AA levels in humans. 
Given that skeletal muscle constitutes the majority of body vitamin C, evaluation of 
the DHA/AA redox ratio in skeletal muscle might offer further insight into the 
oxidative stress mileu of human tissues. Moreover, skeletal muscle DHA/AA could 
potentially serve as a useful marker of tissue oxidative stress in people with T2D.  
 
1.7.3. Summary and significance #7  
 
Oxidative stress might increase the DHA/AA ratio in plasma and tissues of people 
with T2D through increased oxidation of AA to DHA. Assessment of intramuscular 
levels of AA, DHA and DHA/AA in people with T2D is currently unexplored. It is of 
interest to quantify these levels in skeletal muscle of people with T2D given the 
importance of skeletal muscle as a site of oxidative stress and dysfunctional insulin 
action in T2D.  Studies investigating changes in intramuscular DHA/AA following 
vitamin C supplementation in association with other markers of oxidative stress 
could help to better establish intramuscular DHA/AA as an important redox marker 
of oxidative stress in T2D. 
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1.8. Vitamin C transporters in skeletal muscle 
1.8.1. AA transport in skeletal muscle: effects of T2D and vitamin C 
supplementation 
 
Vitamin C levels in the body are regulated by vitamin C transporters. Vitamin C in its 
reduced AA form can be taken up by most organs via sodium-dependent vitamin C 
transporters (SVCTs) including SVCT1 and SVCT2 (254). Uptake occurs with a 
stoichiometry of two sodium cations transported for every ascorbate anion co-
transported (255, 256). The high-capacity, low-affinity carrier SVCT1, expressed 
predominantly in epithelial cells and in the liver and kidney (254) (Figure 1.10), 
appears to be mainly involved in absorption of dietary ascorbic acid and in kidney-
based reabsorption (257). SVCT1 thus appears to play a role in maintaining circulating 
levels of AA and in regulating whole-body vitamin C homeostasis (257). On the other 
hand, expression of the low-capacity, high-affinity carrier SVCT2 is more widespread, 
being expressed in diverse tissues and cells such as the brain, choroid plexus, 
Schwann cells, skeletal muscle, spleen and endothelial cells (184, 254, 258) (Figure 
1.10). SVCT2 appears to be primarily involved in maintaining intracellular AA levels in 
metabolically active tissues (257).  
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Figure 1.10. Tissue distribution of human SVCT1 and SVCT2 expression 
 Solid lines indicate SVCT1 distribution; broken lines indicate SVCT2 distribution 
(from (259))  
 
Gene and protein expression of SVCT2 reflects ascorbic acid transport in skeletal 
muscle cells (236, 260). Previous studies investigating transport kinetics of AA in 
C2C12 mouse cells calculated AA uptake in time-dependent and concentration-
dependent experiments using Michaelis-Menten kinetics (236, 260). These studies 
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matched AA transport activity with protein and gene expression levels of SVCT2 in 
muscle (236, 260). 
Levels of SVCT2 have been little explored in human skeletal muscle. Early studies 
using northern blot techniques failed to detect SVCT2 mRNA in human skeletal 
muscle (261). However, Low et al. (258) recently detected SVCT2 protein in human 
lumbar skeletal muscles using immunohistochemistry. Intracellular levels of AA might 
exert a negative feedback-type regulation of SVCT abundance, such that expression 
of SVCTs are increased when intracellular levels of AA are low but are reduced when 
levels of AA are high (262, 263). Expression of SVCT2 in skeletal muscle might also be 
regulated by intracellular redox state (236). In vitro studies utilizing murine skeletal 
muscle cell lines have shown that when intracellular levels of oxidants increase, 
expression of SVCT2 is also increased (236, 260). Conversely, SVCT2 transporter 
expression was shown to be down-regulated when muscle cells were treated with 
the antioxidant lipoic acid (236).  
Therefore, given the above regulatory characteristics of SVCT2, it could be 
hypothesized that SVCT2 transporter expression will be increased in skeletal muscle 
in people with T2D as a consequence of intracellular oxidative stress. Moreover, it 
could also be hypothesised that expression levels of SVCT2 will be decreased in 
diabetic skeletal muscle following AA supplementation due to increased intracellular 
antioxidant levels and/or reduced oxidant levels. Studies of vitamin C 
supplementation in people with T2D are now required to test out these hypotheses. 
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1.8.2. DHA transport in skeletal muscle: Effects of T2D and vitamin C 
supplementation  
 
Unlike AA, transport of DHA occurs via facilitative transport by hexose transporters. 
Specifically, GLUT1, GLUT3 and GLUT4 have been implicated in the transport of DHA 
in vitro (264-266).  DHA is believed to be rapidly reduced to AA following cellular 
uptake (184). In conditions characterized by chronic oxidative stress such as T2D, 
cellular uptake of DHA might be of increased importance to facilitate a cellular supply 
of AA since the pro-oxidative environment might lead to increased oxidation of 
extracellular AA to DHA (184).  
Given its predominance as a glucose transporter in skeletal muscle, GLUT4 might play 
an important role in mediating skeletal muscle DHA transport. It has been 
demonstrated in vitro that DHA uptake by GLUT4 is increased markedly following 
insulin stimulation (266).  However an impaired insulin-mediated translocation of 
GLUT4 to the plasma membrane in people with T2D could impair DHA transport as 
well as glucose transport in skeletal muscle.  
GLUT1 and GLUT3 are expressed at low levels in human skeletal muscle (267, 268). 
Studies have reported reduced (44) or unaltered (42, 45, 267, 269) protein levels of 
GLUT1 in membrane fractions of muscle in people with T2D. Decreased expression of 
GLUT3 in skeletal muscle of severely insulin-resistant individuals has also been found 
(267).  However, it has been argued that the presence of erythrocytes and perineurial 
cells in muscle samples could result in artifactually elevated levels of GLUT1 and 
GLUT3 respectively, thus complicating findings of these studies (268). 
DHA uptake by skeletal muscle cells is impaired by high glucose levels in vitro (270). 
Specifically, reduced DHA uptake in rat L6 skeletal muscle cells incubated with 
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glucose was found to be the result of a combination of competition between glucose 
and DHA for available GLUT transporters and a hyperglycaemia-mediated down-
regulation of GLUT1 expression (270). Hyperglycaemia associated with T2D might 
therefore impair cellular uptake of DHA by muscle cells via a direct down-regulation 
of GLUT1 transporter levels and/or through an increased competition between 
glucose and DHA for available GLUT transporters. This could in turn promote 
decreased intracellular AA levels. Effects of vitamin C supplementation on GLUT 
expression levels in skeletal muscle of people with T2D has not yet been explored.  
Given the non-specificity of GLUT transporters for DHA, it would be difficult to 
ascertain if effects of vitamin C supplementation on GLUT transporter expression 
were a result of direct (DHA-related) or indirect (glucose metabolism-related) 
modulation. Additional investigations of DHA transport to protein expression 
analyses would be required to further elucidate direct versus indirect effects of 
supplementation on GLUT expression in skeletal muscle. 
 
1.8.3. Summary and significance #8  
 
Skeletal muscle vitamin C transporters regulate intramuscular vitamin C 
concentrations. Assessment of vitamin C transporter levels in T2D could therefore 
be important in understanding altered tissue levels of vitamin C in T2D. The effects 
of vitamin C supplementation on gene and protein expression of SVCT2 and GLUT 
transporters in skeletal muscle in people with T2D are presently unknown. 
Expression of SVCT2 might be increased in skeletal muscle of people with T2D, 
consistent with decreased levels of AA and/or increased levels of ROS. Moreover, 
vitamin C supplementation could potentially normalise elevated SVCT2 expression 
in people with T2D.  
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1.9. Effects of vitamin C supplementation on nitric oxide metabolism 
1.9.1. Skeletal muscle nitric oxide synthase levels in T2D 
 
Nitric oxides (NO) are bioactive chemicals synthesized endogenously from L-arginine 
via various nitric oxide synthases (NOS) (271) (Figure 1.11A). NO acts as a signalling 
molecule in the regulation of central biological processes in almost all tissues (272). 
Both endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase 
(nNOS) are expressed in skeletal muscle (273). Inducible nitric oxide synthase (iNOS) 
is not normally expressed abundantly in skeletal muscle but can be induced in 
response to inflammatory stress (142), obesity (274) and endotoxin-induced stress 
(273). Impaired NO production in skeletal muscle has been implicated in reduced 
recruitment of microvasculature and glucose uptake in response to insulin 
stimulation (275-277).  NO appears to potentiate glucose transport in skeletal muscle 
via a signalling pathway involving the activation of guanylate cyclase and increased 
cyclic GMP levels (278). Impaired skeletal muscle basal and insulin-stimulated total 
NOS activities were found in people with T2D (279, 280). Altered NOS activity found 
in T2D appears to be isoform-specific however, with endothelial NOS (eNOS) activity 
being reduced but inducible NOS (iNOS) activity being increased (142).  
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Figure 1.11. Nitric oxide production by human eNOS  
Modelling of human eNOS activity. A: Nitric oxide (NO) and L-citrulline (L-Cit) are 
formed via eNOS from L-arginine (L-Arg) and oxygen (O2). Tetrahydrobiopterin (BH4) 
serves as a cofactor for NO production by NOS. Ascorbic acid (AscH) can act to 
maintain BH4 in its reduced state by reducing the BH4 radical trihydrobiopterin (BH3) 
back to BH4. B: Increased oxidative stress, in particular peroxynitrite (ONOO-) can 
cause oxidation of BH4 and promote uncoupling of eNOS activity. This enhances the 
formation of superoxide (·O2-) rather than NO via eNOS (From (281)).  
 
NO is also capable of reacting with ·O2- in tissues to form ONOO-, a highly reactive 
nitrogen species (RNS) (111). Thus, although NO production appears to be beneficial 
in normal glucose metabolism, it can produce detrimental effects at high 
concentrations. In particular, NO levels can increase dramatically in response to iNOS 
induction (142). iNOS-induced NO can react with ·O2-, in turn increasing ONOO- levels 
rapidly and causing impaired skeletal muscle insulin sensitivity through nitration of 
key insulin signalling proteins (282-284).  Therefore, measurement of levels of 
specific NOS isoforms could prove valuable in the assessment of NO metabolism in 
diabetic skeletal muscle when compared with levels of total NO and total NOS activity 
alone. 
B A 
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1.9.2 Effect of vitamin C supplementation on nitric oxide synthase levels in T2D 
 
Through its antioxidant scavenging of ·O2-, ascorbic acid is theoretically able to 
minimize the interaction between ·O2- and NO and reduce ONOO- formation. Another 
outcome of this antioxidant action is that less NO is inactivated by ·O2- and more is 
available for biological activity in skeletal muscle (285). ROS/RNS including ·O2- and 
ONOO- were shown to inactivate nNOS via oxidation of the NOS cofactor 
tetrahydrobiopterin (BH4), causing impaired NO production and increased ·O2- 
production in human kidney cells transfected with rat nNOS (286). On the other hand, 
repletion of decreased BH4 levels resulting from excess ·O2- and ONOO- formation can 
restore nNOS activity and NO production in these cells (286). ONOO--induced 
uncoupling of eNOS via BH4 oxidation has also been demonstrated in cultured BAEC 
cells (287) (Figure 1.11B). 
A proposed specific role of ascorbic acid in vivo additional to its general antioxidant 
effects is to maintain BH4 in its reduced state (288, 289). Ascorbic acid is able to 
reduce the BH4 radical (trihydrobiopterin, BH3) back to BH4 and prevent eNOS 
uncoupling (287) (Figure 1.11A). Enhanced NOS activity and BH4 levels were found in 
aortic walls of C57BL/6J mice following prolonged oral vitamin C supplementation 
(290). Furthermore, supplementation with ascorbic acid, L-arginine and BH4 was 
found to increase calcium-dependent NOS (nNOS & eNOS) activity and eNOS protein 
expression; and reduce nitrotyrosine levels (a marker of ONOO- stress) in skeletal 
muscle of ischaemic mice (291). In this latter study, the addition of vitamin C to 
combined L-arginine and BH4 supplementation potentiated total eNOS protein 
expression but did not further increase NOS activity in ischaemic skeletal muscle. 
Interestingly, ascorbic acid has also been shown to stimulate eNOS activity in human 
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endothelial cells through a mechanism involving activation of AMP-kinase (AMPK) 
that is independent of BH4 (292).  
In light of findings of impaired NOS activity in T2D and the potential mechanistic role 
of ascorbic acid in NO metabolism through BH4-related and/or antioxidant-related 
effects, an investigation of effects of vitamin C supplementation on NOS activity and 
NOS isoform expression levels in skeletal muscle of people with T2D is warranted. 
 
1.9.3. Summary and significance #9 
 
In addition to its general antioxidant actions, vitamin C also appears to play an 
important role in normal nitric oxide metabolism by maintaining the NOS cofactor 
BH4 in its reduced state. Vitamin C supplementation could potentially enhance 
impaired skeletal muscle NOS activity in people with T2D, thus facilitating 
enhanced glucose uptake through improved nitric oxide production and decreased 
ROS/RNS-induced inactivation of key components of insulin signalling 
transduction. Studies investigating effects of vitamin C supplementation on 
markers of oxidative stress, antioxidant enzymes, NOS activity and activation levels 
of key insulin-signalling subunits in skeletal muscle could prove useful in linking 
redox-related mechanisms of action of vitamin C in skeletal muscle with 
improvements in insulin signalling and insulin sensitivity. 
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1.10 Overall summary & significance 
 
Antioxidant vitamin C therapy offers the potential of a relatively safe and effective 
treatment for skeletal muscle insulin resistance in T2D through its scavenging of 
excess ROS, a key underlying factor in the pathophysiology of T2D.   
Clinical studies investigating effects of antioxidant vitamin C supplementation on 
insulin resistance, glycaemic control and oxidative stress in people with T2D have 
reported mixed findings. Studies finding no benefits were arguably too short in 
duration (<6 weeks) and/or used vitamin C dosages that were too low (<1 g/day) to 
elicit improvements in oxidative stress and clinical outcomes. Furthermore, the effect 
of vitamin C supplementation on insulin resistance in skeletal muscle versus liver 
using the hyperinsulinaemic, euglycaemic clamp coupled to “Hot-Ginf” glucose tracer 
techniques in people with T2D has not been studied to date.   
Since skeletal muscle is a major site of ROS production and insulin resistance in 
people with T2D, investigations looking at the antioxidant effects of vitamin C at this 
pivotal site are warranted. Currently, effects of vitamin C supplementation on levels 
of vitamin C, oxidative stress, insulin signalling and activation of NOS in skeletal 
muscle have not been explored in people with T2D.  Furthermore, the effects of 
vitamin C supplementation on levels of oxidized versus reduced forms of vitamin C 
and expression of vitamin C transporters SVCT2 and GLUT1 in skeletal muscle, which 
are important in the context of oxidative stress and regulation of vitamin C levels 
respectively, have not yet been investigated in people with T2D. Future studies 
targeting these research shortcomings are now required. 
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1.11 Research aims, hypotheses and conceptual overview 
1.11.1 Research Aims 
 
To investigate the effects of chronic, high dose oral vitamin C supplementation on: 
1) Glucoregulatory control in people with T2D, including: 
x Skeletal muscle insulin sensitivity and endogenous glucose production  
(primary measures) 
x Clinical diabetes measures including HbA1c, fasting glucose, fasting insulin 
and lipids (secondary measures) 
2) Vitamin C concentrations in people with T2D, including: 
x Concentrations of total vitamin C in skeletal muscle and plasma  
3) Oxidative stress in people with T2D, including: 
x Skeletal muscle levels of F2-Isoprostanes, GSH/GSSG and DCFH oxidation 
4) Levels of oxidized versus reduced forms of vitamin C in people with T2D, 
including: 
• Skeletal muscle levels of ascorbic acid and dehydroascorbic acid 
5) Vitamin C transporter expression levels in people with T2D, including: 
x SVCT2 protein abundance in skeletal muscle  
6) Nitric oxide synthase levels in people with T2D, including: 
x Activation and expression levels of nitric oxide synthase in skeletal muscle  
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1.11.2. Research Hypotheses 
 
1) High-dose and long-term vitamin C supplementation will improve skeletal 
muscle insulin sensitivity and insulin-stimulated non-oxidative glucose 
metabolism in people with T2D 
2) Vitamin C supplementation will increase vitamin C concentrations in skeletal 
muscle and plasma of people with T2D 
3) Vitamin C supplementation will reduce ROS/RNS levels and improve markers 
of oxidative stress including F2-Isoprostanes, GSH/GSSG and DCFH oxidation 
in skeletal muscle of people with T2D 
4) Vitamin C supplementation will increase AA levels and improve the DHA/AA 
ratio in skeletal muscle and plasma of people with T2D 
5) Vitamin C supplementation will promote a decrease in protein expression of 
sodium-dependent vitamin C transporter SVCT2 in skeletal muscle of people 
with T2D 
6) Vitamin C supplementation will increase total NOS activity in skeletal muscle 
of people with T2D 
 
1.11.3. Conceptual overview of research 
 
These research aims and hypotheses were addressed through the undertaking of a 
clinical trial that investigated effects of vitamin C supplementation in people with T2D 
(Figure 1.12). 
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Figure 1.12. Conceptual overview of thesis research project 
Key foci of aims and hypotheses of the thesis relate to data obtained from a clinical 
trial of vitamin C supplementation in people with T2D 
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2.0. VITAMIN C SUPPLEMENTATION IN HEALTHY MALES 
 
2.1. Background 
 
Prior to the major project of this thesis, a study was undertaken in healthy individuals 
in whom several key skeletal muscle measurements were made.  The study was 
undertaken as part of an honours project by student researcher, Raquel Baptista. The 
study investigated the bioavailability of high dose oral vitamin C supplementation in 
skeletal muscle of healthy young males. Key targets of investigation were muscle and 
plasma vitamin C concentrations, skeletal muscle antioxidant and oxidative stress 
levels, and skeletal muscle SVCT2 transporter expression.  The study provides insights 
into effects of vitamin C supplementation in basal human skeletal muscle, which is of 
relevance to the major project of the thesis.  Study participant recruitment and data 
collection was undertaken by Raquel Baptista; and the project was conceived and 
designed by Dr Glenn Wadley.  Sample analyses of vitamin C concentration and 
antioxidant enzyme levels as detailed within a manuscript recently accepted in Free 
Radical Biology and Medicine Journal (293) were conducted by both Raquel Baptista 
and the current author. SVCT2 western blotting was undertaken solely by the current 
author. The development and optimisation of all analyses including the measurement 
of plasma and skeletal muscle vitamin C concentrations using HPLC, the antioxidant 
and oxidative stress measurements, and SVCT2 western blotting were undertaken by 
the current author. Manuscript preparation was also predominantly completed by 
the current author. Thus, this chapter of the thesis has been devoted to aspects of 
this research study in which the current author had a major contribution. 
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2.2. Introduction 
 
Vitamin C is a potent water-soluble antioxidant that scavenges ROS and reduces 
oxidative stress in vitro and in vivo (176, 178, 179). Skeletal muscle contains the 
largest proportion (~65 %) of total body vitamin C (219, 234) with approximately 3-4 
mg ascorbic acid per 100 g of tissue (234). Skeletal muscle is also a key site of ROS 
production (117) and intramuscular ascorbic acid likely acts to reduce elevated 
muscle ROS levels (260), which can occur acutely during bouts of physical exercise 
(116) and chronically in individuals with insulin resistance (64). High dose antioxidant 
vitamin C supplementation could potentially benefit individuals with skeletal muscle 
and systemic oxidative stress including people with T2D (141, 169). Oral vitamin C 
supplementation increases skeletal muscle vitamin C concentrations in humans (233, 
241). However, the time course of vitamin C accumulation in skeletal muscle during 
high dose vitamin C supplementation is unclear and remains to be determined. 
Establishing a time course accumulation of vitamin C in skeletal muscle during 
supplementation could help to optimize vitamin C supplementation regimens that 
target skeletal muscle oxidative stress in disease. 
Transport of ascorbic acid into cells occurs via specific sodium-dependent vitamin C 
transporters (SVCT1 & SVCT2) at a stoichiometry of two sodium ions to one ascorbic 
acid molecule (255, 256). Of these transporters, only SVCT2 has been identified in 
mature skeletal muscle (258, 260). Studies in various human cell types suggest that 
SVCT2 expression is inversely regulated by intracellular ascorbic acid concentration 
(259, 262).  Thus, interventions aimed at increasing tissue vitamin C concentrations 
could potentially result in decreased tissue SVCT2 expression and attenuated vitamin 
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C accumulation in accordance with intracellular vitamin C content. In mice who are 
capable of producing vitamin C endogenously, oral vitamin C supplementation is 
largely ineffective at increasing tissue vitamin C concentrations due to strict control 
exerted by SVCT transporters (294). The situation could be different in humans, 
however, who are incapable of producing vitamin C endogenously. Moreover, the 
effect of vitamin C supplementation on SVCT2 protein expression in human skeletal 
muscle has not yet been investigated in vivo. 
In contrast to its potential clinical benefits, high dose vitamin C supplementation may 
be detrimental to exercise-related metabolic adaptations including mitochondrial 
biogenesis, antioxidant enzyme induction and insulin sensitization in healthy 
individuals (118, 295, 296). Compared with exercise training studies, there is a 
relative lack of investigation into basal effects of chronic antioxidant 
supplementation in healthy human skeletal muscle.  Strobel et al. (297) reported 
decreased markers of mitochondrial biogenesis in skeletal muscle of healthy rats 
following high dose antioxidant vitamin E supplementation that was independent of 
exercise training. It is possible therefore that redox changes induced by antioxidant 
supplementation could also impair skeletal muscle mitochondrial biogenesis and 
antioxidant concentrations basally in humans. Among the findings of Strobel et al. 
(297) was a decrease in skeletal muscle citrate synthase activity following antioxidant 
supplementation. Citrate synthase activity exhibits a strong association with 
mitochondrial content in healthy human skeletal muscle (298). Therefore, the 
measurement of citrate synthase activity before and after vitamin C supplementation 
can provide insight into effects of regular high dose vitamin C intake on mitochondrial 
content in skeletal muscle.   
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Given the potential for high dose vitamin C supplementation to modulate SVCT2 
expression, antioxidant concentrations, oxidative stress and mitochondrial content 
in skeletal muscle, studies in humans are required to clarify these issues. Thus, the 
aims of the present study were to firstly, investigate the time course effects of high 
dose vitamin C supplementation on vitamin C concentrations in skeletal muscle and 
plasma of healthy individuals; secondly, to investigate effects of vitamin C 
supplementation on SVCT2 transporter expression levels; and thirdly, to investigate 
effects of vitamin C supplementation on markers of oxidative stress, antioxidant 
concentrations and mitochondrial content in healthy individuals. 
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Materials and methods 
Subjects 
Healthy male participants (n=8) aged 18-40 years were recruited for the study 
through local community- and university- wide advertising. Potential participants 
completed a prior medical screening session and questionnaire to rule out any 
cardiovascular, pulmonary, renal or metabolic disease. Individuals were excluded if 
they were smokers, if they suffered from a bleeding disorder or heart murmur, if they 
were highly trained athletes or if they were consuming any vitamin supplements. This 
study was conducted according to the guidelines laid down in the Declaration of 
Helsinki and all procedures involving human subjects were approved by the Deakin 
University Human Research Ethics Committee (Ethics approval # 2011-021). Written 
informed consent was obtained from all subjects.  
 
Research design 
The study was a double-blinded, placebo-controlled trial that involved consumption 
of a capsule containing 500 mg ascorbic acid (capsule ingredients: 500 mg L-ascorbic 
acid, microcrystalline cellulose, vegetable cellulose, vegetable magnesium stearate; 
Solgar Inc., Leonia NJ) or a gelatine-based placebo capsule (ingredients: 560 mg 
gelatine, 8 mg calcium carbonate, vegetable magnesium stearate, vegetable 
cellulose; Solgar Inc., Leonia NJ) twice daily with morning and evening meals for six 
weeks. The study had a cross-over design and a wash-out period of at least four 
weeks separated the two six-week treatment arms (mean ± SEM wash-out: 44.1 ± 3.8 
days).  Treatment order was implemented in a randomized counterbalanced manner 
to participants. Concealment and randomization of treatments was undertaken by a 
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third party individual not directly involved in the trial. Vitamin C and placebo capsules 
were almost identical in appearance and were provided to participants in identical 
sealed opaque bottles. Supplements were commercially available products 
purchased through online retail stores. Capsules randomly selected from vitamin C 
and placebo bottles were tested for vitamin C content using HPLC. Vitamin C capsules 
tested in this manner were found to contain >99.9 % of the expected ascorbic acid 
level while placebo capsules contained 0 % ascorbic acid. The dose of vitamin C used 
in the present study (500 mg twice daily) was chosen because it represents a prudent 
upper limit for vitamin C intake based on estimations of a no observed adverse effect 
level (189). Moreover, this daily supplemental dose also represents a commonly 
recommended intake of vitamin C using commercially available vitamin C tablets and 
capsules. 
Participants visited the clinical research facility at Deakin University in Melbourne for 
morning testing (07:00) in an overnight (10-12h) fasted state (from 21:30) on days 0 
(baseline), 1, 7 and 42 during each six-week treatment period. To minimize effects of 
acute vitamin C ingestion on vitamin C measurements, vitamin C and placebo 
capsules were not consumed by participants on the morning of trials. Participants 
were asked to maintain their usual physical activity and dietary intake during the trial. 
Participants were requested to avoid any strenuous exercise during the 24 hours 
prior to each testing day. Participants were also asked to consume the same originally 
self-reported 24-h dietary intake on the day preceding each testing day. There were 
no differences reported for energy intake, macronutrient composition or vitamin C 
intake during the pre-trial 24-h period between any trial days when calculated using 
Foodworks® 2009 software (v.6.0.2562, Xyris Software, Kenmore Hills, Australia) 
(data not shown).  
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Muscle biopsies 
Muscle biopsy samples were taken on days 0, 1, 7 and 42 during supplementation 
periods for assessment of skeletal muscle vitamin C concentration, protein 
expression (SVCT2 and antioxidant enzymes), antioxidant enzyme activities and 
citrate synthase activity.  Muscle sampling was performed according to the 
percutaneous needle biopsy sampling method of Bergstrom (299) modified to 
include suction. Samples of approximately 100-200 mg were obtained. After the brief 
removal of visible blood and connective tissue from samples, approximately 50 mg of 
the muscle was collected for vitamin C analysis and the remaining sample was rapidly 
snap-frozen and stored in liquid nitrogen until sample analysis. For vitamin C analysis, 
fresh muscle was homogenized on ice 1:20 (wt:vol) in phosphate-buffered saline 
using a glass-glass Tenbroeck homogenizer (Wheaton, Millville, NJ). The homogenate 
was then mixed with an equal volume of 0.1 g/ml metaphosphoric acid and stored 
airtight at -80 °C until analysis. The remainder of the homogenate was stored 
separately at -80 °C for antioxidant enzyme assays. Biopsy samples were taken from 
the same thigh during each arm of the trial, approximately 1-2 cm proximal to the 
previous sampling site. 
 
Blood sampling 
Fasting blood samples were collected in lithium heparin-containing tubes on days 0, 
1, 7 and 42 to assess effects of vitamin C intake on plasma vitamin C concentration 
and antioxidant enzyme activities. Samples taken were immediately centrifuged at 
3000 g for 15 minutes at 4 °C to separate out the plasma portion. Plasma was mixed 
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with an equal volume of 0.1 g/ml metaphosphoric acid for vitamin C analysis. Plasma 
samples were stored at -80 °C until analysis.  
 
Vitamin C analysis 
Total vitamin C (ascorbic acid + dehydroascorbic acid) concentrations were measured 
in muscle and plasma samples using HPLC coupled with UV detection (Agilent 
technologies Inc. 1100 series, Santa Clara, CA). Methods of analysis were adapted 
from Lykkesfeldt (243) and Wechtersbach & Cigic (300). Samples were eluted on a 
Luna C18 column (particle size 3 μm, 150 x 4.6 mm i.d., Phenomenex Inc., Torrance, 
CA) connected to a Security Guard C18 column (Phenomenex Inc.).  The mobile phase 
was adapted from Lykkesfeldt (243) to contain 0.5 % (vol:vol) methanol, and was pH 
adjusted to 4.8 using orthophosphoric acid. Samples were combined with an equal 
volume of a 0.05 g/ml metaphosphoric acid solution containing 5mmol/l EDTA and 
10mmol/l tris (2-carboxyethyl) phosphine. Samples were then flushed with a light 
stream of nitrogen gas for 20 seconds and incubated at 20°C for 120 minutes to 
facilitate reduction of sample DHA to ascorbic acid. 45 μl was injected onto the 
column for analysis. Column flow rate was 0.6 ml/min and ascorbic acid was detected 
at a wavelength of 265 nm. The ascorbic acid peak was verified by spiking muscle and 
plasma samples with known amounts of ascorbic acid (obtaining recoveries of 94-104 
% of expected values) and through treatment of samples with 20 units ascorbate 
oxidase to selectively eliminate the ascorbic acid peak. Quantification of peak area 
for ascorbic acid was made using Agilent ChemStation software (v. B.03; Agilent 
technologies, Santa Clara, CA). Sample concentrations were determined from linear 
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(r2>0.99) standard curves generated from ascorbic acid standards prepared daily in 
mobile phase.  
 
Western blot analyses 
Muscle samples (~20-30 mg) were homogenized on ice in a freshly prepared ice-cold 
buffer consisting of 50 mmol/l Tris (pH 7.5), 1 mmol/l EDTA, 10 % (vol:vol) glycerol, 1 
% (vol:vol) Triton-X, 50 mmol/l NaF, 5 mmol/l NaPP, 1 mmol/l DTT, 1 mmol/l PMSF, 
and 5 μl/ml protease inhibitor cocktail (Sigma P8340). Samples were then centrifuged 
for 15 minutes at 13,000 g and supernatants frozen at -80 °C until analysis. Tissue 
lysates were solubilised in Laemmli sample buffer and equal amounts of protein (75 
μg protein) were boiled for 5 minutes at 90 °C and then loaded onto 10 % 
polyacrylamide gels. All samples for an individual were run on the same gel in the trial 
order undertaken. Gels were subjected to electrophoresis and electrotransferred 
onto PVDF membranes. Membranes were blocked in 0.05 g/ml bovine serum 
albumin, followed by an overnight incubation at 4 °C in a primary SVCT2 goat 
polyclonal antibody (sc-9926; Santa Cruz). Membranes were washed and incubated 
in an anti-goat secondary antibody (LI-COR IRDye® 680LT or 800LT, LiCor Biosciences, 
Lincoln, USA) at room temperature for 1h. Detection and quantification of target 
proteins were made using the Odyssey® Infra-red Imaging system (LiCor Biosciences). 
Results are presented as measured integrative intensity as done previously (301).  
A mouse polyclonal GAPDH antibody (Sigma-Aldrich) was used as a protein loading 
control for SVCT2. There were no effects of treatment found for GAPDH expression 
(data not shown). Additional control samples containing protein amounts below and 
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above sample amounts were loaded onto each gel to confirm the linear range of 
quantification for both target protein and loading control (302).  
Enriched human blood platelet fractions were used as positive controls for SVCT2 
western blotting. For platelet isolation, whole blood was collected from a single 
participant in EDTA tubes containing citrate buffer and centrifuged at 200 g for 15 
mins.  The platelet rich fraction was then mixed 10:1 (vol:vol) with acid-citrate-
dextrose buffer and centrifuged at 900 g for 15 mins. The washed pellet was re-
suspended in a buffer containing 25 mmol/l tris (pH 8.0), 1 mmol/l EDTA, 0.05 g/ml 
SDS and 5 μl/ml protease inhibitor cocktail (Sigma P8340) and subjected to ultra-
sonication (262).  
 
Antioxidant assays 
Muscle and plasma samples were prepared and undertaken in accordance with 
recommended procedures by assay kit manufacturers and did not include any known 
interfering compounds. Catalase activity was determined using a commercially 
available assay kit (#707002, Cayman Chemical Company). In short, the assay 
involved the reaction of catalase with methanol in the presence of hydrogen peroxide 
and the colorimetric detection of formaldehyde formed at 540 nm with 4-amino-3-
hydrazino-5-mercapto-1,2,4-trizole. Total SOD activity (including all SOD isoforms) 
was determined using a commercial assay kit (#706002, Cayman Chemical Company) 
that utilized a tetrazolium salt to detect superoxide radicals produced by xanthine 
oxidase and hypoxanthine.  Total antioxidant capacity was assessed using a 
commercial assay kit (#709001, Cayman Chemical Company). The assay measured 
the capacity of all antioxidants within a sample to inhibit oxidation of 2,2’-Azino-di-
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[3-ethylbenzthiazoline 6-sulphonic acid] to its radical cation by metmyoglobin. A 
lower absorbance for a sample at 750 nm relative to a Trolox standard curve indicated 
a higher antioxidant concentration in that sample. Total glutathione concentration of 
samples was assessed using a commercially available kit (Bioxytech ® GSH/GSSG-
412TM, OxisResearch, Portland, OR). The assay involved the reaction of dithiobis-2-
nitrobenzoic acid with glutathione in the presence of glutathione reductase. The rate 
of change of absorbance at 412 nm was measured following sample treatment with 
NADPH, with the observed rate reflecting total glutathione concentration. Finally, 
glutathione peroxidase (GPx) activity was measured using a commercially available 
assay kit (#703102, Cayman Chemical). In this assay GPx activity was measured 
indirectly via glutathione reductase and NADPH-dependent recycling of glutathione 
disulphide formed from the reduction of cumene hydroperoxide by GPx. The rate of 
decrease in absorbance at 340 nm was reflective of GPx activity in a sample.  
 
DCFH Assay 
The probe 2’,7’ – dichlorodihydrofluorescin (DCFH) has previously been used to 
measure levels of oxidant species in rodent skeletal muscle (303, 304). While use of 
this probe is limited by non-specificity of reaction with oxidant species (305), it allows 
for a convenient general measurement of oxidative stress in samples (305). Muscle 
samples (0.01 mg protein) prepared in the same lysis buffer as for western blot 
samples were added in duplicate to 96-well fluorescent plates to which 290 μl assay 
buffer (130 mmol/l KCl, 5 mmol/l MgCl2, 20 mmol/l NaH2PO4, 20 mmol/l tris-HCl and 
30 mmol/l D-glucose, pH 7.4 (304)) was added.  The reaction was initiated with 
addition of 1.2μl DCFH-DA (2,7-Dichlorodihydrofluorescein diacetate; Cayman 
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Chemical) dissolved in methanol (5 μmol/l final concentration).  To facilitate 
deacetylation of DCFH-DA to DCFH by sample esterases, plates were incubated at 
37°C for 15 minutes in the dark.  DCFH was then rapidly oxidized to fluorescent DCF 
in the presence of sample ROS and reactive nitrogen species(306). The rate of change 
in fluorescence was measured using a Biotek® Synergy 2 spectrophotometer (Biotek 
Instruments, Inc., Winooski, VT) with an excitation wavelength of 485 nm and an 
emission wavelength of 528 nm over 30 minutes.  The rate of change of sample 
fluorescence was linear for at least 60 minutes over a range of different protein 
concentrations. After 60 minutes, 1667 μmol/l H2O2 was added to all samples, 
causing a rapid increase in fluorescence in all samples that increased linearly for at 
least 30 minutes. This demonstrated that added DCFH was not saturated by sample 
oxidant levels. An H2O2 standard curve was created in pooled muscle homogenates, 
and the rate of fluorescence change was linear for added H2O2 concentrations (0-
3330 μmol/l) over 60 minutes (r2=0.97).  Sample concentration was expressed as 
H2O2 equivalents (in μmol) per mg protein.  Treatment of samples with 1mmol/l 
glutathione (an H2O2 scavenger) attenuated the increase in sample-induced 
fluorescence by approximately 60 %, while treatment of samples with 1mmol/l 
ascorbic acid (a general ROS/RNS scavenger) attenuated the increase in fluorescence 
by approximately 90 % (data not shown). 
 
Citrate synthase assay 
Muscle samples were prepared and homogenized in the same lysis buffer as for 
western blotting. In brief, the assay involved the reaction of acetyl coenzyme A with 
oxaloacetate and the subsequent reaction of formed thiol-bound coenzyme A with 
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DTNB. This produced a detectable spectrophotometric product at 412 nm. An 
extinction coefficient of 13,600 M-1.cm-1 for DTNB (307) was used in calculations and 
citrate synthase activity was expressed per gram total protein. 
 
Total protein analysis 
Total protein content of samples used for western blotting, antioxidant assays and 
citrate synthase activity was determined using the bicinchoninic acid assay (308) with 
bovine serum albumin as the reference standard.  
 
Statistical analyses 
Normality of data was tested via the Shapiro-Wilk test. Data found to violate Gaussian 
normality were log-transformed prior to parametric testing. The two-way repeated 
measures ANOVA was used to compare vitamin C and placebo treatments over time 
points for all measurements. For significant treatment versus time interactions 
found, Bonferroni-corrected multiple comparisons were used to determine specific 
time points at which the treatments differed.  Correlation coefficients were used to 
evaluate relationships between SVCT2 protein expression and plasma and skeletal 
muscle vitamin C concentration. A p value of p<0.05 was used for all statistical tests.  
All statistical analyses were performed using GraphPad Prism (v. 6.0; La Jolla, CA) and 
SPSS software (v.21.0, IBM Corp).   
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2.4. Results 
Participants 
All eight enrolled participants completed the trial as outlined. Participants were aged 
25.9 ± 2.3 years and had a mean height and weight of 178.9 ± 3.8 cm and 81.8 ± 4.2 
kg respectively. Baseline plasma vitamin C concentrations of participants were 58.1 ± 
6.7 μmol/l while skeletal muscle concentrations were 2.9 ± 0.2 mg/100 g wet weight. 
All participants had adequate baseline plasma vitamin C concentrations according to 
plasma cut-off levels reported by Jacob & Sotoudeh (242).  Baseline skeletal muscle 
concentrations were also consistent with previously reported levels in age-matched 
humans (234). No adverse side effects such as gastrointestinal complications (189) 
were reported by participants during either treatment of the study.  
 
Effects of supplementation on plasma and skeletal muscle vitamin C levels 
Analysis using two-way repeated measures ANOVA found increased plasma vitamin 
C concentrations after 1 day compared with placebo (p<0.001). Plasma vitamin C did 
not significantly increase during vitamin C treatment after this time but remained 
significantly different to placebo at 7 days (p<0.001) and 42 days (p<0.001) (Figure 
2.1A). Vitamin C supplementation significantly increased skeletal muscle vitamin C 
concentrations after seven days of supplementation compared with placebo 
(p=0.027) and remained significantly higher after 42 days (p=0.001) (Figure 2.1B).  
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Figure 2. 1. Vitamin C supplementation increases vitamin C concentration in healthy 
males.  
A. plasma vitamin C during 42 days of supplementation. B. skeletal muscle vitamin C 
during 42 days of supplementation. The last vitamin C or placebo capsule was 
consumed 10-12 hours prior to sample collection on days 1, 7 and 42. Data points are 
mean ± SEM. Data are for n=8 participants. * Denotes significantly different to 
placebo p<0.05. Effect of vitamin C supplementation on vitamin C concentrations in 
healthy males 
 
SVCT2 protein expression 
Skeletal muscle SVCT2 protein data required log transformation in order to 
approximate Gaussian normality prior to ANOVA analysis. There was no significant 
treatment x time interaction effect, although vitamin C treatment increased SVCT2 
expression during supplementation compared with placebo (p=0.006 main effect of 
treatment, Figure 2.2).  An increase in skeletal muscle SVCT2 expression occurred in 
all subjects after one day of vitamin C supplementation, albeit variable, with 
increases between 19% and 613 % compared with baseline levels (Figure 2.2). The 
increase in SVCT2 expression after one day of supplementation correlated 
significantly with plasma vitamin C measured at day 1 (r=0.559, p=0.032; Figure 2.3A). 
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In addition, the measured skeletal muscle SVCT2 expression at day 1 predicted the 
skeletal muscle vitamin C concentration observed at day 7 (r=0.692, p=0.005; Figure 
2.3B); and also the change in skeletal muscle vitamin C concentration from day 1 to 
day 7 (r=0.551, p=0.036). These latter correlations demonstrate a temporal 
relationship between the increase in SVCT2 expression and subsequent increase in 
skeletal muscle vitamin C concentration. 
 
Figure 2. 2. Vitamin C supplementation increases skeletal muscle SVCT2 protein 
expression in healthy individuals.  
Top: an example western blot for a participant on days 0, 1, 7 and 42; bottom: SVCT2 
protein expression in skeletal muscle during 42 days of supplementation. Data are 
presented as individual data and as mean ± SEM. Statistical analyses were conducted 
on data from n=7 participants due to an incomplete data set for one participant. 
*Denotes significantly different to placebo, p<0.05.  
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Figure 2. 3. Plasma and skeletal muscle vitamin C concentrations correlate with 
skeletal muscle SVCT2 protein expression.  
A. Spearman’s correlation of plasma vitamin C concentration at t=1 day and the 
change in SVCT2 protein expression from t=0 to t=1 day. B. Spearman’s correlation of 
SVCT2 protein expression at t=1 day and muscle vitamin C concentration at t=7 day. 
A single data point is missing due to insufficient sample for SVCT2 measurement in 
one participant.  
 
Antioxidants 
Data for muscle catalase activity, plasma catalase activity and muscle antioxidant 
capacity required log-transformation in order to approximate Gaussian normality 
prior to parametric ANOVA analyses. There were no main effects of treatment or 
interaction effects observed for the antioxidant measurements in muscle (Figure 2.4) 
or plasma (data not shown).  
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Figure 2. 4. Vitamin C supplementation does not alter basal skeletal muscle 
antioxidant enzyme activities and concentrations over 42 days in healthy individuals. 
 A. Total SOD activity. B. Catalase activity. C. Total antioxidant capacity. D. Total 
glutathione concentration. Data are mean ± SEM. All analyses were conducted with 
n=8 participants. 
 
DCFH oxidation 
Vitamin C treatment had no significant effect on DCFH oxidation in skeletal muscle 
using two way repeated measures ANOVA (Figure 2.5). 
 
Vitamin C study in healthy males 
 
89 
 
 
Figure 2. 5. Vitamin C supplementation does not affect basal skeletal muscle DCFH 
oxidation over 42 days in healthy individuals.   
Data points are mean ± SEM. Data are for n=8 participants. 
 
Citrate synthase activity 
Vitamin C supplementation had no significant effect on skeletal muscle citrate 
synthase activity (Figure 2.6) when comparing treatments pre- and post-
supplementation using two way repeated measures ANOVA (p=0.13 for treatment x 
time interaction).  
 
Figure 2. 6. Vitamin C supplementation does not affect skeletal muscle citrate 
synthase activity after 42 days in healthy individuals.   
Data points are mean ± SEM. Data are for n=8 participants. 
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2.5. Discussion 
 
A major finding of the present study was that seven days of vitamin C 
supplementation (500 mg twice daily) was required to cause a significant increase in 
vitamin C concentration in skeletal muscle to significantly increase in healthy males 
with adequate baseline vitamin C concentrations.  Vitamin C concentration did not 
increase further in skeletal muscle after seven days of vitamin C supplementation, 
although the increase compared to placebo was greatest (~1.3 times placebo) at 42 
days.  In contrast, plasma vitamin C was more sensitive to vitamin C supplementation, 
increasing as early as one day post supplementation and reaching a concentration of 
approximately 1.8 times the placebo level at 42 days. Previously the time course 
accumulation of vitamin C in skeletal muscle during vitamin C supplementation had 
not been well characterized in healthy individuals. Indeed, a placebo-controlled study 
by Hellsten et al. (241) reported similar changes in muscle (~1.4 times) and plasma 
(~1.8 times) vitamin C to our study after seven days of supplementation with a high 
dose antioxidant combination including 1500 mg of ascorbic acid in healthy males. 
However it was uncertain from the Hellsten et al. (241) study how quickly vitamin C 
concentrations had increased in muscle during supplementation and/or if vitamin C 
levels would have continued to increase beyond seven days if supplementation had 
persisted for longer.  Another study (233) found supplementation with vitamin C in 
the form of golden kiwi fruit (53 or 212 mg vitamin C/day) to effectively increase 
skeletal muscle ascorbate concentrations in marginally vitamin C-deficient males 
after 42 days. Again it was uncertain from this latter study how quickly muscle vitamin 
C concentrations had increased in response to vitamin C supplementation. Based on 
the current findings it is proposed that in future clinical studies investigating effects 
of exogenous vitamin C in skeletal muscle, at least seven days of high dose 
Vitamin C study in healthy males 
 
91 
 
supplementation should be undertaken to ensure skeletal muscle vitamin C 
concentration is significantly elevated.    
A novel finding in the present study was that high dose vitamin C supplementation 
significantly increased SVCT2 protein expression in skeletal muscle of healthy males. 
A significant correlation found between the change in skeletal muscle SVCT2 
expression and plasma vitamin C concentration would appear to confirm an 
augmentative effect of supplemental vitamin C on skeletal muscle SVCT2 expression. 
Findings from previous in vitro and in vivo experimental studies investigating non-
muscle cells and tissue suggest that intracellular ascorbic acid concentration could 
exert a negative feedback regulation on cellular SVCT2 expression (262, 309). This 
could potentially limit the effectiveness of high dose vitamin C supplementation in 
elevating tissue vitamin C levels. However, recent evidence suggests that substrate 
regulation of SVCT2 expression varies in different types of cells and tissues (310-312). 
Moreover, findings of this study show that SVCT2 expression increases in human 
muscle in response to high dose supplementation, therefore likely facilitating 
intramuscular vitamin C accumulation.  This is supported by a significant correlation 
between SVCT2 expression at t=1 day and the increased skeletal muscle vitamin C 
concentration measured at t=7 days. Although no significant treatment x time 
interaction was found, it was clear that the largest difference in SVCT2 expression 
between treatments occurred at t=1 day (average 2.5-fold greater expression in the 
vitamin C group).  After this time there was only a 1.5-fold average elevation in SVCT2 
expression during vitamin C supplementation compared with placebo. Importantly, 
no decrease in SVCT2 expression below the baseline level was observed after t=1 day 
during vitamin C supplementation despite an increased skeletal muscle vitamin C 
concentration.  Therefore it appears that skeletal muscle vitamin C concentrations 
Vitamin C study in healthy males 
 
92 
 
achievable with this high dose regimen do not negate the intramuscular transport of 
ascorbic acid in healthy individuals. It should be noted that SVCT2 transport activity 
was not assessed in this study. A previous study in C2C12 myotubes observed an 
increase in ascorbic acid transport in association with increased levels of SVCT2 
protein expression (236). Thus, SVCT2 protein expression appears to be a good 
indicator of SVCT2 transporter activity in skeletal muscle.   
Vitamin C supplementation did not alter skeletal muscle oxidative stress, as assessed 
by oxidation of DCFH. This finding is perhaps not surprising given the healthy, vitamin 
C- sufficient status of our participants. Levine et al (226) found no effect of high dose 
vitamin C supplementation on systemic lipid peroxidation measures in healthy 
individuals. On the other hand, high dose vitamin C has been found to improve 
systemic oxidative stress markers in individuals with chronic oxidative stress (169, 
179, 181). The effect of high dose vitamin C on markers of oxidative stress in skeletal 
muscle of clinical populations with chronic oxidative stress has been little explored 
however. This will be the focus of the main study in this thesis.  
High dose vitamin C supplementation had no effect on total antioxidant capacity or 
on antioxidant enzyme activities in skeletal muscle. Khassaf et al. (313) similarly 
found no effect of eight weeks of supplementation with 500mg vitamin C per day on 
skeletal muscle catalase or SOD activities in healthy males. In another study, lower 
skin glutathione concentrations were observed in healthy individuals after eight 
weeks of supplementation with 500mg vitamin C per day during which time skin 
vitamin C concentrations increased significantly (314). In the latter study the authors 
speculated that vitamin C supplementation could have promoted a reduction in 
endogenous antioxidant levels due to their displacement by increased exogenous 
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ascorbic acid. Tissue-specific effects of vitamin C supplementation might underlie 
these different findings in skin and skeletal muscle.  
No change in muscle citrate synthase activity was found following vitamin C 
supplementation. Previous studies in humans and animals have reported attenuating 
effects of antioxidant supplementation on skeletal muscle mitochondrial biogenesis 
with or without exercise training (118, 295-297). In contrast, findings of the current 
study suggest that high dose vitamin C supplementation is unlikely to significantly 
alter basal antioxidant enzyme activities or mitochondrial content in healthy males. 
These results lend support to recent studies in healthy humans and animals (315-317) 
that found no impairment in skeletal muscle mitochondrial biogenesis or antioxidant 
enzyme induction following high dose antioxidant supplementation. For clinical 
populations who have oxidative stress and impaired mitochondrial biogenesis in 
skeletal muscle (92, 141), high dose vitamin C could potentially enhance skeletal 
muscle antioxidant capacity without further impairing mitochondrial content.  
This study demonstrated that high dose oral vitamin C supplementation significantly 
increases skeletal muscle vitamin C concentrations in healthy males after seven days. 
Therapeutic interventions aimed at increasing vitamin C concentrations in skeletal 
muscle might therefore require at least seven days to significantly enhance muscle 
vitamin C. Supplementation with Vitamin C also increased SVCT2 protein expression 
in skeletal muscle. Given the potential for regular high dose vitamin C to safely 
increase skeletal muscle vitamin C without impairing muscle antioxidant activities or 
mitochondrial content, research of its effects in clinical populations with skeletal 
muscle oxidative stress are warranted. 
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3.0. CLINICAL TRIAL METHODS 
 
3.1. Clinical trial characteristics 
3.1.1. Study design 
 
The clinical trial was a placebo-controlled trial in people with T2D that involved oral 
consumption of a capsule containing 500 mg ascorbic acid or a placebo twice daily in 
the morning and evening for four months (mean ± SEM: 121 ± 1.8 days; Figure 3.1). 
The study had a cross-over design, and a wash-out period of one month (34.6 ± 2.7 
days) separated the two treatments. The trial was undertaken in a double-blinded 
manner, with a third party individual not directly involved in the study responsible 
for the assignment of participants to treatments and the concealment of treatment 
order. Treatment order was randomized via coin toss. 
                   
Figure 3. 1. Basic structure of clinical trial 
Pre supplementation
Euglycaemic clamp
Muscle biopsies, DXA
Indirect calorimetry
4 months (randomized) 
Vitamin C or Placebo 
supplementation
Post supplementation
Euglycaemic clamp
Muscle biopsies, DXA
Indirect calorimetry
1 month wash-out or
Trial complete
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3.1.2. Study population 
 
It was planned a priori that 12-24 females and males with T2D aged 35-70 years 
would be recruited to participate in the clinical trial. Sample size was chosen based 
on: (a) calculations using an online power analysis (318) of data from relevant 
published research (169, 181) and our own data from the study in Chapter 2 (on page 
85); and (b) allowance for participant drop-outs during the trial as a result of the long 
study duration and invasiveness of study procedures used (Table 3.1). Based on this 
power analysis, 12-24 participants would provide high power (>90 %) to detect ≈ 50 
% changes in whole-body insulin sensitivity, whole-body non-oxidative glucose 
metabolism and skeletal muscle vitamin C concentration (Table 3.1). On the other 
hand, 12-24 participants would provide a somewhat underpowered (<50 % power) 
sample size to confidently detect changes in fasting plasma insulin and HbA1c (169). 
The proposed sample size also has a high power (>90 %) to detect changes in markers 
of oxidative stress. However, oxidative stress data used in the power analysisis was 
from plasma only, so calculated power might not be directly applicable to skeletal 
muscle outcomes. Both females and males were chosen for the clinical trial since T2D 
affects genders at a similar rate (5). Also, the age range of 35-70 years was chosen 
since diabetes prevalence is elevated within this age range in Australia (5). Moroever, 
this age group has not previously been investigated using this study design. 
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Table 3. 1. Power determination of key variables in major study 
Reference Measure Δ Mean* SD† N 
(80 %)‡ 
Power 
(n=12)§ 
Power 
(n=24)ǁ 
Advantages Disadvantages 
Insulin Sensitivity 
Paolisso 
et al. 
(169) 
WBGD 11.9 
(μmol.kg 
FFM/min) 
2.68 4 99% 100% very 
relevant 
high power 
WBGD not Δ 
Rd 
Paolisso 
et al. 
(169) 
NOGM 11.6 
(μmol/kg 
FFM/min) 
2.68 4 99% 100% very 
relevant 
high power 
calculated 
from WBGD 
not Δ Rd 
Oxidative stress 
Evans et 
al. (181) 
ROS 1.7 
(arbitrary) 
0.8 10 92% 99% Relevant 
high power 
in plasma  
Evans et 
al. (181) 
TBARS 9.17 
(arbitrary) 
1.17 4 100% 100% Relevant 
high power 
in plasma 
Paolisso 
et al. 
(169) 
GSH 0.22 
(μmol/l) 
0.19 14 73% 96% relevant, 
good power 
in plasma; 
only an 
antioxidant 
measure 
Vitamin C levels 
Mason et 
al. (293) 
Total 
vitamin 
C in 
muscle 
0.96 
(mg/100g 
wet 
weight) 
0.64 6 99% 99% very 
relevant 
high power  
in healthy 
muscle 
Mason et 
al. (293) 
Total 
vitamin 
C in 
plasma 
55.89 
(μmol/l) 
22.7 4 99% 100% very 
relevant 
high power  
in healthy 
plasma 
 
(*minimal detectable mean difference; †standard deviation; ‡n required for at least 
80% power; §power with minimum study sample number; ǁpower with maximum 
study sample number; WBGD-whole body glucose disposal; FFM – fat-free mass; 
NOGM-non-oxidative glucose metabolism; Rd-skeletal muscle insulin sensitivity; 
TBARS – thiobarbituric acid reactive substances; GSH – reduced glutathione) 
 
3.1.3. Inclusion/exclusion criteria 
 
Inclusion/exclusion criteria for participation included: HbA1c >6.5 % and <10.0 %; 
total cholesterol <6.5 mmol/l; HDL cholesterol >0.9 mmol/l; triglycerides <4.0 
mmol/l; body mass index <35 kg/m2; systolic blood pressure <160 mmHg; diastolic 
blood pressure <90 mmHg; a non-smoker; no major medical illness apart from T2D; 
no history of cardiovascular, renal, respiratory or neurological disease; no heart 
murmur condition or bleeding disorder; no incidence of haemochromatosis or iron 
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overload disorder; not taking any diabetic medications other than metformin (≤ 2000 
mg total per day), a sulfonylurea and/or a dipeptidyl-peptidase-4 inhibitor (≤ 2 
diabetes medications in total); not taking any vitamin or herbal supplements during 
the month prior to participation; not taking any medications known to influence 
insulin sensitivity; not engaging in regular intensive exercise training; and not 
pregnant or planning a pregnancy during the trial.  It was furthermore expected that 
participants demonstrated stable glucose control (∆ HbA1c ± 0.5 % for at least 6 
months) prior to the trial. Final approval for participation was granted by our medical 
doctor (Dr Andrew Garnham) following a medical screening. 
 
3.1.4. Supplementation 
 
Vitamin C capsules contained 500 mg L-ascorbic acid, microcrystalline cellulose, 
vegetable cellulose and vegetable magnesium stearate (Solgar, Inc, Leonia, NJ) and 
placebo capsules contained 560 mg gelatine, 8 mg calcium carbonate, vegetable 
magnesium stearate and vegetable cellulose (Solgar, Inc, Leonia, NJ). Vitamin C and 
placebo capsules were almost identical in appearance and were provided to 
participants in identical sealed opaque bottles. Supplements were commercially 
available products purchased through online retail stores. Capsules randomly 
selected from vitamin C and placebo bottles were tested for vitamin C content using 
HPLC. Vitamin C capsules tested in this manner were found to contain >99.9 % of the 
expected ascorbic acid level while placebo capsules contained 0 % ascorbic acid (data 
not shown). The dose of vitamin C used (500 mg twice daily) was chosen because it 
represents a prudent upper limit for vitamin C intake based on estimations of a no 
observed adverse effect level (189). Moreover, this daily supplemental dose also 
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represents a commonly recommended intake of vitamin C using commercially 
available vitamin C tablets and capsules. 
 
3.1.5. Ethics statement 
 
This study was approved by the Deakin University Human Research Ethics Committee 
(Ethics approval # 210-256). The study was also retrospectively registered in the 
Australian and New Zealand Clinical Trials registry (registration # 
ACTRN12614000239662). Participants were required to provide written consent in 
order to participate and to provide biological samples for analyses.        
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3.2. Participant recruitment and screening 
 
A number of different strategies were employed to recruit participants for the T2D 
clinical trial. These included: 
x Melbourne-wide general practitioner (GP) Network (Medicare local) 
newsletter articles 
x Flyer postings at local GP clinics 
x Flyer postings at community health centres 
x Flyer postings around Deakin University 
x Online advertising on the Diabetes Autralia Victoria website 
x Regular advertising in the Herald Sun newspaper 
x Newspaper advertising in the local Whitehorse Leader newspaper 
x Oral presentations at Diabetes Support Groups in Melbourne 
x A radio interview on 3WBC community radio 
x Online community and university noticeboard advertising 
x Online clinical research trial website advertising 
 
Participants tentatively approved via telephone and email communications attended 
a pre-test screening session at Deakin University (Figure 3.2). During this session the 
following tasks were undertaken: (a) a medical questionnaire was completed; (b) a 
fasting blood sample was taken; (c) height, weight and blood pressure were 
measured; (d) a plain language statement of the study was provided and explained 
in detail; and (e) informed consent for both trial participation and sample provision 
for research purposes was provided by potential participants. Informed consent from 
the individual’s GP was further expected in order to participate in the study. This 
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latter requirement was based on the necessity to withdraw from anti-diabetic 
medications for two consecutive days on four occasions throughout the trial (see 
Section 3.3.2 on page 103). Based on clinical screening outcomes and pathology 
blood test results, eligible participants commenced the clinical trial. A complete 
summary of individual characteristics of all screened individuals can be found in 
Appendix 10.1 on page 266. 
 
 
Figure 3. 2. Flowchart of participant recruitment and screening in the clinical trial 
Telephone/email screening (n=83)
not included due to:
- medication incompatibility (n=18)
- trial-related issues (n=16)
- clinical disease (n=4)
- recent diagnosis (n=4)
-smoking (n=2)
- other/unable to follow-up (n=14)
Clinical screening (n=25)
not included due to:
- HbA1c low/high (n=7)
- lifestyle/ medication (n=2)
-withdrew (n=3)
Participants (n=13)
- completed (n=7)
withdrew (n=6) due to:
- medication-related (n=3)
- personal-related (n=3)
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3.3. Pre-testing preparation  
3.3.1. Diet and physical activity checklist 
 
During the seven days prior to the first and third testing sessions (i.e. at pre-
supplementation timepoints), participants completed a diet checklist to evaluate 
usual dietary vitamin C intake. Guided by portion size guides and photographic 
examples, participants were asked to tick the appropriate portion size box that 
approximated their daily intake of a specified vitamin C-rich food item. The checklist 
was derived from the AUSNUT database and included foods and beverages that 
constitute the largest proportion of dietary vitamin C in the adult Australian diet (188) 
(Appendix 10.2 on page 267). It also included less commonly consumed foods that 
are considered rich sources vitamin C and foods and beverages fortified with vitamin 
C. For quantifying vitamin C intake, foods and beverages consumed were able to be 
directly and objectively entered into the Foodworks® 2009 software (Xyris Software, 
Highgate Hill, QLD) for determination of daily intakes. A 24-h diet recall was 
undertaken for the day prior to the first testing session and this diet was replicated 
prior to all subsequent testing sessions for each participant.  
On day seven, participants completed a brief physical activity survey to assess 
physical activity performed over the previous week.  The survey was derived from the 
Active Australia Questionnaire (319) which has previously been used in several state 
and national Australian surveys (319). Estimation of physical activity energy 
expenditure (in kcals) was undertaken using this data as done previously (320). An 
example completion of one day of the diet checklist along with the physical activity 
recall survey is included in Appendix 10.2 on page 267. 
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3.3.2. Diabetes medication withdrawal 
 
Forty-eight hours prior to each testing session, participants were requested to stop 
taking their anti-diabetic medications so as not to interfere with measurements 
associated with insulin and glucose metabolism. Participants were asked to monitor 
their blood glucose levels during this period of medicine withdrawal; and if glucose 
levels were observed to increase by more than 3mmol/l above normal during this 
time, they were advised to recommence their medications and be withdrawn from 
the study. During the study no participant deviated by more than 3 mmol/l above 
their usual blood glucose level during this medication withdrawal period. 
Participants fasted from 21:30 on the day prior to testing and visited the laboratory 
at 07:00 for testing.  Participants were asked not to take any medications on the 
morning of testing days, including vitamin C or placebo supplements. 
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3.4. Clinical trial testing  
3.4.1. Fasting blood samples  
 
At the commencement of each testing day, fasting blood samples were collected for 
assessment of glycated haemoglobin (HbA1c), fasting glucose, fasting insulin, serum 
lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides), renal and 
hepatic function, plasma vitamin C, plasma F2-Isoprostanes, plasma lactate, whole-
blood glutathione (GSH) and glutathione disulphide (GSSG), and plasma inflammation 
markers (adiponectin, resistin, interleukin-6, interleukin-8, interleukin-10 and TNF-α; 
Figure 3.3). Plasma samples taken for vitamin C analysis were combined with an equal 
volume of 10 % (w/v) metaphosphoric acid (MPA) containing 5mmol/l 
ethylenediaminetetraacetic acid disodium salt dihydrate (disodium EDTA).  For F2-
Isoprostane measurements, 0.005 % (w/v) 3,5-Di-tert-4-butylhydroxytoluene (BHT) 
was added to plasma.  For GSSG measures, 3mmol/l 1-methyl-2-
vinylpyridiniumtrifluoromethanesulfonate (M2VP) was added to whole blood 
samples. Samples collected were either immediately relocated for standard 
pathology testing (Healthscope Pathology, Melbourne, VIC) or were frozen at -80°C 
for later analyses. 
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Figure 3. 3. Testing day procedure in the clinical trial 
Following collection of a fasting blood sample, participants underwent infusion of 6,6-
D2 glucose tracer. After 150 minutes of basal tracer equilibration, a 
hyperinsulinaemic, eulgycaemic clamp was commenced with infusion of insulin and a 
10% glucose solution containing 1 % 6,6-D2 glucose.  Muscle biopsies and indirect 
calorimetry were undertaken during basal and insulin-stimulated conditions at the 
indicated time points. Regular blood samples were taken for measurement of blood 
glucose and plasma tracer enrichment. Testing was concluded with a measurement 
of body composition using dual-energy X-ray absorptiometry (DXA).
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3.4.2. 6, 6-D2 glucose tracer infusion  
A primed intravenous infusion of the stable 6, 6-D2 glucose tracer (99.1 % isotopic 
purity; Cambridge Isotope Laboratories, Inc., Andover, MA) began at 07:30 on each 
testing day (Figure 3.3).  An infusion bolus of 3 mg tracer/kg bodyweight infused over 
five minutes was followed by a constant infusion rate of 2.4 mg tracer/kg/h for the 
remainder of the infusion periods (321). During the infusion periods, plasma samples 
were taken from a catheterized heated hand vein (≈ 55 °C). Arterialization of the 
venous blood was regularly verified by measuring oxygen saturation of the blood to 
be between 90-98 % (322) using an ABL 800 glucose analyser (Radiometer Medical 
ApS, BrØnshØj, Denmark). A basal equilibration period of 150 minutes was allowed for 
the tracer to reach a steady enrichment level in the body (323).  Basal plasma samples 
for tracer measurements were taken at: -150, -60, -30, -20, -10 and 0 mins prior to 
clamp commencement.  Basal tracer calculations (see Section 4.1.3 on page 112) 
were determined during the final 30 minutes of the basal period. Figure 3.4 illustrates 
the pooled change in plasma 6, 6-D2 glucose enrichment as measured during the 
clinical trial.  Levels of tracer MPE in plasma were relatively stable when measured 
from 90 minutes after commencement of the basal tracer infusion until the end of 
the hyperinsulinaemic, euglycaemic clamp.  
Clinical trial methods 
107 
 
 
Figure 3. 4. 6, 6-D2 glucose tracer enrichment in plasma during the T2D clinical trial 
Moles percent excess (MPE) of 6, 6-D2 glucose in plasma samples of trial participants 
during the glucose tracer infusion procedures after correction for fasting glucose 
levels.  Time = 0 corresponds to commencement of the hyperinsulinaemic, 
euglycaemic clamp. Data are mean ± SEM (n=32 clamps). 
 
 
3.4.3. Hyperinsulinaemic, euglycaemic clamp  
 
At time (t) = 0 minutes, a primed intravenous infusion of short-acting insulin 
(Actrapid, Novo Nordisk, Novo allé, Bagsvaerd) was commenced through a catheter 
inserted into the arm contralateral to the glucose tracer infusion. A bolus of 9 mU/kg 
delivered over one minute was followed by a constant infusion rate of 40 mU/m2/min 
for 180 minutes. Blood glucose measurements were taken at 5-minute intervals 
during the clamp (Figure 3.3) and glucose was measured using an ABL 800 glucose 
analyser (Radiometer Medical ApS).  Blood glucose was clamped at 5.5 mmol/l by 
means of a variable infusion of 10 % glucose (Baxter Laboratories, Boronia, VIC) based 
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on methods of DeFronzo et al. (324). Glucose concentrations of glucose infusates 
were measured using the ABL800 analyzer rather than assumed. Glucose infused 
contained 1 % 6,6-D2 tracer (mean tracer enrichment: 1.14 ± 0.04 MPE, n=32 clamps) 
in order to avoid errors associated with inter-compartmental tracer gradients (217). 
In the event that participants hadn’t achieved a stable glucose infusion rate by t=180 
minutes, the clamp was extended until glucose infusion rates were stable (+/- 10%) 
for at least 30 mins. Thereafter, clamp durations were held constant for each 
participant for all trials undertaken (mean clamp duration: 196.7 ± 3.7 min, n=32 
clamps). Glucose infusion was continued after completion of the insulin infusion 
procedure in order to prevent potential residual hypoglycaemic effects of insulin.  
Participants were also provided with a small meal at this time in order to restore basal 
glucose levels. Once glucose levels of participants had returned to basal levels, the 
glucose infusion was stopped.  
Plasma samples were taken for tracer measurements during the clamp at t=30, 60, 
90, 120, 130, 140, 150, 160, 170, 180 and if necessary every 10 minutes thereafter 
until completion of the clamp. Insulin-stimulated tracer calculations (see Section 
4.1.3 on page 112) were determined during the final 60 mins of the clamp. Samples 
were taken for analysis of insulin levels at t=0, 30, 60, 120, 150 and 180 minutes. A 
plasma sample was also taken at t=180 mins for assessment of plasma lactate.  
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3.4.4. Indirect calorimetry 
 
Participants breathed expired air into Douglas bags through a mouthpiece-nose-clip 
indirect calorimetry system (Hans Rudolph, Inc., Shawnee, KS) to calculate resting 
rates of carbohydrate oxidation, fat oxidation, energy expenditure and respiratory 
exchange ratio (RER). It was previously reported that mouthpiece-nose-clip indirect 
calorimetry systems produce similar values for VO2, VCO2, RER and resting energy 
expenditure when compared with ventilated hood systems (325). On each testing 
occasion, participants underwent a 10-15 minute period of familiarization with the 
indirect calorimetry system. This was followed by testing for 15-minute periods 
during both the basal and insulin-stimulated periods (Figure 3.3), from which the final 
10-minutes of expired gas was collected for subsequent calculations. A small sample 
of the expired gas was assessed for % O2 and % CO2 using a Moxus modular metabolic 
system (AEI technologies, Pittsburgh, PA). The metabolic system was calibrated prior 
to use on each testing day. Ventilation rate was calculated after determining the total 
volume of expired air using a dry gas metre (Harvard Apparatus, Holliston, MA). VO2 
and VCO2 were then calculated using standard equations after conversion to STPD 
values. Rates of carbohydrate and fat oxidation were determined using the equations 
of Frayn et al. (326) assuming urinary nitrogen excretion as a constant value of 0.009 
g/min (327) (see Appendix 10.3 on page 281 for equations). RER was calculated as 
the ratio of carbon dioxide production to oxygen uptake (VCO2/VO2). 
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3.4.5. Muscle biopsies  
 
Muscle biopsy samples were taken firstly during the final 30 minutes of the basal 
period (basal sample); and secondly, after 60 minutes of insulin infusion during the 
hyperinsulinaemic, euglycaemic clamp (insulin-stimulated sample; Figure 3.3). 
Muscle sampling was performed according to the percutaneous needle biopsy 
sampling method of Bergstrom (299). Briefly, a local anaesthetic (Lidocaine) was 
injected into the fascia of the vastus lateralis muscle and a small scalpel incision was 
made. The biopsy needle, with an inside cutting cylinder, was inserted through the 
incision site into the underlying muscle belly. Samples of ~100-200 mg were obtained 
via syringe suction. After the brief removal of visible blood and connective tissue, 
samples were rapidly frozen in liquid nitrodgen and stored until analysis. Subsequent 
biopsy samples on the same day were taken approximately 1-2 cm proximal to the 
previous sampling site. The sampling leg was alternated on different trial days. 
 
3.4.6. Dual-energy X-ray Absorptiometry 
 
Body composition including fat-free mass, fat mass and percent body fat, were 
determined using a Lunar Prodigy whole-body scanner (GE Medical Systems, 
Madison, WI) in Total Body scan mode after completion of the clamp procedure 
(Figure 3.3). Briefly, the participant lay still in the supine position and was subjected 
to low-dose X-rays from a mobile scanner. The different body components (fat, lean 
body mass & bone) produce distinct X-ray absorption profiles whereby fat and lean 
composition can be calculated from the linear decomposition of the localised tissue 
X-ray attenuation according to calibrated samples (328).
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4.0. ANALYTICAL RESEARCH METHODS 
 
4.1. Glucoregulatory Measurements 
4.1.1. Glucose, lipid, organ function & inflammation measures  
 
Fasting blood samples collected for HbA1c, serum cholesterol (total, LDL-C & HDL-C), 
serum triglycerides and serum renal and hepatic function were measured according 
to standardized laboratory procedures by a commercial pathology laboratory 
(Healthscope Pathology, Melbourne, VIC).  Whole blood fasting glucose was 
measured using an ABL 800 glucose analyser (Radiometer Medical ApS). General 
indices of basal glucose control including Homeostasis Model Assessment (HOMA)-IR 
(insulin resistance), HOMA-S (insulin sensitivity) and HOMA-B (beta cell function) 
were calculated using fasting values for glucose and insulin with an online HOMA-2 
calulator (http://www.dtu.ox.ac.uk/HOMACalculator).  Basal plasma inflammation-
related measures, including adiponectin, resistin, interleukin-6, interleukin-8, 
interleukin-10 and TNF-α were measured using a human adipokine magnetic bead 
multiplex assay (Cat # HADK1MAG-61K; EMD Millipore, Billerica, MA) and a human 
cytokine magnetic bead multiplex assay (Cat # HCYTOMAG-60K; EMD Millipore) 
according to the manufacturer’s instructions on a Bio-Plex Multi-plex system (Bio-Rad 
Laboratories, Hercules, CA).  
 
4.1.2. Plasma insulin 
Plasma insulin was calculated during all trials at time points: t=-150 (fasting), t=0, 
t=30, t=60, t=120, t=150 and t=180 mins using a sandwich ELISA assay (Cat # EZHI-
14K; EMD Millipore) according to the manufacturer’s instructions. Insulin levels 
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obtained using this specific assay kit have previously been shown to produce insulin 
concentrations approximately 50 % of the absolute values obtained using 
radioimmunassay methods (329). Thus, for purposes of comparability with previous 
studies, insulin concentrations of fasting (t=-150) and insulin-stimulated (t=180) 
plasma samples were also measured using a human-specific radioimmunassay kit 
(Cat # HI-14K; EMD Millipore) on an automatic gamma counter (Wallac Wizard 1470, 
Waltham, MA).  
 
4.1.3. 6, 6 D2-glucose tracer measurements  
Enrichment of 6, 6-D2 tracer in plasma samples was assessed using electron-ionizing 
gas chromatography-mass spectrometry (GC-MS).  Methods were adapted from 
McConell et al. (330). In brief, 50 μl of plasma was deproteinized with 50 μl 0.3 mol/l 
BaOH2 and 50μl 0.3 mol/l ZnSO4. 80 μl of supernatant was then dehydrated and 
subsequently derivatized with 100 μl of a 2:3 pyridine/acetic anhydride solution into 
glucopyranose pentaacetate derivatives. Samples were injected using a 1:50 split 
ratio onto a HP-5MS 5 % Phenyl Methyl Siloxane column (30.0 m x 250 μm x 0.25 μm; 
Agilent technologies, Santa Clara, CA) connected to an Agilent 6890 Gas 
Chromatograph. Target compounds were detected via an Agilent 5975 Mass 
Spectrometer. The GC program consisted of a 20 °C/min ramp starting at 100 °C. A 
final temperature of 260 °C was then held for five minutes. Hydrogen was used as the 
carrier gas with a flow rate of 1.1 ml/min.  The mass ratio of derivatized tracer (100 
m/z) to derivatized glucose (98 m/z) was used in the determination of tracer MPE:  
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MPE =                           100 m/z – (100/98 [0 MPE] X 98 m/z)                                      
       100 m/z + 98 m/z – (100/98 [0 MPE] X 98 m/z) – (98/100 [100MPE] X 100 m/z) 
 
(where 100/98 [0 MPE] = 100/98 m/z ratio determined from 0 MPE standard; and 
 98/100 [100 MPE] = 98/100 m/z ratio determined from 100 MPE standard) 
 
Sample MPE was determined from standard curves created from 6, 6-D2 standards 
ranging from 0 to 12.5 MPE. MPE of glucose and tracer infusates used in trials was 
measured via GC-MS and not assumed. Calculations of rate of glucose disappearance 
(Rd) and rate of glucose appearance (Ra) were calculated according to formulas of 
Steele for single-pool, non-steady-state conditions (331) modified for use with stable 
tracers (323).  The pool fraction was assumed to be 0.65 and the glucose space as 25 
% in calculations (323).  
Clamp Rd was calculated as the average of each 10-minute Rd value during the final 
60 minutes of the euglycaemic clamp. Basal Rd was calculated as the average of each 
10-minute Rd value during the final 30-minutes of the basal period. Insulin-
stimulated glucose disposal (Δ Rd) was calculated as the difference between clamp 
Rd and basal Rd. A failure to account for effects of basal glucose disposal on glucose 
disposal during the clamp can lead to an underestimation of the defect in insulin-
stimulated glucose disposal in T2D (332, 333).  Clamp Ra, basal Ra and Δ Ra were 
calculated in the same manner as for Rd. Glucose metabolic clearance rate (MCR) was 
calculated as Rd divided by blood glucose level. Clamp MCR, basal MCR and Δ MCR 
were calculated in the same manner as for Rd. Endogenous glucose production (EGP) 
was calculated as the difference between Ra and rate of exogenous glucose infusion. 
Clamp EGP, basal EGP and Δ EGP were calculated in the same manner as for Rd. Non-
oxidative glucose metabolism (NOGM) was calculated as the difference between Rd 
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and carbohydrate oxidation rate determined using indirect calorimetry. Clamp 
NOGM, basal NOGM and Δ NOGM were calculated in the same manner as for Rd. 
Equations used to determine tracer-derived variables are provided in Appendix 10.3 
on page 281. The optimization of GC-MS methods is discussed in Section 5.1 on page 
127. 
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4.2. HPLC measurements  
4.2.1. Vitamin C & uric acid concentrations  
 
Ascorbic acid (AA) and total ascorbic acid (AA + dehydroascorbic acid [DHA]; TAA) 
concentrations were measured in muscle and plasma samples using high 
performance liquid chromatography (HPLC) coupled with UV detection (Agilent 
technologies Inc. 1100 series, Santa Clara, CA). Methods of analysis were adapted 
from Lykkesfeldt (243) and Wechtersbach & Cigic (300). Samples were eluted on a 
Luna C18 column (particle size 3 μm, 150 x 4.6 mm i.d., Phenomenex Inc., Torrance, 
CA) connected to a Security Guard C18 column (Phenomenex Inc., Torrance, CA).  1.0 
L mobile phase consisted of: (A) 129 mmol/l sodium dihydrogen phosphate 
monohydrate, 215 mmol/l sodium acetate annydrous, 1 mmol/l disodium EDTA and 
189 μmol/l n-docyltrimethylammonium chloride dissolved in 990 ml Milli-Q®, 
combined with (B) 36.6 μmol/l tetraoctylammonium bromide dissolved in 10ml 
methanol.  The combined solution was pH-adjusted to 4.8 using orthophosphoric 
acid. The mobile phase was filtered under vacuum through a 0.45 μm filter.  
Frozen muscle samples (25-35 mg) were homogenized in a glass-glass Duall tissue 
grinder (Kimble Chase, Rockwood, TN) on ice in 5% (w/v) MPA containing 5 mmol/l 
disodium EDTA. Muscle sample homogenates and defrosted plasma samples were 
centrifuged for 3 minutes at 16,000 g. Sample supernatants were then filtered 
through 0.2 μm syringe filters and 200 μl was transferred to two amber autosampler 
vials, to which an either an equal volume of a 5 % (w/v) MPA solution containing 5mM 
disodium EDTA (for AA analysis) or an equal volume of a 5% (w/v) MPA solution 
containing 5mM disodium EDTA and 20 mmol/L tris (2-carboxyethyl) phosphine 
(TCEP; for TAA analysis) was added. Vials were flushed with a light stream of nitrogen 
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gas for 20-30 seconds and capped.  To facilitate reduction of sample DHA to AA, TAA 
samples were incubated at 20 °C for 120 minutes. 45 μL of sample was injected onto 
the column for analysis. Column flow rate was 0.6 ml/min. AA was detected at a 
wavelength of 265 nm and had a retention time of approximately 3.2 minutes. DHA 
was calculated as the difference between TAA and AA. The percentage of DHA as a 
fraction of TAA (DHA/TAA) was considered as a measure of the vitamin C redox 
status.  
Measurement of uric acid (UA) in samples served as an endogenous internal standard 
for the calculation of DHA as previously recommended (243). UA was measured at a 
UV wavelength of 300 nm and had a retention time of approximately 6 minutes. AA 
standards were prepared fresh daily in mobile phase and both AA and UA standards, 
ranging from 0.63 μmol/l to 100 μmol/l, were run daily to generate standard curves 
for calculation of sample concentrations. All linear regression standard curves were 
r2>0.99. HPLC optimization experiments are outlined in Section 5.2 on page 134. 
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4.3. Oxidative stress measurements  
4.3.1. F2 Isoprostanes  
 
Muscle samples (25-35 mg) were homogenized 1:20 (w/v) in a 0.1 mol/l phosphate 
buffer containing 1 mmol/l EDTA and 0.005 % (w/v) BHT using polypropylene pellet 
grinders on ice.  This was followed by 2 x 20 s bursts of ultrasonication on ice 
(Vibracell™ Sonics & Materials inc., Newtown, CT).  Muscle homogenates and plasma 
samples (stored in 0.005% BHT) were mixed 1:1 with 15 % KOH, flushed with a light 
stream of nitrogen gas for 20-30 s, and incubated for 60 minutes at 40 °C to facilitate 
hydrolysis of esterified F2-Isoprostanes. This allows for the measurement of total F2-
Isoprostanes (i.e. bound + free) in samples. Following this step, 8 x sample volumes 
of ice-cold ethanol containing 0.01 % (w/v) BHT were added to samples. Samples 
were incubated on ice for 10 minutes and then centrifuged for 10 minutes at 3300 g 
to precipitate out proteins. Sample supernatants were then dried using vacuum 
centrifugation (HetoVac; Heto, Scandinavia). Dried samples were re-suspended in 30 
% acetic acid (final pH 4.0), centrifuged to remove any remaining undissolved debris, 
and then applied to C18 reverse-phase solid phase extraction columns (Item #400020 
Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s instructions. F2-
Isoprostanes in both skeletal muscle and plasma samples were eluted in a 1 % 
methanol: ethyl acetate solution, dried under vacuum centrifugation, and then 
diluted 1:3 in 8-Isoprostanes EIA kit assay buffer (Cayman Chemical). Total F2-
Isoprostane concentrations were determined in samples using a commercial EIA 
assay kit (8-Isoprostane EIA kit; Cayman Chemical) according to the manufacturer’s 
instructions. Plasma samples prepared in the manner above reportedly correlate 
highly (r2=0.99) with F2-Isoprostane measurements by GC/MS methods. Data from 
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optimization experiments in muscle and plasma are provided in Section 5.3.1 on page 
141.  
 
4.3.2. DCFH assay 
 
2’,7’- dichlorofluorescein (DCF) was used as a fluorescent probe to measure levels of 
reactive species in skeletal muscle homogenates (304, 305). This assay was 
undertaken twice, firstly as a stand-alone oxidative stress assay; and secondly as a 
post-hoc investigation of oxidative stress in both basal and insulin-stimulated muscle. 
In the first experiment, insulin-stimulated muscle samples (≈10-15 mg) were 
homogenized 1:50 (w/v) in assay buffer consisting of 130 mmol/l KCl, 5 mmol/l MgCl2, 
20 mmol/l NaH2PO4, 20 mmol/l Tris-HCl and 30 mmol/l glucose, pH 7.4 (304). In the 
second experiment, basal and insulin-stimulated muscle samples were homogenized 
1:10 (w/v) in a buffer consisting of 25 mmol/l Tris-HCl (pH 7.4), 1mM EDTA and 1mM 
EGTA. Samples in the second experiment were then diluted 1:5 in the above assay 
buffer. In both experiments, 10 μl of sample was added in duplicate to 96-well 
fluorescent plates, to which 290 μl of assay buffer was further added.  The reaction 
was initiated with addition of 1.2μL 2, 7-Dichlorodihydrofluorescein diacetate (DCFH-
DA; Cayman Chemical) dissolved in methanol (5 μmol/l final concentration).  To 
facilitate deacetylation of DCFH-DA to DCFH by sample esterases, plates were 
incubated at 37 °C for 15 minutes in the dark.  DCFH was then rapidly oxidized to 
fluorescent DCF in the presence of sample reactive species, including ROS such as 
H2O2, HO· and ROO·; and RNS such as ·NO and ONOO- (306). 
The rate of change in fluorescence was calculated using a Biotek® Synergy 2 
spectrophotometer (Biotek Instruments, Inc., Winooski, VT) with an excitation 
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wavelength of 485 nm and an emission wavelength of 528 nm every 3-minutes over 
60 minutes. After 60 minutes, samples were spiked with 1667 μmol/l H2O2. The 
addition of H2O2 caused a rapid increase in fluorescence in all samples over a linear 
range for at least 30 minutes. This demonstrated that added DCFH was not saturated 
by oxidant levels of samples.  Sample concentration was expressed as H2O2 
equivalents (μmol) per mg protein. Δ DCF fluorescence was calculated as the 
difference between clamp DCF fluorescence and basal DCF fluorescence. The 
measurement of Δ DCFH oxidation could reflect an insulin-stimulated antioxidant 
measurement in people with type 2 diabetes (334, 335). Optimization experiments 
for the DCFH assay in skeletal muscle are provided in Section 5.3.2 on page 144.  
 
4.3.3. GSH and GSSG  
 
Muscle samples (~45 mg) were freeze-dried and then powdered. Visible portions of 
connective tissue and fat were removed and samples were portioned out and 
weighed as two samples: one for total glutathione (TGSH) and one for GSSG. For TGSH 
analysis, muscle samples were homogenized 1:80 (w/v) in 5% MPA. For GSSG 
analysis, muscle samples were homogenized 1:80 (w/v) in a buffer containing 5 % 
MPA and 3 mmol/l M2VP.  M2VP acts as a scavenger of GSH in samples, thus allowing 
for the determination of GSSG levels only (336). Homogenized samples were 
centrifuged for 15 minutes at 16,000 g to pellet out protein. Sample supernatants 
were diluted for assay: 1:40 for GSH and 1:8.5 for GSSG based on prior assay 
optimization for linearity based on protein concentration and time (see Appendix 
10.4 on page 282).  Glutathione concentration of samples was measured based on 
methods of Tietze (337) using a commercially available assay kit (Bioxytech ® 
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GSH/GSSG-412TM, OxisResearch, Portland, OR). The assay involved the reaction of 
dithiobis-2-nitrobenzoic acid (DTNB) with glutathione in the presence of glutathione 
reductase. In this reaction, all GSSG present in the sample is reduced to GSH, allowing 
for the measurement of TGSH. The rate of change of absorbance at 412 nm reflects 
TGSH concentration (337); and was measured over three minutes following sample 
treatment with nicotinamide adenine dinucleotide phosphate (NADPH). Reduced 
GSH was calculated according to the formula: GSH = TGSH – 2 x GSSG. GSH and GSSG 
levels of blood samples were determined according to the assay kit recommended 
methods. The ratio of reduced GSH to GSSG (GSH/GSSG) was considered as a 
measure of oxidative stress. All assay plates included protein sample controls that 
demonstrated the linearity of the assay in relation to the protein concentration of 
samples (see Appendix 10.4 on page 282). 
Analytical methods 
121 
 
4.4. Muscle enzyme activity and metabolite measures 
4.4.1. Nitric oxide synthase activity  
 
Basal and insulin-stimulated samples (~10 mg) were homogenized 1:10 (w/v) in a 
buffer containing 250 mmol/l Tris-HCL (pH 7.4), 10 mmol/l EDTA and 10 mmol/l EGTA 
(item #10007063, Cayman Chemical) using polypropylene pellet grinders on ice. 
Samples were then centrifuged for 10,000 g for 5 minutes at 4 °C. Supernatants were 
assayed for total NOS activity using a radioactive-based assay kit (item #781001; 
Cayman Chemical) according to the manufacturer’s instructions. The assay is based 
on the biological conversion of L-arginine to nitric oxide and L-citrulline by NOS. In 
brief 5 μl of sample supernatant was added to 45 μl of reaction mixture containing 
25 mmol/l Tris-HCl (pH 7.4), 3 μmol/l tetrahydrobiopterin (BH4), 1 μmol/l flavin 
adenine dinucleotide, 1 μmol/l flavin adenine mononucleotide, 1 mmol/l NADPH, 1 
μl [3H] arginine (1 μCi/μl), 75 μmol/l CaCl2 and 0.1 μmol/l calmodulin (all final 
concentrations indicated). Samples were then incubated at room temperature for 30 
minutes followed by the addition of 400 μl of Stop buffer containing 50 mmol/l HEPES 
(pH 5.5) and 5 mmol/l EDTA.  Equilibrated resin was added to samples (1:5 v/v), which 
were transferred to spin cups and centrifuged at 22,000 g for 5 minutes.  Sample 
eluates were then transferred to scintillation vials and radioactive citrulline was 
quantitated using a liquid scintillation counter (Tricarb®, Perkin Elmer, Waltham, 
MA). A positive control (murine recombinant iNOS) was used in experiments.  To 
determine sample NOS activity, citrulline counts from a “blank” sample treated with 
the NOS inhibitor nitro-L-arginine (L-NNA) was subtracted from each sample count. 
Optimization experiments are presented in Section 5.4 on page 147.  NOS activity was 
expressed as pmol citrulline formed per gram protein per minute. 
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4.4.2. Superoxide dismutase activity  
 
Muscle samples (10-15 mg) were homogenized (1:50) in a buffer consisting of 100 
mmol/l NaH2PO4 (pH 7.0) with 1 mmol/l EDTA and 0.5 % Triton-X100 using 
polypropylene pellet grinders on ice. A prior optimization of lysis buffer was 
undertaken for this assay (see Appendix 10.5 on page 284). Samples were centrifuged 
at 1500 g for 10 minutes to remove cellular debris.  Supernatants were then diluted 
1:10 in assay buffer consisting of: 50 mmol/l Tris-HCl (pH 8.0), 0.1 mmol/l 
diethylenetriaminepentaacetic acid (DTPA) and 0.1 mmol/l hypoxanthine for assay. 
Total superoxide dismutase activity (including Cu/Zn SOD, MnSOD and FeSOD) was 
determined using a commercial spectrophotometric assay kit (item #706002; 
Cayman Chemical) that utilized a tetrazolium salt to detect ·O2- produced by xanthine 
oxidase and hypoxanthine. All assay plates included protein sample controls that 
demonstrated the linearity of the assay in relation to the protein concentration of 
samples (see Appendix 10.5 on page 284). 
 
4.4.3. Citrate synthase activity 
 
Citrate synthase activity was assessed as a marker of mitochondrial content in 
skeletal muscle (338). Muscle samples were prepared as for the SOD assay above with 
an additional freeze-thaw cycle. Assay buffer consisting of 66 mmol/l Tris (pH 8.3), 
0.6 mmol/l Acetyl CoA, 0.1 mmol/l DTNB and 0.6 mmol/l oxaloacetate (all final 
concentrations) was added to 5μl sample supernatant in 96-well plates and the 
change in absorbance was read over 5 minutes at 412 nm on a spectrophotometer. 
The assay was based on the reaction of acetyl-CoA with oxaloacetate and the 
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subsequent reaction of the formed thiol-bound CoA-SH with DTNB (307). Citrate 
synthase activity was expressed as μmol per gram protein per minute assuming an 
extinction coefficient of 13,600 M-1cm-1 for DTNB (339). 
 
4.4.4. Muscle glycogen assay  
 
Freeze-dried powdered muscle samples (≈1 mg) were assessed for glycogen 
concentration as previously described (340). In brief, samples were incubated in 2M 
HCl for two hours at 95-100 °C followed by neutralization with 0.667 mol/l NaOH. 
Samples were then assayed in a buffer cocktail consisting of 50 mmol/l Tris, 1 mmol/l 
MgCl2, 0.5 mmol/l DTT, 0.3 mmol/l ATP (pH 7.0), 50 μmol/l NADP+ and G-6-P-DH. 2.5 
μl of sample was combined with 250 μl of buffer and read on a fluorometer at 365 
nm. Hexokinase was then added to samples which were incubated in the dark for 1h. 
Sample absorbances were then read spectrophotometrically (341) and glycogen 
concentration determined from NADH and glucose standards. Glycogen 
concentration was assessed in both basal and insulin-stimulated muscle samples. 
 
4.4.5. Total protein analysis  
 
Total protein content of muscle samples used in assays was determined using the 
bicinchoninic acid assay (308) with bovine serum albumin as the reference standard. 
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4.5. Western blot analyses  
4.5.1. SVCT2 and NOS isoform expression 
 
Muscle samples (20-25 mg) were homogenized on ice in a freshly prepared ice-cold 
buffer consisting of 50 mmol/l Tris (pH 7.5), 1 mmol/l EDTA, 10 % (v/v) Glycerol, 1 % 
(v/v) Triton X, 50 mmol/l NaF, 5 mmol/l NaPP, 1 mmol/l DTT, 1 mmol/l PMSF, and 5 
μl/ml protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO #P8340, consisting of 
104 mmol/l AEBSF, 80 μmol/l Apoprotinin, 2 mmol/l Leupeptin, 4 mmol/l Bestatin, 
1.5 mmol/l Pepstatin A and 1.4 mmol/l E-64)(340). Samples were then centrifuged 
for 15 minutes at 13,000 g and supernatants frozen at -80 °C until analysis.  
4 x Loading buffer (40 % v/v glycerol, 285 mmol/l SDS, 250 mmol/l Tris [pH 6.8], 400 
mmol/l DTT and 1 % w/v bromophenol blue) was added to muscle samples (total 
protein: 20 μg for nNOS, 30 μg for eNOS and 60 μg for SVCT2), boiled for 5 minutes 
at 95 °C, and then loaded into 8-10 % polyacrylamide gels. The protein loading 
amount for each target protein was determined from previous optimization 
experiments that established the optimal range of linearity for protein quantification 
(refer to Section 5.5 on page 149 for SVCT2 optimization). Gels were subjected to 
electrophoresis and transferred onto PVDF membranes via electroblotting. 
Membranes were blocked in 5 % bovine serum albumin, followed by an overnight 
incubation at 4 °C with a mouse monoclonal anti-nNOS antibody (BD Biosciences; 
Franklin Lakes, NJ, diluted 1:1000), a mouse monoclonal anti-eNOS antibody (BD 
Biosciences, diluted 1:1000) or a goat polyclonal anti-SVCT2 antibody (S-19; Santa 
Cruz Biotechnology, Dallas, TX, diluted 1:400). Membranes were then incubated with 
a relevant secondary antibody (LI-COR IRDye® 680LT, LiCor Biosciences, Lincoln, USA). 
Detection and quantification of target proteins were made using the Odyssey® Infra-
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red Imaging system (LiCor Biosciences). A primary mouse monoclonal antibody for 
iNOS (Santa Cruz) was also tested on muscle samples ranging from 20-80 μg protein, 
but no detectable reactive band was observed despite a strong band found for 
recombinant iNOS (data not shown). 
A mouse monoclonal α-tubulin antibody (Cell Signaling, Beverly, MA) was used as a 
protein loading control for nNOS and eNOS. A mouse polyclonal GAPDH antibody 
(Sigma-Aldrich) was used as a protein loading control for SVCT2 due to the co-
localization of α-tubulin with SVCT2 on western blots. In addition, on each gel, control 
samples containing protein amounts both below and above the target protein 
amount were loaded. These additional control samples demonstrated a linearity of 
quantification in the range of sample loading for both the target protein and the 
loading control. For example, loading 20ug and 40ug of total protein for the control 
sample on each gel/membrane resulted in a doubling of signal intensity (302). Target 
proteins were normalized to loading controls for statistical analyses. 
Rat gastrocnemius muscle samples were used as positive controls for both nNOS and 
eNOS expression in human muscle homogenates. Enriched human blood platelet 
fractions were used as positive controls for SVCT2 western blotting in muscle 
homogenates. For platelet isolation, whole blood was collected from a single 
participant in EDTA tubes containing citrate buffer and centrifuged at 200 g for 15 
minutes.  The platelet rich fraction was then mixed 10:1 with acid-citrate-dextrose 
buffer and centrifuged at 900 g for 15 minutes. The washed pellet was re-suspended 
in a buffer containing 25 mmol/l Tris (pH 8.0), 1 mmol/l EDTA, 0.5 % SDS and 5 μl/ml 
protease inhibitor cocktail (Sigma P8340) and subjected to ultra-sonication (262).  
Optimization of western blotting is outlined in Section 5.5 on page 149. 
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4.6. Statistics 
 
Prior to parametric analyses, data normality was evaluated using a Shapiro Wilk test.  
When datasets violated the assumption of Gaussian normality, they were log-
transformed. Vitamin C (VC) and placebo (PLA) trials were compared using the two-
way repeated measures ANOVA with SPSS software (v. 21, IBM Corporation, Armonk, 
NY). Statistically significant treatment versus time interactions found were further 
assessed using Bonferroni-corrected multiple comparisons with Prism software 
(v.6.0, GraphPad Software Inc., La Jolla, CA). For select measures of glucose 
metabolism and oxidative stress that involved both basal and insulin-stimulated 
measurements, a general effect of hyperinsulinaemia (basal vs. insulin-stimulated) 
was determined using paired t-tests with pooled data for treatment (VC, PLA) and 
time (Pre treatment, Post treatment). Paired t-tests were also used to compare self-
reported vitamin C intake and physical activity energy expenditure between VC and 
PLA trials. Pearson’s correlations were used to assess associations between vitamin 
C concentration and oxidative stress and glucoregulatory measures; and for testing 
the repeatability of vitamin C intake between trial #1 and trial #2 using the 7-day diet 
checklist. Data are presented as mean ± SEM and as individual values. Log-
transformed data are presented as geometric mean ± 95% CI. p<0.05 was considered 
significant for all analyses. No significant differences were found for any measured 
variable at baseline when comparing vitamin C and placebo trials using two-tailed 
paired t-tests (data not shown). Power analyses from previous published data (169) 
and our own data (Chapter 2, on page 85) determined that n=6 participants were 
required to complete the trial to ensure >80 % power for both a 50 % increase in 
levels of insulin-stimulated Rd (+11.9 ± 2.7 μmol/kg FFM/min; mean increase ± SD) 
and muscle vitamin C (+9.6 ± 0.6 μg/g tissue) (318) (see Table 3.1 on page 97).  
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5.0. OPTIMIZATION OF ANALYTICAL METHODS 
 
5.1. Optimization of GC-MS methods 
Determination of 6, 6-D2 glucose tracer enrichment using GC-MS required prior 
optimization experiments to validate specificity and sensitivity of measurements.  
The protocol was based on quantification of the ratio of 100 m/z to 98 m/z mass 
products detected after sample derivatization with acetic anhydride and pyridine and 
electron ionization as done previously (330).  The protocol required adaptation from 
helium to hydrogen as a carrier gas.  A wide spectrum mass scan of derivatized 6, 6-
D2 glucose tracer standards and plasma samples was firstly undertaken to confirm 
the specificity of the 100/98 m/z ratio for discriminating 6, 6-D2 glucose in samples. 
Figure 5.1A illustrates two glucose pentaacetate stereoisomers identified in a scan of 
a plasma sample spiked with a small amount (≈ 5 % MPE) of 6, 6-D2 glucose tracer.  
Figure 5.1B shows the total ion mass scan within the first stereoisomer peak. It can 
be seen that 98 m/z is of much higher abundance when compared with 100 m/z in 
human plasma. Similarly, Figures 5.1C and 5.1D illustrate peaks of a derivatized 
sample of 99.1 % isotopically pure 6, 6-D2 glucose and its mass scan. In contrast to 
plasma, 100 m/z has proportionally higher abundance than 98 m/z in 6, 6-D2 glucose 
(Figure 5.1D). Figure 5.1E shows selected peaks of a 50 % MPE 6, 6-D2 glucose 
standard and its mass scans when favouring either the 100 m/z peak (Figure 5.1F) or 
the 98 m/z peak (Figure 5.1G). It can be seen that the 98 m/z and 100 m/z masses are 
similar in terms of their relative abundance in this mixed sample. Collectively these 
preliminary scans demonstrate that 98 m/z and 100 m/z mass products are sensitive 
to changes in 6, 6-D2 glucose concentrations in samples.  
Analytical method optimization  
128 
 
A      B 
 
C      D 
 
E      F 
    
              G                  
       
 
10.66 10 .67 10.68 10 .69 10.70 10.71 10.72 10.73 10.74 10.75 10.76 10.77 10.78 10.79
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
13000
14000
T ime-->
Abundanc e
Ion   98 .00  (97 .70  to  98 .70): D 2PLASM A_1.D \ data .ms
Ion  100.00  (99 .70  to  100.70): D 2PLASM A_1.D \ data .ms
3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 1 5 0 1 6 0 1 7 0 1 8 0 1 9 0 2 0 0
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
1 0 0 0 0
1 2 0 0 0
1 4 0 0 0
1 6 0 0 0
1 8 0 0 0
2 0 0 0 0
2 2 0 0 0
m / z - - >
1 1 5 . 0
9 8 . 0
1 5 7 . 0
2 0 0 . 01 4 0 . 05 9 . 9
8 1 . 0
1 7 0 . 0
1 8 6 . 0
1 0 . 6 6 1 0 . 6 7 1 0 . 6 8 1 0 . 6 9 1 0 . 7 0 1 0 . 7 1 1 0 . 7 2 1 0 . 7 3 1 0 . 7 4 1 0 . 7 5 1 0 . 7 6 1 0 . 7 7 1 0 . 7 8 1 0 . 7 9
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
2 5 0 0 0 0
3 0 0 0 0 0
3 5 0 0 0 0
4 0 0 0 0 0
4 5 0 0 0 0
5 0 0 0 0 0
5 5 0 0 0 0
6 0 0 0 0 0
T im e -->
A b u n d a n c e
I o n   9 8 . 0 0  (9 7 . 7 0  t o  9 8 . 7 0 ):  D 2 G L U C O S E 1 0 0 _ 0 . D \ d a t a . m s
I o n  1 0 0 . 0 0  (9 9 . 7 0  t o  1 0 0 . 7 0 ):  D 2 G L U C O S E 1 0 0 _ 0 . D \ d a t a . m s
3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 1 5 0 1 6 0 1 7 0 1 8 0 1 9 0 2 0 0
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
2 5 0 0 0 0
3 0 0 0 0 0
3 5 0 0 0 0
4 0 0 0 0 0
4 5 0 0 0 0
5 0 0 0 0 0
5 5 0 0 0 0
6 0 0 0 0 0
6 5 0 0 0 0
7 0 0 0 0 0
5 0 0 0 0
m / z - - >
1 1 5 . 0
1 0 0 . 0 1 5 7 . 0
1 7 1 . 0
2 0 2 . 0
1 4 2 . 0
1 2 9 . 07 3 . 0
6 0 . 0 8 6 . 0 1 8 9 . 0
1 0 . 6 6 1 0 . 6 7 1 0 . 6 8 1 0 . 6 9 1 0 . 7 0 1 0 . 7 1 1 0 . 7 2 1 0 . 7 3 1 0 . 7 4 1 0 . 7 5 1 0 . 7 6 1 0 . 7 7 1 0 . 7 8 1 0 . 7 9
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
1 0 0 0 0 0
1 2 0 0 0 0
1 4 0 0 0 0
1 6 0 0 0 0
1 8 0 0 0 0
2 0 0 0 0 0
2 2 0 0 0 0
2 4 0 0 0 0
2 6 0 0 0 0
2 8 0 0 0 0
T im e -->
A b u n d a n c e
I o n   9 8 .0 0  (9 7 . 7 0  to  9 8 . 7 0 ):  D 2 G L U C O S E 5 0 _ 5 0 . D \ d a ta .m s
I o n  1 0 0 . 0 0  (9 9 . 7 0  t o  1 0 0 . 7 0 ):  D 2 G L U C O S E 5 0 _ 5 0 .D \ d a ta . m s
3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 1 5 0 1 6 0 1 7 0 1 8 0 1 9 0 2 0 0
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
2 5 0 0 0 0
3 0 0 0 0 0
3 5 0 0 0 0
4 0 0 0 0 0
4 5 0 0 0 0
5 0 0 0 0 0
5 5 0 0 0 0
m / z - - >
1 1 5 . 0
1 5 7 . 0
1 0 0 . 0
1 7 1 . 0 2 0 2 . 01 4 5 . 0
7 3 . 0
8 5 . 0 1 2 9 . 06 0 . 0
1 8 6 . 0
3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 1 5 0 1 6 0 1 7 0 1 8 0 1 9 0 2 0 0
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
2 5 0 0 0 0
3 0 0 0 0 0
3 5 0 0 0 0
4 0 0 0 0 0
4 5 0 0 0 0
5 0 0 0 0 0
5 5 0 0 0 0
6 0 0 0 0 0
6 5 0 0 0 0
7 0 0 0 0 0
m / z - - >
1 1 5 . 0
1 5 7 . 0
9 8 . 0
1 4 0 . 0 2 0 0 . 0
1 7 1 . 07 3 . 0
6 0 . 0
1 8 6 . 0
Figure 5. 1. Verification of 
100/98 m/z ratio for 
quantification of 6, 6-D2 
glucose in samples  
Total ion chromatograms and 
mass scans for: A & B: a 
plasma sample with ≈ 5 % MPE 
6, 6-D2 glucose; C & D: neat 
6,6-D2 glucose; and E-G: 50 % 
MPE 6, 6-D2 glucose (refer to 
text for their descriptions).  
98 m/z 
100 m/z 
100 m/z 
98 m/z 
100 m/z 
98 m/z 
98 m/z 
100 m/z 
100 m/z 
98 m/z 
Analytical method optimization  
129 
 
A more sensitive GC-MS method was subsequently developed to selectively monitor 
only the 98 m/z and 100 m/z products in samples. The GC program consisted of a 20 
°C/min ramp starting at 100 °C. A final temperature of 260 °C was then held for five 
minutes. Hydrogen flow rate was set at 1.1 ml/min.  A split ratio injection of 1:50 was 
chosen based on a trade-off between high sample throughput and sample sensitivity.  
A lower split ratio allowed improved sensitivity, however it proved to shorten the life 
of columns and produce a more frequent need to clean the mass spectrometer ion 
source. The two glucose pentaacetate stereoisomers eluted sequentially, but the 
separation was adequate for quantification purposes.  Only the first of the two 
stereoisomers was used in calculations of MPE. Typical chromatographic outputs are 
shown in Figure 5.2 for neat plasma, plasma after 90 minutes of tracer infusion, a 25 
% MPE standard, and a 99 % MPE standard with the selective ion mode selected.  
Due to the potential of sample matrix effects of added 6, 6-D2 glucose, standards 
created in aqueous glucose solution versus plasma were compared. Both aqueous 
glucose and plasma standards were similar and linear in the range of 0 - 10 MPE as 
required for the current study (Figure 5.3). Thus, aqueous glucose 6, 6-D2 glucose 
standards were used in the current study for determination of plasma sample MPE 
(Figure 5.4).  
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D 
 
Figure 5. 2. Typical chromatographic output for the GC-MS calculations   
98 & 100 m/z peaks and shown for a plasma sample (A), a sample of the same plasma 
after glucose tracer was infused for 90 minutes (B), a 25 % MPE 6, 6-D2 glucose 
standard (C), and a 99 % MPE 6, 6-D2 glucose standard (D). 
 
 
Figure 5. 3. Comparison of aqueous and plasma 6, 6-D2 glucose standards 
Each point on the curve represents a mean of two different derivatized standard 
samples for a given concentration. 6, 6-D2 glucose standards were diluted in either 
equimolar aqueous glucose or equimolar human plasma 
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Figure 5. 4. A typical standard curve of 6, 6-D2 glucose produced in aqueous glucose 
Each point on the curve represents the mean 100/98 m/z ratio of duplicate 
standards 
 
Derivatized plasma and aqueous 6, 6-D2 glucose standard samples were stable for at 
least 24 h at room temperature as evidenced by no change in the 100/98 ratio over 
a range of different MPE concentrations (data not shown).  Finally, a retrospective 
investigation of the stability of samples when stored at -80 °C was undertaken by re-
testing samples for one participant twelve months after the first testing occasion.  
There was only marginal change in the calculated MPE for all samples after this time 
(Figure 5.5). Furthermore, the insulin-stimulated calculations for Rd and EGP were 
very similar after this time (Figure 5.5). 
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Figure 5. 5. Evaluation of stability of plasma tracer samples stored at -80°C 
Data points are n=1 (mean of duplicate injections). Samples indicated with open boxes 
were derivatized and measured using GC-MS two weeks after collection and storage 
at -80 °C. Samples indicated with closed boxes were derivatized and measured 12 
months after collection and storage at -80 °C.  All samples underwent a single freeze-
thaw process. Moles percent excess of 6, 6-D2 glucose is normalized to fasting glucose 
concentration. Rd and EGP were calculated during the final 60 minutes of the clamp. 
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5.2. Optimization of HPLC methods 
 
Determination of concentrations of AA in skeletal muscle homogenates and plasma 
using HPLC methodology required prior optimization experiments to validate 
specificity and sensitivity of measurements. The protocol was based in part on 
methodology of Lykkesfeldt (243).  Adaptations to the method were required based 
on the different UV-based detection system compared with electrochemical 
detection (243) and also to optimize identification of AA in skeletal muscle. 
Preliminary experiments using neat AA and UA standards enabled the generation of 
linear standard curves using the HPLC system (Figure 5.6).  AA proved highly unstable 
in aqueous solution, and required the addition of 5 mmol/l EDTA or preparation in 
mobile phase to ensure stability of standards for measurements. Given the capacity 
of the HPLC system to measure AA in a linear range of relevance to the biological 
samples, it was then necessary to determine sensitivity and specificity in skeletal 
muscle and plasma samples.  
 
Figure 5. 6. Linear standard curves generated for ascorbic acid (A) and uric acid (B) 
using HPLC 
Data points are the mean of duplicate measurements 
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Through a large number of experimental manipulations that included altering mobile 
phase constituent concentrations and pH, modifying sample preparation techniques, 
and changing run method and UV detection parameters; the most optimal conditions 
were established for detection of AA and TAA in samples. Illustrative examples of 
differences in chromatographic output before and after some of these manipulations 
are outlined in Figure 5.7. Typical chromatograms for muscle and plasma AA and TAA 
after all of these changes are shown in Figure 5.8. To validate the established 
conditions for sensitivity and specificity of AA in samples, recovery studies were 
undertaken for AA and TAA in skeletal muscle (Figure 5.9) and plasma. These studies 
involved spiking both skeletal muscle and plasma samples with known amounts of AA 
and comparing the measured concentrations with expected concentrations (Table 
5.1). A similar process was also undertaken for UA in both skeletal muscle (Figure 
5.10 & Table 5.2 on page 139) and plasma. Recoveries of 93 – 108 % of expected 
concentrations were found for AA and UA in recovery studies undertaken in both 
muscle and plasma. Finally, to additionally verify the specificity of the AA peak, 
samples were treated with the selective AA oxidizer, ascorbate oxidase, in order to 
selectively attenuate the ascorbic acid peak. An example of this experiment in plasma 
is illustrated in Figure 5.11). In this example, it can be seen that the AA peak is almost 
undetectable following 30 minutes of treatment with ascorbate oxidase. 
To measure system stability and inter-day variability of AA and UA over the course of 
all sample testing days, a control plasma sample was run on each day. The control 
sample demonstrated excellent stability over time, with overall intra-day and inter-
day coefficients of variation for peak area of < 5 % for both AA and UA (data not 
shown). 
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Figure 5. 7. Some key 
methodological 
alterations made to 
improve ascorbic acid 
detection in samples.  
A (L-R): improved 
separation of AA by 
decreasing the mobile 
phase methanol content 
from 25 % to 1 % (plasma 
sample); B (L-R): reduced 
interference of TAA in 
samples by dissolving 10 
mmol/l TCEP in 5% MPA 
solution and incubating at 
room temperature for 120 
mins instead of using a 
McIlvaine-TCEP buffer 
(plasma sample); C (L-R): 
improved separation of 
AA in skeletal muscle TAA 
samples by increasing the 
mobile phase pH from 
4.70 to 4.80. AA – ascorbic 
acid, UA - uric acid.   
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Figure 5. 8. Typical chromatograms for ascorbic acid in samples 
A: Reduced ascorbic acid in skeletal muscle; B: total ascorbic acid in skeletal muscle; 
C: reduced ascorbic acid in plasma; D: total ascorbic acid in plasma. AA – ascorbic acid 
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Figure 5. 9. An example of an ascorbic acid recovery study in skeletal muscle 
Chromatograms illustrate the addition of varying amounts of ascorbic acid to a 
skeletal muscle sample. AA: Ascorbic acid. 
 
Table 5. 1. Results of AA recovery study in skeletal muscle 
Added  
(in μmol/l) 
Added  
(in μg/g) 
Concentration 
(μg/g) 
Expected 
(μg/g) 
Recovery 
(%) 
0.00 0.00 8.16 8.16 - 
2.50 20.13 27.74 28.29 98.04 
5.00 40.26 46.68 48.42 96.41 
12.50 100.66 101.91 108.82 93.65 
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Figure 5. 10. An example of a uric acid recovery study in skeletal muscle  
Chromatograms illustrate addition of varying amounts of uric acid to a skeletal 
muscle sample. UA: uric acid. 
 
Table 5. 2. Results of UA recovery study in skeletal muscle 
Added  
(in μmol/l) 
Added  
(in μg/g) 
Concentration 
(μg/g) 
Expected 
(μg/g) 
Recovery 
(%) 
0.00 0.00 5.82 5.82 - 
5.00 38.43 44.09 44.25 99.63 
25.00 192.15 186.29 197.97 94.10 
50.00 384.30 384.29 390.12 98.50 
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A     
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Figure 5. 11. Treatment of a plasma sample with ascorbate oxidase  
A: chromatogram of a sample pre-treatment; B: the same sample after 30 minutes 
incubation with 20 units ascorbate oxidase at 25 °C, pH 5.5-adjusted (note: sample in 
B. is diluted 1:2 compared to A.) 
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5.3. Optimization of oxidative stress measures 
5.3.1. Optimization of F2-Isoprostanes assay 
 
Demonstration of suitability of the F2-Isoprostanes ELISA (8-Isoprostanes, Cayman 
Chemical) for human skeletal muscle was required based on a prior lack of data in 
human skeletal muscle homogenates using the assay.  Initial experiments using 
human muscle homogenates, rat muscle homogenates and human plasma 
demonstrated a non-linearity of quantification with respect to protein concentration 
and/or dilution using the assay.  It was therefore necessary to remove sample 
interferences through additional purification steps prior to assay.  Furthermore, given 
the presence of F2-Isoprostanes in both free and esterified forms in vivo (342), an 
hydrolysis step was also undertaken to enable measurement of total F2-Isoprostanes 
in both muscle and plasma samples. It was found that single use reverse phase C18 
solid phase extraction columns (Item #400020 Cayman Chemical, Ann Arbor, MI) 
were more reliable in allowing a consistent measurement of total F2-Isoprostanes in 
both skeletal muscle and plasma samples when compared with multi-use 
commercially available purification columns (Item # 10367, Cayman Chemical; data 
not shown). Sample hydrolysis, deproteinization and purification steps were 
undertaken according to recommended methods of the assay kit manufacturer.  
Linearity of the 8-Isoprostanes assay was then established in both skeletal muscle 
(Figure 5.12) and plasma (Figure 5.13) with respect to total protein concentration and 
sample dilution in assay buffer respectively. All assay plates included sample controls 
that demonstrated the linearity of the assay in relation to the sample protein 
concentration and/or dilution (Figure 5.14). 
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Figure 5. 12. Optimization of muscle protein concentration for 8-Isoprostanes assay   
Optimization experiment involving three different human muscle samples and their 
estimated concentrations using the 8-Isoprostanes assay over a range of different 
protein concentrations. The most optimal collective linear range for sample 
concentration in the assay is circled, with 1.67 mg/ml used in the assay. 
 
 
Figure 5. 13. Optimization of plasma dilution for plasma total 8-Isoprostanes assay  
Optimization experiment involving two different extracted human plasma samples 
and their estimated concentrations using the 8-Isoprostanes assay over a range of 
different dilutions. The most optimal collective linear range for sample dilution in the 
assay is circled, with a dilution of 1:3 (plasma: assay buffer) used in the assay. 
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Figure 5. 14. Control samples in skeletal muscle and plasma F2-Isoprostanes assays 
Demonstration of linearity of sample protein concentration and dilution in F2-
Isoprostanes assays for (A) skeletal muscle and (B) plasma respectively. Data are 
mean ± SEM (n=3 for skeletal muscle; n=2 for plasma).
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5.3.2. Optimization of DCFH assay 
 
The DCFH assay was adapted for use in 96-well fluorescent plates from previous 
studies in skeletal muscle homogenates (304, 305). This required a number of 
optimization experiments to extensively verify the accuracy of the assay. Firstly, the 
linearity of the assay with respect to both protein concentration and time were 
investigated using a few different homogenization buffers (Figure 5.15). Samples 
were homogenized in DCFH assay buffer (130 mmol/l KCl, 5 mmol/l MgCl2, 20 mmol/l 
NaH2PO4, 20 mmol/l Tris-HCl and 30 mmol/l glucose, pH 7.4 (304)) or in western blot 
lysis buffer (50 mmol/l Tris (pH 7.5), 1 mmol/l EDTA, 10% (v/v) Glycerol, 1 % (v/v) 
Triton X, 50 mmol/l NaF, 5 mmol/l NaPP, 1 mmol/l DTT, 1 mmol/l PMSF, and 5 μl/ml 
protease inhibitor cocktail [Sigma Aldrich, # P8340]) or in a buffer consisting of 25 
mmol/l Tris-HCl (pH 7.4), 1 mmol/l EDTA and 1 mmol/l EGTA. Samples homogenized 
in all three buffers produced approximately linear rates of fluorescence change over 
a range of different protein concentrations when measured every 3 minutes during a 
60 minute period (Figure 5.15). However, values were lower in the western blot lysis 
buffer, and thus this buffer was not chosen for use in subsequent assays.  Based on 
these experiments, a sample protein concentration of 2 mg/ml (0.067 mg/ml final 
assay concentration) was chosen for use in assays. Both the DCFH assay buffer and 
the Tris/EDTA/EGTA buffer were used in assays. All assay plates included protein 
sample controls that demonstrated the linearity of the assay with respect to protein 
concentration of samples (data not shown). 
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Figure 5. 15. Optimization experiments for DCFH assay in muscle homogenates 
Optimization included use of different protein concentrations and homogenization 
buffers. Change in DCF fluorescence was linear over 60 mins and concentrations were 
calculated over 30 minutes. The most optimal buffers and linear range tested are 
circled. 
 
Skeletal muscle homogenates exhibited a profound matrix effect with respect to the 
measured DCF fluorescence after addition of H2O2 to samples based on predicted 
recoveries using an aqueous DCFH-H202 standard curve (data not shown). Thus, for 
quantification of DCF fluorescence in samples, an H2O2 standard curve was created 
in pooled muscle sample homogenates. The rate of fluorescence change was shown 
to be approximately linear for added H2O2 concentrations (0-3330 μmol/l) over 60 
minutes in all experiments (Figure 5.16). To further demonstrate the redox sensitivity 
of the assay, samples were treated with either 1 mmol/l GSH (an H2O2 scavenger) or 
1 mmol/l ascorbic acid (a general ROS/RNS scavenger) in a series of experiments 
(Figure 5.17). Measured change in fluorescence was attenuated by approximately 60 
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% in samples after treatment with GSH, while change in flouresence in samples was 
decreased by approximately 90 % after treatment with ascorbic acid.  
 
Figure 5. 16. Typical standard curve for hydrogen peroxide generated in muscle 
homogenates  
Change in DCF fluorescence in pooled muscle homogenates was linear over 60 mins 
and concentrations were calculated over 30 minutes. 
 
 
Figure 5. 17. Effect of redox modulation on DCF fluorescence in skeletal muscle 
samples 
Pooled results of n=10 experiments for demonstration of sensitivity of the DCFH assay 
to treatment with hydrogen peroxide and antioxidants glutathione (GSH) and 
ascorbic acid (AA). SAMPLE refers to a human muscle sample. The amount of H2O2 
added varied in experiments; although 1 mmol/l of GSH and AA were added in each 
experiment. Data are mean ± SEM. 
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5.4. Optimization of enzyme activity assays 
5.4.1. Optimization of NOS activity assay 
 
Optimization experiments were required to establish the optimal conditions for 
undertaking the NOS activity assay in skeletal muscle samples.  Firstly, linearity of the 
assay was determined with respect to muscle protein concentration and time. An 
experiment was conducted where samples ranging from 2.5-10 mg/ml protein were 
assayed for 15 minutes or 30 minutes at 37 °C according to assay kit instructions. It 
was demonstrated that the assay was approximately linear for a sample protein 
concentration between 5mg/ml and 10mg/ml after 15 minutes (Figure 5.18A), but 
only for 5 mg/ml samples between 15 and 30 minutes. A second experiment was then 
undertaken to evaluate the temperature conditions of assay for a 5 mg/ml sample 
over 15-45 minutes. The sample was incubated at either room temperature or 37 °C 
(Figure 5.18B), for 15 minutes, 30 minutes or 45 minutes. Similar to findings of the 
first optimization experiment, the assay was linear with respect to time using a 5 
mg/ml sample. However, in this experiment, the room temperature incubation 
produced a slightly more linear trajectory of change in measured radioactive counts 
between 15-45 minutes when compared with the 37 °C incubation; although they 
were almost identical after 45 minutes (Figure 5.18B).  Therefore, 30-minute room 
temperature assay incubations using samples containing 5mg/ml protein were used 
in the final assays.  
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Figure 5. 18. Optimization experiments for the NOS activity assay in skeletal muscle  
A: The experiment demonstrated linearity between 5 mg/ml and 10 mg/ml protein 
samples after 15 mins and also for the 5 mg/ml protein sample between 15 and 30 
minutes at 37 °C. B: The experiment demonstrated approximate linearity for the assay 
performed with 5 mg/ml protein samples over 45 minutes at either room temperature 
or 37 °C 
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5.5. Optimization of western blotting methods 
 
It was necessary to evaluate the effectiveness of western blotting to discriminate 
SVCT2 protein in human skeletal muscle homogenates.  Previous data in non-muscle 
human cell types has shown that human SVCT2 migrates to approximately 50 kDa 
using SDS western blotting as compared with 65-75 kDa for murine SVCT2 (236, 256, 
259, 260, 262). A goat polyclonal antibody, S-19 (Santa Cruz biotechnology, Inc), was 
chosen for western blotting as it has been widely used for SVCT2 detection in 
published research (e.g. (236, 262, 343, 344)). Furthermore, according to the 
antibody manufacturer’s product data sheet (http://datasheets.scbt.com/sc-
9926.pdf), human SVCT2 has a molecular weight of 50 kDa.  
Given the previous detection of SVCT2 in human platelets in vivo using this particular 
antibody, whole blood was collected from a participant for isolation of a platelet-rich 
portion to serve as a positive control. Both the platelet-rich positive control and 
human skeletal muscle homogenates were run on a 10 % SDS gel using western 
blotting. As expected, platelet-rich samples produced a strong reactive band at ≈50 
kDa (Figure 5.19). Skeletal muscle also produced a distinct reactive band at ≈50 kDa 
(Figure 5.19). However, additional bands were also detected at ≈80 kDa and ≈45 kDa 
(a doublet band) in skeletal muscle, but not in platelets.  Since these bands were not 
detected in the platelet samples, it could be argued that they are not SVCT2-specific.  
However, one cannot discount the possibility that the higher molecular weight band 
detected is a glycosylated form; and that the lower molecular weight doublet band is 
a shorter isoform of SVCT2 in skeletal muscle. In fact, a shorter inactive but inhibitory 
isoform of SVCT2 has been detected in various cells (345). It should be noted, 
however, that the 45 kDa doublet was not detectable in all participants’ skeletal 
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muscle. In consideration of this information, only the 50 kDa band was consequently 
chosen for SVCT2 quantification in skeletal muscle.  
 
                                              
                                                                
Figure 5. 19.  Detection of SVCT2 in skeletal muscle and platelets using western 
blotting 
The left lane is a human skeletal muscle homogenate (≈100 μg protein), the middle 
lane is a human platelet-rich sample, and the third lane is a molecular weight ladder 
 
In order to determine the optimal linear range for detection of SVCT2 in skeletal 
muscle using western blotting, an optimization experiment based on protein amount 
loaded was undertaken. Protein amounts ranging from 20 – 100 μg per lane were 
loaded in duplicate to determine the most optimal amount to load (Figure 5.20). The 
reactive band quantification was approximately linear across this entire loading 
range, with proportional increases relative to the amount loaded. A consistent salient 
band was detectable from approximately 40 μg upwards. Thus, 60 μg was chosen as 
the loading amount for SVCT2 western blotting. A similar process for determining 
Skeletal 
muscle 
Platelets MWT 
ladder 
50 kDa 
37 kDa 
75 kDa 
SVCT2 
Analytical method optimization  
151 
 
protein loading amount used for SVCT2 was also undertaken for both nNOS and eNOS 
in skeletal muscle, establishing optimal loading amounts of 20 μg and 30 μg total 
protein respectively (data not shown).  
 
 
Figure 5. 20. Optimization of SVCT2 protein loading for western blotting in skeletal 
muscle 
Top: A representative western blot involving a range of different total protein 
amounts for optimization of the linear protein quantification range for SVCT2 in 
skeletal muscle homogenates. Bottom: Measured integrative intensity output from 
this same experiment in duplicate. Data is mean ± SEM. 
 
On each gel run during the study for SVCT2, nNOS and eNOS, pooled muscle was 
loaded at amounts less than and more than the amount of total protein loaded for 
samples in order to demonstrate linearity of quantification for target proteins. An 
example western blot and summary data for SVCT2, eNOS and nNOS during the study 
are shown in Figure 5.21. 
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Figure 5. 21. Control samples run on western blots for SVCT2, nNOS and eNOS 
Doubled protein control samples run on each western blot for (A) SVCT2 and the 
loading control GAPDH, (B) nNOS and the loading control α-Tubulin, and (C) eNOS and 
the loading control α-Tubulin demonstrate a doubling of signal intensity. In each 
image, a representative blot is provided in which each protein amount is loaded in 
duplicate. At the bottom of each image is the summary data from all western blots 
during the study. Data are mean ± SEM.  
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6.0. RESULTS 
 
6.1. General Results 
6.1.1. Participant characteristics  
 
Of the thirteen participants that commenced the trial, seven participants were 
compliant with trial requirements. Three participants were withdrawn during the trial 
due to alterations in their anti-diabetic medication regimens, and three participants 
withdrew for personal reasons relating to family, work and health concerns 
respectively. Capsule compliance, as determined by the equation:  number of 
capsules consumed/ number of capsules expected for full compliance X 100 %, were: 
vitamin C (VC) trial: 97.5 ± 0.9 % and placebo (PLA) trial: 96.6 ± 2.0 %. General 
characteristics of participants that commenced the trial compared with compliant 
participants are presented in Table 6.1). Unpaired two-tailed t-test comparisons 
revealed no significant differences (p>0.05) between compliant and non-compliant 
participants for any baseline characteristics (data not shown). Overall, participants 
had stable moderate glucose control as shown by the HbA1c measures (range 6.5 - 
9.4 %) prior to the trial; and twelve out of the thirteen participants were on single or 
dual oral anti-diabetic medications (see Appendix 10.1 on page 266). Participants 
were middle-aged (range 40.3 - 68.7 y) and had excess total body adiposity (range 
29.5 - 44.0 %) (346). Additional medications for lipid control, blood pressure control 
and health-specific indications used by participants were maintained during the 
course of the study (see Appendix 10.1 on page 266).  
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Table 6. 1. Baseline participant characteristics 
 All Participants Compliant 
Participants 
N (Gender) 13 (12 male, 1 female) 7 (6 male, 1 female) 
Age (years) 57.9 ± 2.5 59.4 ± 3.5 
Years since diabetes diagnosis 5.2 ± 1.4 4.1 ± 1.1 
Diabetes treatment  
(n treatment) 
11 Met*, 5 Sulf†, 5  
Dpp-4‡, 1 Diet§ 
7 Met, 2 Sulf, 4 Dpp-4 
Principal ethnicity 10 Caucasian/3 Asian 6 Caucasian/ 1 Asian 
Height (m) 172 ± 2 173 ± 3 
Weight (kg) 89.9 ± 3.1 91.6 ± 3.8 
BMI (kg.m-2) 30.5 ± 0.8 30.8 ± 1.3 
Fat-free mass (kg) 59.3 ± 2.1 59.3 ± 3.3 
Body fat (%) 34.7 ± 1.3 36.1 ± 2.1 
Systolic blood pressure (mm Hg) 135.7 ± 4.0 141.4 ± 5.4 
Diastolic blood pressure (mm Hg) 82.5 ± 2.0 83.1 ± 3.4 
Plasma vitamin C (μmol.l-1) 45.1 ± 3.1 46.6 ± 5.1 
M-value (mg.kg FFM-1.min-1)‖ 3.5 ± 0.3 3.6 ± 0.5 
HbA1C (%) 7.6 ± 0.2 7.4 ± 0.2 
Fasting glucose (mmol.l-1) 9.6 ± 0.5 9.5 ± 0.7 
Total cholesterol (mmol.l-1) 4.6 ± 0.3 4.1 ± 0.4 
LDL-cholesterol (mmol.l-1) 2.4 ± 0.2 2.2 ± 0.3 
HDL-cholesterol (mmol.l-1) 1.2 ± 0.1 1.1 ± 0.1 
Triglycerides (mmol.l-1) 2.1 ± 0.3 1.7 ± 0.8 
Serum urea (mmol.l-1) 6.3 ± 0.5 6.2 ± 0.7 
Serum creatinine (μmol.l-1) 81.8 ± 2.8 79.7 ± 4.5 
GGT (U.l-1)# 40.8 ± 7.9 48.3 ± 13.2 
AST (U.l-1)** 22.8 ± 1.8 24.6 ± 2.1 
ALT (U.l-1)†† 35.3 ± 4.0 36.6 ± 4.6 
 
(Data are expressed as mean ± SEM; *Metformin; †Sulfonylurea; ‡DPP-4 inhibitor; 
§Diet-only treated; ǁM-value – rate of whole-body glucose metabolism calculated 
during the final 60 minutes of the hyperinsulinaemic, eulgycaemic clamp in 20-minute 
intervals according to formula of DeFronzo et al. (324);  #GGT - serum gamma 
glutamyl transpeptidase; **AST - serum aspartate aminotransferase; ††ALT - serum 
alanine aminotransferase) 
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6.1.2. Adverse effects  
 
One participant reported minor gastrointestinal discomfort during the early stages of 
the VC trial, although symptoms disappeared after 1-2 weeks. No other adverse 
events were reported during either VC or PLA trials. 
 
6.1.3. Basal glucose, lipids, body composition and inflammation 
 
There were no statistically significant effects of vitamin C treatment on HbA1c, fasting 
glucose, HOMA indices, serum cholesterol, triglycerides, renal function or hepatic 
function when compared with placebo in compliant participants (Table 6.2). Vitamin 
C supplementation also had no significant effect on plasma levels of adiponectin, 
resistin, interleukin-6, interleukin-10 or TNF-α (p>0.05 for all comparisons; Table 6.2). 
A significant treatment x time interaction was found for plasma interleukin-8 
(p=0.050; Table 6.2), reflecting increased pre-post levels with vitamin C 
supplementation compared with decreased pre-post levels with placebo 
supplementation.  However, in relation to this interaction, post-hoc tests were not 
statistically significant, suggesting an equivocal effect of supplementation on plasma 
interleukin-8 levels. 
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Table 6. 2. Changes in basal characteristics of compliant participants  
 Placebo Vitamin C 
Pre Post Pre Post 
Weight (kg) 91.2 ± 3.9 90.1 ± 3.7 91.1 ± 3.5 90.8 ± 3.4 
Height (cm) 172.4 ± 3.0 172.5 ± 2.9 172.7 ± 2.8 172.7 ± 2.9 
BMI (kg.m-2) 30.7 ± 1.3 30.3 ± 1.1 30.6 ± 1.1 30.5 ± 1.2 
Body fat (%) 36.1 ± 2.2 35.0 ± 1.9 35.6 ± 2.0 35.5 ± 2.2 
Fat mass (kg) 31.3 ± 2.1 30.2 ± 1.9 30.8 ± 1.8 30.7 ± 2.0 
Fat-free mass (kg) 59.1 ± 3.4 59.5 ± 3.2 59.5 ± 3.2 59.4 ± 3.2 
HbA1c (%) 7.3 ± 0.2 7.4 ± 0.2 7.1 ± 0.2 7.4 ± 0.3 
Glucose (mmol.l-1) 
HOMA-IR* 
HOMA-S (%)* 
HOMA-B (%)* 
10.3 ± 0.7 
3.4 ± 0.3 
30.3 ± 2.0 
57.8 ± 6.7 
10.0 ± 0.5 
3.5 ± 0.4 
31.1 ± 3.0 
59.4 ± 7.1 
10.1 ± 0.8 
3.3 ± 0.3 
31.9 ± 3.1 
60.4 ± 9.0 
10.1 ± 0.9 
3.0 ± 0.1 
34.1 ± 1.5 
59.3 ± 11.9 
Total cholesterol (mmol.l-1) 3.9 ± 0.3 3.9 ± 0.3 3.8 ± 0.3 3.9 ± 0.3 
LDL-cholesterol (mmol.l-1) 2.1 ± 0.1 2.0 ± 0.3 2.1 ± 0.2 2.1 ± 0.2 
HDL-cholesterol (mmol.l-1) 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.1 ± 0.1 
Triglycerides (mmol.l-1) 1.7 ± 0.3 1.8 ± 0.2 1.5 ± 0.2 1.5 ± 0.1 
Adiponectin (μg.ml-1) 
Resistin (pg.ml-1) 
Interleukin-6 (pg.ml-1) 
Interleukin-8 (pg.ml-1) 
Interleukin-10 (pg.ml-1) 
TNF-α (pg.ml-1)† 
10.1 ± 2.5 
20.9 ± 2.5 
10.3 ± 6.5 
4.8 ± 0.5 ‡ 
11.8 ± 2.8 
9.7 ± 1.4 
9.6 ± 2.0 
20.0 ± 3.1 
11.9 ± 5.6 
4.1 ± 0.3  
10.7 ± 2.9 
9.6 ± 1.6 
10.6 ± 2.6 
20.2 ± 3.7 
7.8 ± 3.7 
4.2 ± 0.4 
10.2 ± 2.8 
9.6 ± 1.3 
10.2 ± 2.4 
21.9 ± 3.9 
9.7 ± 4.7 
4.8 ± 0.7 
14.2 ± 2.8 
9.6 ± 1.4 
Serum urea 5.3 ± 0.5 5.6 ± 0.5 5.7 ± 0.4 5.4 ± 0.5 
Serum creatinine (μmol.l-1) 78.1 ± 5.4 79.4 ± 5.9 82.0 ± 5.8 78.6 ± 5.7 
eGFR (ml.min-1.1.73m-2)§ 83.7 ± 2.9 84.9 ± 2.4 83.3 ± 3.2 85.6 ± 2.6 
GGT (U.l-1) 46.3 ± 13.0 47.4 ± 14.1 47.1 ± 12.5 46.3 ± 11.8 
AST (U.l-1) 23.6 ± 2.4 24.1 ± 3.1 23.1 ± 1.2 24.4 ± 3.5 
ALT (U.l-1) 39.0 ± 7.2 39.6 ± 8.8 34.7 ± 5.3 38.4 ± 7.4 
 
(Data are expressed as mean ± SEM; * as calculated using an online Homeostasis 
Model-2 calculator [http://www.dtu.ox.ac.uk/HOMACalculator/]; † tumor-necrosis 
factor-alpha; ‡ indicates main treatment x time interaction; § eGFR-estimated age-
adjusted glomerular filtration rate) 
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6.1.4. Diet and physical activity measurements  
 
There were no significant differences between VC and PLA trials for self-reported 
vitamin C intake (VC: 105.6 ± 14.4 mg/day vs. PLA: 99.0 ± 20.7 mg/day, p=0.651) or 
physical activity energy expenditure (VC: 440.6 ± 95.5 kJ/day vs. PLA: 748.0 ± 188.7 
kJ/day, p=0.054) in compliant participants when compared using two-tailed paired t-
tests. To further investigate reliability of the vitamin C dietary checklist to assess self-
reported vitamin C intake throughout the trial, Pearson’s correlations were 
undertaken to compare intake in trial #1 and trial #2. The vitamin C dietary checklist 
was found to be a highly repeatable measure of dietary vitamin C intake in individuals 
as evidenced by significant correlations between trial #1 and trial #2 vitamin C intake 
after normalisation to muscle (r=0.86, p=0.013) or plasma (r=0.97, p<0.001) vitamin 
C concentration (Figure 6.1). 
 
Figure 6. 1. Reliability of the 7-day diet checklist for assessment of vitamin C levels 
Repeatability of self-reported vitamin C intake using the 7-day diet checklist for 
assessment of vitamin C levels in individuals after normalisation to skeletal muscle (A) 
and plasma (B) vitamin C concentration using Pearson’s correlations 
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6.2. Glucose and substrate metabolism 
6.2.1. Plasma insulin, clamp glucose and glucose infusion rate 
 
Plasma insulin was significantly increased at t=30 minutes during the 
hyperinsulinaemic, euglycaemic clamp compared with t=0 minutes (p<0.001) and did 
not change after this time when assessed using the human insulin ELISA kit (Figure 
6.2). There was no effect of vitamin C treatment on plasma insulin at any time point 
when assessed using the human ELISA kit (Figure 6.2). Despite lower absolute values 
reported for insulin with the ELISA kit compared with the RIA kit, fasting insulin values 
correlated highly between assays (r=0.93, p<0.001) using Pearson’s correlation. 
Similar to the ELISA results, no significant effect of treatment on either fasting 
(p=0.352 for treatment x time interaction; Figure 6.3A) nor clamp (p=0.086 for 
treatment x time interaction; Figure 6.3C) insulin levels were observed when 
assessed using the human insulin RIA kit.   
 
Figure 6. 2.  Effect of supplementation on plasma insulin levels as measured using 
the human ELISA kit 
Values are mean ± SEM; Pre: pre supplementation, Post: post supplementation 
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Figure 6. 3.  Effect of supplementation on fasting and clamp plasma insulin levels 
using the human RIA kit 
A & B: fasting insulin; C & D: steady-state clamp insulin; A & C: values are mean ± 
SEM; B & D: values are individual data.  
 
Neither blood glucose nor the glucose infusion rate differed significantly between 
vitamin C and placebo trials at pre- and post- supplementation time points during the 
hyperinsulinaemic, euglycaemic clamp (Figure 6.4). Blood glucose decreased 
progressively over time until 120 minutes during the clamp, after which time it 
remained stable at 5.5 mmol/L (Figure 6.4). In contrast, the glucose infusion rate 
increased progressively during the clamp until 120 minutes, after which time it did 
not change significantly (Figure 6.4). 
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Figure 6. 4. Effect of supplementation on blood glucose and glucose infusion rate 
during the hyperinsulinaemic, euglycaemic clamp 
Blood glucose (left y axis data) and glucose infusion rate (right y axis data) during the 
clamp pre- and post- supplementation. Data are mean ± SEM; Placebo pre- and post- 
trials are indicated with negative error bars; Vitamin C pre- and post- trials are 
indicated with positive error bars; GIR – glucose infusion rate. 
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6.2.2. Rates of glucose disappearance and metabolic clearance of glucose 
 
Vitamin C treatment had no effect on basal Rd (Figure 6.5A), clamp Rd (Figure 6.5A) 
or MCR (Table 6.3). There was a trend for clamp Rd to increase following vitamin C 
after correcting for plasma insulin (Rd/I) (p=0.078 for treatment x time interaction).  
Δ Rd (insulin-stimulated glucose disposal) significantly increased following vitamin C 
treatment when compared with placebo (p=0.009 for treatment x time interaction; 
Figure 6.5C).  Δ Rd remained significantly elevated following VC treatment after 
correcting for the change in plasma insulin during the clamp (p=0.013 for treatment 
x time interaction). Δ MCR was also significantly increased following vitamin C 
treatment (p=0.025 for treatment x time interaction; Table 6.3).  
 
6.2.3. Endogenous glucose production  
 
EGP decreased significantly from basal levels during the hyperinsulinaemic, 
euglycaemic clamp by approximately 74 % independent of treatment and time 
(p<0.001). However, vitamin C treatment had no significant effect on basal EGP, 
clamp EGP or Δ EGP (Table 6.3).  
 
6.2.4. Rates of substrate oxidation and non-oxidative glucose metabolism 
  
There were no significant differences between basal and clamp values for 
carbohydrate oxidation rate or resting energy expenditure rate (p>0.05). Vitamin C 
treatment had no effect on basal or insulin-stimulated rates of carbohydrate or lipid 
oxidation, resting energy expenditure, RER or plasma lactate (Table 6.3). There was 
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also no significant effects of vitamin C treatment on basal or clamp NOGM (Figure 
6.6A); although there was a tendency for Δ NOGM to improve with vitamin C 
treatment (p=0.065 for treatment x time interaction; Figure 6.6C).  
 
6.2.5. Muscle glycogen  
 
There was no significant difference between basal and clamp measures of muscle 
glycogen independent of treatment and time (p=0.077; Table 6.3). Vitamin C 
treatment had no significant effect on levels of basal muscle glycogen, clamp muscle 
glycogen or Δ muscle glycogen when compared with placebo (p>0.05; Table 6.3). 
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Figure 6. 5. Effect of supplementation on rate of glucose disappearance 
A & B: Rd measured during the final 30 minutes of basal conditions and the final 60 
minutes of the hyperinsulinaemic, euglycaemic clamp; C & D: Δ Rd; A & C: values are 
mean ± SD; B & D: data are individual values; *denotes significantly different to pre, 
p<0.05; #denotes significantly different to placebo, p<0.05; PLA – placebo; VC – 
vitamin C.  
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Table 6. 3. Substrate kinetics pre- and post- supplementation 
 PLACEBO VITAMIN C 
Pre Post Pre Post 
MCR (ml.kg FFM-1.min-1)     
       Basal 
       Clamp  
       Delta 
2.1 ± 0.2 
4.3 ± 0.4 
2.2 ± 0.3 
1.9 ± 0.3 
4.7 ± 0.4 
2.8 ± 0.3 
2.3 ± 0.2 
4.3 ± 0.5 
2.0 ± 0.5 
1.8 ± 0.4 
5.3 ± 0.8 
3.5 ± 0.6 *† 
EGP (μmol.kg FFM-1.min-1)     
       Basal 18.6 ± 1.9 16.8 ± 1.9 20.2 ± 2.2 14.5 ± 2.3 
       Clamp  4.3 ± 0.6 5.2 ± 1.4 4.8 ± 1.3 4.2 ± 1.4 
       Delta -14.3 ± 1.6 -11.5 ± 1.5 -15.4 ± 2.4 -10.3 ± 3.3 
‡CHO ox (μmol.kg FFM-1.min-1) §     
       Basal 16.6 ± 5.5 11.6 ± 2.3 13.7 ± 2.8  13.2 ± 5.2 
       Clamp 17.8 ± 3.9 17.1 ± 4.2 16.6 ± 4.0 14.1 ± 3.2 
       Delta 1.2 ± 2.2  5.5 ± 2.3  2.9 ± 3.4 0.8 ± 4.9 
‡Fat ox (μmol.kg FFM-1.min-1) ǁ     
       Basal  1.02 ± 0.39  0.98 ± 0.18 1.17 ± 0.23 0.93 ± 0.32 
       Clamp  0.70 ± 0.34 0.46 ± 0.21 0.86 ± 0.30  0.83 ± 0.31 
       Delta -0.31 ± 0.21 -0.52 ± 0.24 -0.30 ± 0.24 -0.09 ± 0.41 
‡Respiratory exchange ratio     
       Basal 0.86 ± 0.04 0.84 ± 0.01 0.84 ± 0.02 0.84 ± 0.04 
       Clamp 0.89 ± 0.03 0.89 ± 0.03 0.87 ± 0.03 0.86 ± 0.03 
       Delta 0.03 ± 0.02 0.05 ± 0.02 0.03 ± 0.03  0.02 ± 0.04 
‡Resting energy expenditure  
(J.kg FFM-1.min-1) 
    
       Basal 86.7 ± 9.4 69.9 ± 11.0 83.0 ± 3.4 77.5 ± 9.6 
       Clamp 79.9 ± 9.2 69.6 ± 11.4 81.7 ± 8.7 72.7 ± 7.3 
       Delta -6.9 ± 2.9 -0.2 ± 4.0 -1.3 ± 5.6 -4.8 ± 4.0 
Plasma lactate (mmol.l-1)     
       Basal 1.39 ± 0.07  1.10 ± 0.07 1.26 ± 0.06 1.21 ± 0.07 
       Clamp 1.06 ± 0.09 1.11 ± 0.12 1.13 ± 0.11 1.07 ± 0.08 
       Delta 
Muscle glycogen  
(mmol.kg-1 dry weight)  
       Basal 
       Clamp 
       Delta 
-0.33 ± 0.12 
 
 
394.0 ± 38.5 
428.1 ± 48.4 
34.1 ± 34.9 
0.01 ± 0.14 
 
 
356.7 ± 11.6 
398.7 ± 21.6 
42.0 ± 30.3 
-0.13 ± 0.12 
 
 
362.1 ± 15.9 
399.2 ± 29.8 
37.1 ± 32.0 
-0.14 ± 0.11 
 
 
397.9 ± 57.6 
493.5 ± 92.9 
95.6 ± 104.7 
 
(Data are expressed as mean ± SEM; * indicates significantly different to placebo; † 
indicates significantly different to pre, p<0.05; ‡n=6 only - one participant was 
removed from analysis due to systematic hyperventilation during indirect calorimetry; 
§ CHO ox – carbohydrate oxidation rate; ǁ Fat ox – fat oxidation rate) 
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Figure 6. 6. Effect of supplementation on non-oxidative glucose metabolism 
A & B: Basal and clamp NOGM; C & D: Δ NOGM; A & C: values are mean ± SEM; B & 
D: data are individual values; data is only n=6 due to systematic hyperventilation by 
one participant; PLA – placebo; VC – vitamin C. 
Results 
166 
 
6.3. Vitamin C concentrations  
6.3.1. Plasma and skeletal muscle total ascorbic acid 
 
Vitamin C supplementation significantly increased concentrations of total ascorbic 
acid in plasma (p=0.005 for treatment x time interaction; Figure 6.7A) and skeletal 
muscle (p=0.017 for treatment x time interaction; Figure 6.7C) compared with 
placebo.  
 
     
 
Figure 6. 7. Vitamin C levels in plasma and skeletal muscle pre- and post- 
supplementation  
A & B: Plasma TAA; C & D: skeletal muscle TAA; values are mean ± SEM; *denotes 
significantly different to pre, p<0.05; #indicates significantly different to placebo, 
p<0.05.  
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6.4. Reduced versus oxidized vitamin C concentrations 
6.4.1. Plasma and skeletal muscle AA and DHA concentrations 
 
Vitamin C supplementation significantly increased reduced AA concentrations in both 
plasma (p=0.004 for treatment x time interaction; Figure 6.8A) and skeletal muscle 
(p=0.017 for treatment x time interaction; Figure 6.9A) compared with placebo. 
Vitamin C supplementation had no effect on DHA levels in either plasma (p=0.807 for 
treatment x time interaction; Figure 6.8C) or skeletal muscle (p=0.230 for treatment 
x time interaction; Figure 6.9C). There was a trend (p=0.051) for the DHA/TAA redox 
ratio to decrease in plasma following vitamin C compared with placebo (Figure 6.8E). 
This was a result of a higher pre-supplementation DHA/TAA level in the vitamin C 
group when compared with placebo and post vitamin C levels. Vitamin C had no 
significant effect on skeletal muscle DHA/TAA (p=0.176 for treatment x time 
interaction; Figure 6.9E).   
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Figure 6. 8. Effect of supplementation on levels of AA and DHA in plasma 
 A & B: Ascorbic acid; C & D: DHA; E & F: DHA/TAA ratio; values are mean ± SEM; 
*denotes significantly different to placebo, p<0.05; #denotes significantly different to 
pre, p<0.05.  
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Figure 6. 9. Effect of supplementation on levels of AA and DHA in skeletal muscle  
A & B: Ascorbic acid; C & D: DHA; E & F: DHA/TAA ratio; values are mean ± SEM; 
*denotes significantly different to placebo, p<0.05; #denotes significantly different to 
pre, p<0.05.   
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6.5. Oxidative stress, antioxidant levels and mitochondrial content  
6.5.1. Blood measures  
 
Whole blood GSSG required prior log transformation in order to approximate a 
normal Gaussian distribution. Vitamin C treatment had no effect on any blood-
derived measures of oxidative stress including whole blood GSSG (Figure 6.10A), 
whole blood GSH/GSSG (Figure 6.10E) or plasma F2 Isoprostanes (Figure 6.11A). 
Vitamin C treatment also had no effect on levels of whole blood TGSH (Figure 6.10B). 
A main effect of treatment was found for serum bilirubin (p=0.021), indicating 
decreased levels during vitamin C treatment versus placebo (Table 6.4). However the 
latter finding was possibly confounded by a trend towards a higher baseline value for 
bilirubin in the placebo group. Indeed, no significant treatment x time interaction was 
observed for serum bilirubin (p=0.759). Vitamin C treatment had no effect on any 
other blood-derived antioxidant measurements (Table 6.4). A single post-vitamin C 
data point was excluded from GSSG calculations due to gross sample oxidation and a 
single pre-vitamin C data point was missing from TGSH calculations due to accidental 
non-collection.  
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Figure 6. 10. Effect of supplementation on glutathione levels in basal whole blood  
A & B: GSSG; C & D: Total GSH; E & F: GSH/GSSG ratio; A: data are geometric mean ± 
95% CI; C & E: data are mean ± SEM; B, D & F: data are individual values.  
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Figure 6. 11. Effect of supplementation on basal F2-Isoprostane levels   
A & B: plasma total F2-Isoprostanes; C & D: skeletal muscle total F2-Isoprostanes; A & 
C: data are mean ± SEM; B & D: data are individual values.  
 
6.4.2. Muscle measures  
 
A trend (p=0.058 for treatment x time interaction) was observed for basal muscle 
GSSG, reflecting a decrease with vitamin C supplementation and an increase with 
placebo supplementation (Figure 6.12A). Similar patterns of change were also found 
for basal muscle GSH/GSSG (p=0.093; Figure 6.12E) and basal muscle F2-Isoprostanes 
(p=0.112; Figure 6.11C). No significant effect of treatment was observed for muscle 
TGSH (p=0.709; Figure 6.12B). A significant (p=0.006) treatment x time interaction 
was found for total SOD activity in skeletal muscle. Post hoc analyses revealed that 
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total SOD activity significantly increased during placebo supplementation but 
decreased during vitamin C supplementation (Table 6.4). No effects of vitamin C 
treatment on muscle GSH or uric acid concentrations were observed (p>0.05; Table 
6.4).  
DCFH oxidation was first investigated in insulin-stimulated muscle only. In this 
experiment, a main effect of treatment was found (vitamin C < placebo, p=0.012; data 
not shown). This finding was then confirmed in insulin-stimulated muscle in a second 
experiment (vitamin C < placebo, p=0.012; Figure 6.13A) that also involved an analysis 
of DCFH oxidation in basal muscle. In contrast to insulin-stimulated muscle, there was 
no significant effect of vitamin C supplementation on DCFH oxidation in basal muscle 
(main treatment effect p=0.079; Figure 6.13A). Δ DCFH oxidation (insulin-stimulated 
sample DCFH oxidation minus basal sample DCFH oxidation) was significantly 
decreased following vitamin C treatment compared with placebo (p=0.006; Figure 
6.13C). When basal and insulin-stimulated samples were compared independently of 
treatment, DCFH oxidation was found to be significantly lower in insulin-stimulated 
muscle than in basal muscle (p<0.001; Figure 6.13A). Given the potential for 
hyperglycaemia to impact ROS/RNS levels, data was then corrected for the prevailing 
glucose level at the times of biopsy sampling. After this correction for glycaemia, 
DCFH oxidation was no longer different between basal and insulin-stimulated DCFH 
oxidation (p=0.279; data not shown); however, the effect of vitamin C treatment on 
DCFH oxidation in insulin-stimulated muscle remained statistically significant (main 
treatment effect p=0.012; data not shown).  
Vitamin C supplementation had no significant effect on skeletal muscle citrate 
synthase activity (p=0.17 for treatment x time interaction; Figure 6.14). 
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Table 6. 4. Antioxidant levels in blood and skeletal muscle pre- and post- 
supplementation 
 PLACEBO VITAMIN C 
Pre Post Pre Post 
Blood     
GSH (μmol.l-1) 747.5 ± 54.5  806.2 ± 41.0 714.0 ± 33.6 784.3 ± 45.9 
Plasma Uric Acid (μmol.l-1) 268.6 ± 24.2 264.3 ± 23.9 264.7 ± 16.1 254.4 ± 24.5 
Serum Albumin (g.l-1) 40.9 ± 1.1 42.0 ± 1.2 40.4 ± 1.0 41.1 ± 0.7 
Serum Bilirubin (μmol.l-1) TR 
 
Skeletal muscle 
12.6 ± 2.3  14.9 ± 4.8 11.9 ± 3.1 13.1 ± 3.2  
GSH (μmol.g-1 protein) 10.2 ± 1.0 10.8 ± 1.0 10.3 ± 0.5 10.6 ± 0.6 
Uric Acid (μg.g-1 tissue) 
SOD activity (U.mg-1 protein) 
7.8 ± 1.1 
11.9 ± 0.5 
8.1 ± 0.6 
13.4 ± 0.8 * † 
8.3 ± 1.1 
12.9 ± 0.7 
7.9 ± 1.3 
11.6 ± 1.0 
 
(Data are mean ± SEM; GSH – reduced glutathione; TR indicates main effect of 
treatment, p<0.05; * indicates significantly different to vitamin C, p<0.05; † indicates 
significantly different to pre, p<0.05) 
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Figure 6. 12. Effect of supplementation on glutathione levels in basal skeletal muscle  
A & B: GSSG; C & D Total GSH; E & F: GSH/GSSG ratio; A, C & E: data are mean ± 
SEM; B, D & F: data are individual values.  
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Figure 6. 13. Effect of supplementation on skeletal muscle DCFH oxidation 
A & B: basal and clamp DCF fluorescence; C & D: Δ DCF Fluorescence (clamp minus 
basal DCF fluorescence); A & C: values are mean ± SEM; B & D: data are individual 
values; *indicates significantly different to placebo, p<0.05; PLA – placebo; VC – 
vitamin C;  equiv.- equivalents.  
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Figure 6. 14. Effect of supplementation on skeletal muscle citrate synthase activity  
A: data are mean ± SEM; B: data are individual values.
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6.6. Vitamin C transporter expression 
6.6.1. SVCT2 protein expression 
 
Vitamin C supplementation significantly increased SVCT2 protein expression in 
skeletal muscle compared with placebo supplementation (p=0.008 for treatment x 
time interaction; Figure 6.15). There was no effect of vitamin C supplementation on 
expression of the the loading control GAPDH when compared to placebo (p>0.05; 
data not shown).    
 
 
    C                            Participant 1                                  Participant 2 
     PLA                           VC                   VC                       PLA 
 
                     T1 PRE   T1 POST      T2 PRE    T2 POST     T1 PRE   T1 POST     T2 PRE   T2 POST  
  SVCT2      
GAPDH  
 
Figure 6. 15. Effect of supplementation on muscle SVCT2 protein expression 
A & B: SVCT2 protein expression normalized to GAPDH; C: a representative western 
blot including two participants (note: the order of samples has not been altered from 
the original membrane scan); A: data are mean ± SEM; B: data are individual values; 
*indicates significantly different to placebo, p<0.05; #indicates significantly different 
to pre, p<0.05. PLA: placebo; VC: vitamin C; T1: trial 1; T2: trial 2; PRE: pre 
supplementation, POST: post supplementation 
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6.7. Nitric oxide synthase levels 
6.7.1. NOS activity 
 
Data for basal NOS activity required log-transformation prior to parametric ANOVA 
analysis. A significant main effect of treatment was found for basal NOS activity 
(p=0.026), reflecting significantly higher levels during vitamin C supplementation 
compared with placebo (Figure 6.16A).  However, this observed effect was possibly 
confounded by a higher pre-supplementation NOS activity in the vitamin C 
supplementation trial compared with placebo.  Indeed, no significant treatment x 
time interaction (p=0.894) nor significant post-hoc comparisons were found, 
suggesting a lack of effect of vitamin C on total NOS activity. No significant effect of 
treatment was observed for total NOS activity in insulin-stimulated muscle (Figure 
6.16B). 
 
 
Figure 6. 16. Effect of supplementation on total NOS activity in skeletal muscle  
A: total NOS activity in basal skeletal muscle; B: total NOS activity in insulin-
stimulated skeletal muscle; A: data are geometric mean ± 95 % CI; B: data are mean 
± SEM.  
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6.7.2. nNOS and eNOS protein expression 
 
Basal and clamp nNOS and eNOS protein expression data required prior log-
transformation after normalization to α-tubulin in order to approximate a Gaussian 
distribution. Vitamin C supplementation had no effect on skeletal muscle basal nNOS 
or eNOS protein expression when compared with placebo (p>0.40 for treatment x 
time interactions; Figure 6.17A & B). There was also no effect of vitamin C treatment 
on nNOS protein expression measured during the clamp (p>0.99 for treatment x time 
interaction; Figure 6.17D). However vitamin C supplemention significantly increased 
eNOS expression in insulin-stimulated muscle samples following vitamin C treatment 
compared with placebo (p=0.022 for treatment x time interaction; Figure 6.17E). 
There was no effect of vitamin C treatment on expression of the loading control α-
tubulin in basal or clamp analyses for either nNOS or eNOS (p>0.05; data not shown). 
Basal nNOS and eNOS ANOVA analyses were made using only n=5 participants due to 
a lack of available tissue for two participants.  
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    C          Basal                         Clamp                     Basal           Clamp 
                                          
                                       
             pre  post pre  post pre  post  pre  post                pre  post  pre  post  pre  post   pre post 
 
            Vitamin C   Placebo   Vitamin C   Placebo                 Vitamin C     Placebo   Vitamin C     Placebo 
    
 
Figure 6. 17. Effect of supplementation on NOS protein expression in skeletal muscle 
A & B: basal nNOS and eNOS protein expression relative to α-tubulin expression; C: 
representative western blots for nNOS and eNOS with α-tubulin as the loading control 
(note: the order of samples from the original membrane scans have not been altered); 
D & E: clamp nNOS and eNOS protein expression relative to α-tubulin expression; data 
are geometric mean ± 95% CI; data analyses for basal nNOS and eNOS were for n=5 
only due to a single randomly missing data point for two participants; pre: pre 
supplementation, post: post supplementation.  
nNOS eNOS 
Tubulin  
Results 
182 
 
6.8. Cross sectional analysis of key measures based on muscle vitamin C 
concentration 
 
At any time point during the trial with or without the consideration of post vitamin C 
supplementation values, muscle vitamin C concentration correlated significantly with 
Δ Rd (r=0.554, p=0.002 for all data and r=0.502, p=0.021 for all data excluding post 
VC trial values), muscle F2-Isoprostanes (r=-0.483, p=0.009 for all data and r=-0.613, 
p=0.003 for all data excluding post VC trial values) and HbA1c (r=-0.462, p=0.013 for 
all data and r=-0.540, p=0.012 for all data excluding post VC trial values). 
Furthermore, two-tailed unpaired t-tests were conducted for Rd, GSH/GSSG, F2-
Isoprostanes and HbA1c in which values corresponding to muscle vitamin C 
concentrations above and below the median vitamin C concentration (24.7 μg/g) 
were compared. It was found that when muscle vitamin C concentration exceeded 
24.7 μg/g, there was significantly higher insulin-stimulated Rd and GSH/GSSG levels 
but significantly lower muscle F2-Isoprostanes and HbA1c (Figure 6.18). 
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Figure 6. 18. Cross-sectional analysis of measures with respect to skeletal muscle 
vitamin C concentration 
Cross sectional comparison of key measures grouped on the basis of the 
corresponding muscle total ascorbic acid (TAA) exceeding or falling below the median 
vitamin C concentration measured during the study. A: Rd measurements; B: Muscle 
GSH/GSSG; C: Muscle F2-Isoprostanes and D: HbA1c; data are mean ± SEM; * indicates 
p <0.05 vs. < 24.7 μg/g tissue as determined using unpaired two-tailed t-tests. Data 
for <24 μg TAA/g tissue are for n=14; data for >24 μg TAA/g tissue are for n=14. 
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7.0. DISCUSSION 
 
7.1. Effect of vitamin C supplementation on glucoregulatory measures 
 
A major finding of the present study was that four months of high dose oral vitamin 
C supplementation significantly improved whole-body insulin-stimulated glucose 
disposal (Δ Rd) by more than 50% when compared with placebo supplementation in 
people with T2D. Skeletal muscle constitutes approximately 75-85% of whole-body 
glucose disposal during insulin-stimulated clamp conditions (25, 333) and is the 
primary defective site of peripheral insulin resistance in T2D (28). Thus, the 
improvement in Δ Rd likely represents predominantly an improvement in insulin-
stimulated skeletal muscle glucose disposal. 
This major finding lends support to a previous investigation in elderly people with 
T2D that similarly found improved whole-body insulin-stimulated glucose disposal 
following high dose oral vitamin C supplementation (169). Although a similar insulin 
infusion level was used in both trials (40mU/m2/min), the current study employed a 
hyperinsulinaemic, euglycaemic clamp while Paolisso et al. (169) used a 
hyperinsulinaemic, isoglycaemic clamp. The latter clamp method involves clamping 
glucose at fasting levels rather than at 5.5 mmol/l as was undertaken in this study. 
Thus, glucose disposal measured from euglycaemic clamps is not strictly comparable 
to glucose disposal measured from isoglycaemic clamps. Isoglycaemic clamps 
arguably represent a state more reflective of physiological conditions in people with 
T2D than do euglycaemic clamps. However, fluctuations in fasting glucose in 
individuals could potentially complicate measurements of changes in glucose 
disposal in individuals when using isoglycaemic rather than euglycaemic clamps. It 
has been shown that glucose MCR, a measure of glucose disposal per unit of blood 
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glucose, correlates highly between isoglycaemic and euglycaemic conditions in 
people with T2D (347). Given that a significant improvement in insulin-stimulated 
MCR (Δ MCR) was also found following vitamin C treatment, it is possible that we 
would have observed significant findings if an isoglycaemic rather than euglycaemic 
clamp were employed.   
In further contrast to the study by Paolisso et al. (169), a glucose infusion containing 
1 % tracer (i.e. “hot” glucose) was used during the hyperinsulinaemic clamp in the 
current study.  It has been proposed that using a “hot” glucose infusion versus a non-
labelled (or “cold”) glucose infusion can minimize potential errors associated with 
compartmental gradient effects and hepatic insulin sensitivity calculations (217). 
Indeed, only one participant displayed a negative value for EGP during the final hour 
of the euglycaemic clamp (-0.43 μmol/kg FFM/min) in this study. Consistent with 
findings of a previous study in T2D (323), EGP was not fully suppressed in participants 
during the final hour of the hyperinsulinaemic, euglycaemic clamp. The magnitude of 
suppression observed throughout the study (≈74 % of basal EGP) is similar to levels 
previously reported by Powrie et al. (323) for T2D.  This apparent hepatic insulin 
resistance was not altered by vitamin C supplementation. Basal EGP, which has been 
shown to be elevated in T2D (348), was also unaffected by vitamin C 
supplementation. The lack of effect of vitamin C supplementation on HOMA-IR 
further indicates a lack of effect of vitamin C on liver insulin resistance. 
Another study (205) that investigated the effect of high dose vitamin C therapy (800 
mg, 1 x/day) in people with T2D did not observe a change in whole-body insulin 
sensitivity. During their study, vitamin C intake for four weeks only partially 
replenished low baseline plasma vitamin C levels in participants (21 ± 3 μmol/l to 48 
± 6 μmol/l). In comparison to the study by Chen et al. (205), participants in the 
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present study did not have low baseline vitamin C levels (baseline vitamin C: 57 ± 5 
μmol/l); and plasma vitamin C was saturated (225) in all participants in the present 
study following vitamin C treatment (post vitamin C: 89 ± 7 μmol/l). A failure to 
sufficiently elevate vitamin C levels could underlie the lack of effect of vitamin C on 
whole body insulin sensitivity in the study by Chen et al. (205). However, it is 
uncertain if the supplementation regimen used in the study by Chen et al. (205) was 
sufficient with respect to dose and duration in order to observe insulin-sensitizing 
effects of high dose vitamin C in people with T2D. Given the poor systemic 
bioavailability of high dose vitamin C (225), a single high daily dose might be less 
effective at increasing body vitamin C content than multiple smaller intakes 
throughout the day. Furthermore, considering firstly that exogenous vitamin C likely 
accumulates slower in tissues compared with plasma (228); and secondly, that 
impaired insulin sensitivity and oxidative stress are chronic impairments in patients; 
the duration of vitamin C intake might need to be prolonged for optimal anti-diabetic 
effects in both tissues and systemically. The necessity of a more prolonged high dose 
intake appears to be supported by the literature in which beneficial effects of vitamin 
C on glucose control and/or oxidative stress are found with supplemental dosages of 
≥ 1 g ascorbic acid/day over ≥ 6-weeks in people with T2D (169, 181, 182, 203-211).    
Four months of high dose vitamin C supplementation did not alter levels of the 
secondary glucoregulatory outcome measures HbA1c, fasting glucose and fasting 
insulin.  Some previous studies found improvements in these measures of glucose 
control in people with T2D following vitamin C supplementation (169, 209-211), 
although many other studies observed no effects (181, 203-208, 212, 214). There is a 
primary causal relationship between insulin resistance and glycaemic control in T2D 
(349). Therefore, a lack of improvement in HbA1c following vitamin C 
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supplementation is perhaps unexpected given the improvement in skeletal muscle 
insulin sensitivity. However, findings of improved skeletal muscle insulin sensitivity 
but unchanged HbA1c are not uncommon in studies using anti-diabetic treatments 
of exercise training and thiazolidinedione therapy in people with T2D (99, 350-352). 
This finding might reflect a lack of effect of vitamin C on factors other than skeletal 
muscle insulin sensitivity that can also affect glycaemic control such as liver glucose 
production and beta cell insulin secretory capacity.  
It must be acknowledged that our study was underpowered to accurately investigate 
the effect of vitamin C specifically on changes in HbA1c (169). Some larger studies 
have indeed reported improvements in HbA1c following chronic high dose vitamin C 
supplementation in people with T2D (169, 209, 210). It therefore remains possible 
that if our study had had improved power (i.e. more participants) for the change in 
HbA1c and/or had involved a more prolonged period of supplementation, an 
improvement in glucose control measures would have also been observed.  Based on 
findings of a previous study (169) that involved a similar design to the current study, 
a cross-over sample size of n=57 participants would be required to obtain 80 % power 
for an improvement in fasting insulin of 2.8 uU/ml with vitamin C; while n=121 
participants would be required to obtain 80 % power for an improvement in HbA1c 
of 0.8 % with vitamin C. Studies involving a considerably greater number of 
participants than the current study are therefore required to investigate these 
secondary outcome measures in response to regular high dose vitamin C 
supplementation.  
Consistent with a previous investigation in people with T2D (169), high dose vitamin 
C supplementation had no effect on basal measures of whole-body oxidative or non-
oxidative glucose metabolism; nor on insulin-stimulated oxidative glucose 
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metabolism. Unlike the previous study (169), a significant improvement in NOGM 
during the clamp following vitamin C treatment was not observed in this study. A 
trend (p=0.065) towards improvement in Δ NOGM following vitamin C 
supplementation was found however. Glycogen synthesis is believed to constitute 
the major cellular pathway of non-oxidative glucose metabolism (353). Thus, given 
the observed trend towards improved Δ NOGM following vitamin C supplementation, 
levels of glycogen in skeletal muscle samples were assessed in both basal and insulin-
stimulated conditions. Vitamin C treatment did not significantly alter glycogen 
concentrations in either basal or insulin-stimulated muscle when compared with 
placebo. However, it should be noted that an insulin-stimulated period of 60 minutes 
did not produce a significant increase in muscle glycogen levels above basal 
conditions in participants when analysed independent of treatment. A 60-minute 
duration of insulin-stimulation prior to muscle sampling was initially chosen in order 
to measure insulin-stimulated effects on insulin signalling components in muscle 
(354, 355), but avoid potential anticipatory effects of the muscle biopsy in individuals 
on their blood glucose concentrations during the critical final hour of the clamp. A 
longer period of insulin infusion prior to muscle sampling might thus have proved 
more optimal in evaluating insulin-stimulated glycogen changes in muscle.  On the 
other hand, it is uncertain based on previous findings (356, 357) that even 180 
minutes of insulin stimulation during the hyperinsulinaemic, euglycaemic clamp 
would have yielded significantly elevated muscle glycogen levels in participants 
above basal levels.  
Other pathways of NOGM in addition to glycogen synthesis cannot be ignored in the 
interpretation of NOGM findings.  These pathways include de novo lipogenesis, non 
oxidative glycolysis to lactate and the pentose phosphate pathway (358). In 
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accordance with previous interpretations (358), lipid synthesis can likely be ignored 
since RER did not exceed 1.0 in our participants in basal or insulin-stimulated 
conditions; and the pentose phosphate pathway is negligible in skeletal muscle (359). 
Non-oxidative glycolysis to lactate might therefore partially explain any observed 
changes in NOGM independent of glycogen synthesis.  Plasma lactate levels were 
unaltered by vitamin C supplementation in this study. Furthermore, plasma lactate 
levels decreased in response to euglycaemic hyperinsulinaemia, while in contrast, 
NOGM increased in response to euglycaemic hyperinsulinaemia. Thus, non-oxidative 
glycolysis likely does not explain our trend for altered Δ NOGM findings.   
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7.2. Effect of vitamin C supplementation on skeletal muscle vitamin C 
concentration 
 
This study reports for the first time the effect of oral vitamin C supplementation on 
skeletal muscle vitamin C concentrations in people with T2D. Vitamin C 
supplementation significantly increased levels of reduced and total ascorbic acid in 
skeletal muscle by 71% and 36% respectively. Given the capacity for transport of 
vitamin C into and out of cells (184), skeletal muscle vitamin C could serve as an 
important reservoir of vitamin C for both intramuscular and systemic antioxidant 
defence. Skeletal muscle vitamin C concentration could also potentially serve as a 
good marker of total body vitamin C content since it contains the bulk (≈ 65 %) of 
total body vitamin C (219-221, 234). Thus, these findings suggest both an enhanced 
reserve of ascorbic acid available for antioxidant scavenging of ROS/RNS in skeletal 
muscle as well as a marked increase in total body vitamin C content following vitamin 
C supplementation. 
A cross-sectional analysis of pooled data from all trials independent of treatment and 
time found statistically significant correlations between muscle vitamin C 
concentration and both Δ Rd (positive association) and HbA1c (negative association) 
when either including or excluding post vitamin C supplementation values.  
Furthermore, when Rd and HbA1c values were compared on the basis of their 
corresponding muscle vitamin C level exceeding or falling below the median vitamin 
C concentration measured (24.7 μg/g tissue) irrespective of treatment, it was found 
that insulin-stimulated Rd and HbA1c were significantly improved at levels above 
24.7 μg/g tissue total ascorbic acid. These findings suggest that establishing a 
sufficient absolute muscle concentration of vitamin C might be an important requisite 
for healthy insulin action in muscle irrespective of nutritional means. Based on 
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findings of the current study, it appears that for most people with T2D, long-term and 
high dose vitamin C supplementation would be an effective means of elevating 
skeletal muscle vitamin C concentrations. 
Vitamin C supplementation also significantly increased plasma levels of reduced and 
total ascorbic acid by 62 % and 59 % respectively. However, unlike skeletal muscle 
vitamin C concentration, plasma vitamin C concentration did not correlate with Δ Rd 
or HbA1c. These different findings in muscle and plasma raise the possibility that 
tissue and plasma vitamin C concentrations are not interchangeable measures of 
vitamin C status in people with T2D. Different associations between leukocyte and 
plasma vitamin C concentrations were also reported in people with T2D by Yamada 
et al. (227). In that study, it was found that both uncomplicated patients with T2D 
and patients with complicated T2D had similar levels of plasma AA compared with 
healthy controls.  However, in the same study, leukocyte levels of AA were lower in 
people with uncomplicated T2D when compared with healthy controls; and lower still 
in people with complicated T2D when compared to people with uncomplicated T2D 
(227). Thus, a lack of investigation of tissue vitamin C levels in addition to plasma 
vitamin C concentration could potentially overlook associations of vitamin C status 
with disease indicators. 
A measurement of vitamin C levels in plasma only without regard for tissue vitamin 
C status might inadequately gauge the effectiveness of a given vitamin C 
supplementation regimen to increase body vitamin C concentrations. It is rather clear 
from the studies summarized in Table 1.2 (on page 37) that vitamin C 
supplementation was effective at increasing plasma vitamin C concentrations in 
people with T2D, seemingly independent of dose or duration of supplementation.  
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However, only studies that incorporated a supplementation regimen of ≥ 1 g vitamin 
C/day for ≥ 6 weeks appeared to be effective at improving glucoregulatory and/or 
oxidative stress measures in people with T2D. Unfortunately the majority of studies 
outlined in Table 1.2 (on page 37) lack data on tissue levels of vitamin C in addition 
to plasma levels to further verify that the regimen used was effective at augmenting 
body vitamin C status.  
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7.3. Effect of vitamin C supplementation on levels of reduced versus 
oxidized vitamin C in skeletal muscle 
 
As already discussed, vitamin C supplementation caused a significant increase in 
levels of reduced ascorbic acid in both skeletal muscle and plasma. A recent 
bioavailability study in otherwise healthy males with low baseline vitamin C levels 
reported an increase in skeletal muscle ascorbic acid levels ≈ 3.5 fold over baseline 
following 42-days of supplementation with 53 or 212 mg of vitamin C (as kiwi-fruit) 
(233). The relative increase reported by Carr et al. (233) was greater than the relative 
increase in skeletal muscle ascorbic acid above pre-supplementation levels found in 
this study (≈ 1.7 fold) despite the use of a considerably higher dose and duration of 
supplementation in this study. The lower baseline ascorbic acid concentration in their 
study appears to account for much of this difference however (≈ 3 μg/g tissue versus 
≈ 6 μg/g tissue in this study), since post supplementation ascorbic acid levels were 
similar in both studies (≈ 12μg/g tissue versus ≈ 11 μg/g tissue). It should be noted 
that the bioavailablity of ascorbate in kiwi fruit does not differ in skeletal muscle 
when compared with synthetic ascorbic acid found in supplements (360) thus 
comparisons between studies would appear to be valid. The relatively lower but 
significant increase in ascorbic acid observed in this study might reflect the capacity 
to further increase muscle ascorbic acid levels with high dose supplementation 
despite being mostly on the flatter portion of the skeletal muscle ascorbic acid 
saturation curve.  This is likely in contrast to participants in the Carr et al. (233) study 
who might have been positioned mostly on the steep portion of the tissue saturation 
curve and thus sensitive to lower levels of intake. However it still remains possible 
that some of the difference in the relative change observed between studies was due 
to differences in skeletal muscle vitamin C bioavailability in people with T2D 
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compared with healthy individuals.  Future studies comparing the effects of the same 
vitamin C supplementation regimen in matched diabetic and healthy participants is 
required to investigate this issue further.  
In the present study ascorbic acid constituted the majority of TAA in plasma (≈ 97%), 
while skeletal muscle was considerably more oxidized (≈ 70% DHA). It is widely 
believed that vitamin C is found predominantly in its reduced, ascorbic acid form 
intracellularly (221, 223, 243). However, experimental studies in animal models have 
produced mixed findings in relation to the oxidative status of vitamin C in healthy 
tissues. In guinea pigs, who like humans cannot synthesize ascorbic acid 
endogenously, the majority of vitamin C in the adrenal glands, brain, testis and liver 
after being fed a diet adequate in vitamin C was reported to be in the reduced, 
ascorbic acid form (246, 247). On the other hand, the majority of vitamin C in the 
heart, spleen, thymus and skeletal muscle was found to be in the oxidized DHA form 
(246, 247).  
Differing methods of measurement and sampling such as HPLC versus enzymatic 
assays; or post mortem tissue analysis versus muscle biopsy sampling might account 
for some of the differences in reported DHA and AA levels in studies. However, 
improper treatment of samples prior to analysis has been suggested to result in 
increased oxidation of AA to DHA and diketogulonic acid, thus leading to artifactually 
increased DHA levels and a potential irreversible loss of vitamin C (243). In this study 
muscle samples were blotted free of blood and visible fat and snap frozen in liquid 
nitrogen within 30 seconds of sampling. Additionally, frozen samples were 
homogenized on ice in an acidic buffer containing a metal chelator (EDTA) and then 
analysed in nitrogen-flushed amber vials within 30 minutes of removal from liquid 
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nitrogen. Therefore, given these precautions taken, it is perhaps unlikely that any 
substantial artifactual sample oxidation occurred after the time the sample was 
removed from the biopsy needle.  The oxidation status of ascorbic acid in human 
diabetic skeletal muscle is currently unknown.  Thus these findings report for the first 
time that vitamin C treatment was unable to significantly alter the vitamin C redox 
status (DHA/TAA) of skeletal muscle in people with T2D. Vitamin C was also unable 
to modulate the relatively oxidized status of skeletal muscle vitamin C in people with 
T2D, despite causing a significant increase in both reduced ascorbic acid and total 
vitamin C content. 
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7.4. Effect of vitamin C supplementation on skeletal muscle oxidative 
stress and mitochondrial content 
 
Vitamin C treatment significantly decreased insulin-stimulated DCFH oxidation.  The 
average post vitamin C treatment DCFH oxidation was approximately 36 % lower 
when compared with placebo treatment during the hyperinsulinaemic, euglycaemic 
clamp. These findings implicate improved insulin-stimulated antioxidant scavenging 
of reactive species in muscle following vitamin C treatment. An increased production 
of reactive species including O2·- and H2O2 in skeletal muscle have been implicated in 
impairments in insulin signalling pathways responsible for normal insulin-stimulated 
glucose transport (64, 126). In particular, increased serine phosphorylation of insulin 
signalling components such as IRS-1 via ROS/RNS- induced stress signalling pathways 
including JNK activation have been shown to be important in impaired insulin 
sensitivity in skeletal muscle (128, 129, 361). Effects of vitamin C supplementation on 
activation levels of insulin signalling or stress signalling pathways in skeletal muscle 
were not investigated in this study. However, it is possible that by reducing ROS/RNS 
levels during insulin-stimulated conditions, high dose vitamin C supplementation was 
able to attenuate ROS/RNS-induced activation of stress signalling pathways and their 
subsequent impairment on insulin signalling in skeletal muscle. This could have then 
facilitated an improved insulin-stimulated glucose disposal via improved insulin-
mediated glucose transport.  
It is uncertain why vitamin C’s effects on DCFH oxidation were observed in insulin-
stimulated conditions but not in basal conditions. It could be speculated that insulin 
exerted a permissive role on vitamin C, such that hyperinsulinaemia was required for 
vitamin C to act effectively as an antioxidant. However, insulin has itself been shown 
to exert intracellular antioxidant effects in vivo (334, 335). For example, 60 minutes 
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of insulin infusion (40mU/m2/min) during a hyperinsulinaemic, euglycaemic clamp 
was shown to increase erythrocyte GSH/GSSG levels via an increase in GSH and a 
decrease in GSSG in people with T2D (334, 335). Consistent with these findings, it was 
observed in the current study that DCFH oxidation decreased in skeletal muscle after 
60 minutes of insulin infusion when compared with basal levels, independent of 
treatment. It is possible that the glucose lowering effect of insulin underlies its 
apparent antioxidant effect in people with T2D. There is evidence to suggest that 
hyperglycaemia induces oxidative stress in skeletal muscle and systemically (125, 
362). Moreover, this hyperglycaemia-induced oxidative stress can be attenuated by 
acute insulin treatment (125). Interestingly, after correcting for the prevailing 
glycaemia at the time of muscle biopsy sampling in the current study, the attenuative 
effect of hyperinsulinaemia on DCFH oxidation disappeared. However, the decreased 
DCFH oxidation following vitamin C treatment remained statistically significant after 
this correction.  These findings suggest that the combined effects of acute 
hyperinsulinaemia and elevated muscle vitamin C concentration could have acted in 
a synergistic manner to significantly improve skeletal muscle oxidative stress and 
insulin sensitivity. A combined effect of vitamin C supplementation and insulin 
therapy was shown in a study by Evans et al. (181) in people with T2D. In that study, 
oral vitamin C supplementation potentiated the beneficial effects of chronic insulin 
therapy on endothelial function and systemic oxidative stress in people with T2D 
(181). 
A limitation of the DCFH probe is that it is sensitive to a diverse range of ROS including 
H2O2, HO· and ROO·; as well as to RNS including ·NO and ONOO- (306).  Therefore it is 
uncertain which (if any) particular reactive species might have been selectively 
attenuated in response to vitamin C treatment. Furthermore, DCFH oxidation was 
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assessed in muscle homogenates rather than in subcellular compartments, thus 
making it difficult to discern the cellular origins of the reactive species that were 
decreased.  In basal conditions cellular ROS is believed to be predominantly of 
mitochondrial origin (103). In addition, evidence from experimental studies 
implicates mitochondria as a key cellular source of excess ROS production in high fat 
diet-induced insulin resistance (64, 126). Despite these findings, there is a lack of 
convincing evidence showing increased levels of mitochondrial ROS production in 
skeletal muscle of people with T2D (97, 137, 138). Furthermore, recent experimental 
investigations in high fat-fed C57BL/6 mice (122, 123) were unable to demonstrate 
improved insulin sensitivity following treatments with mitochondrial-targeted 
antioxidants despite improvements in skeletal muscle oxidative stress. Sources of 
excess non-mitochondrial-derived reactive species have also been implicated in T2D.  
In particular, excess ROS produced during endoplasmic reticulum stress, by NADPH-
oxidases and by xanthine oxidases have also been found to be important sites of 
excess ROS production in diabetes (124, 125, 363).  It is therefore possible that the 
reactive species observed to be decreased in muscle homogenates following vitamin 
C supplementation originated from mitochondrial and/or non-mitochondrial cellular 
locations.  
Despite the observed findings using the DCFH probe, no statistically significant 
changes in levels of other markers of oxidative stress in skeletal muscle or in whole 
blood or plasma were observed following vitamin C treatment. There were trends 
toward improvements in basal muscle oxidative stress markers GSSG, GSH/GSSG and 
F2-Isoprostanes during vitamin C treatment compared with their worsening during 
placebo treatment. Given the relatively small number of participants that completed 
the trial in full compliance, it remains possible that this study lacked statistical power 
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to fully realize a significant effect of treatment on these markers of oxidative stress 
in muscle. However, it should also be noted that these oxidative stress measures 
were performed in basal muscle samples only, and thus unlike for DCFH oxidation, an 
insulin-stimulated effect of treatment on these oxidative stress measures was not 
explored. Unfortunately there was a lack of sufficient sample remaining to investigate 
GSH/GSSG or F2-Isoprostanes levels in insulin-stimulated muscle also. 
Despite the lack of statistically significant improvements for muscle GSH/GSSG and 
F2-Isoprostanes following vitamin C treatment, cross-sectional analyses were 
undertaken to explore relationships between vitamin C concentration and oxidative 
stress measures independent of treatment and time. When GSH/GSSG and F2-
Isoprostanes data were compared on the basis of their corresponding muscle vitamin 
C concentration exceeding or falling below the median muscle vitamin C 
concentration measured (24.7 μg/g tissue), both GSH/GSSG and F2-Isoprostanes 
levels were significantly improved at vitamin C concentrations > 24.7 μg/g tissue. This 
suggests that achieving a sufficient skeletal muscle vitamin C concentration 
regardless of nutritional means might be important in improving skeletal muscle 
oxidative stress in people with T2D. 
Interestingly, total SOD activity in skeletal muscle was marginally, but significantly 
lower post vitamin C treatment compared with placebo treatment.  The relative 
decrease in SOD activity found following vitamin C treatment might reflect an 
improved overall antioxidant scavenging of ·O2- in muscle due to exogenous ascorbic 
acid and a compensatory reduction in endogenous SOD activity.  SOD activity and 
SOD isoform protein expression show mixed relationships with oxidative stress in 
diabetic skeletal muscle. Studies have shown SOD levels to be reduced (364), 
unaltered (365), or increased (366) in association with increased oxidative stress in 
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diabetic skeletal muscle. In theory, decreased SOD levels could contribute to 
oxidative stress in T2D due to a reduced capacity for scavenging of ·O2- produced, 
while on the other hand increased levels could represent a compensatory response 
to increased levels of ·O2- and oxidative stress. The case for SOD activity better 
reflecting the latter of these theoretical situations is supported by the very similar 
patterns of change found for muscle DCFH oxidation, muscle GSSG and muscle F2-
Isoprostanes when compared with SOD activity during both vitamin C and placebo 
supplementation. In all of these measurements, levels tended to decrease following 
vitamin C treatment but increase following placebo treatment.     
Vitamin C treatment did not significantly alter levels of citrate synthase activity in 
skeletal muscle. Citrate synthase has been shown to be highly associated with 
skeletal muscle mitochondrial content in humans (298). Decreased skeletal muscle 
mitochondrial biogenesis has been implicated as a cause of impaired insulin 
sensitivity in people with T2D (367), although findings are not consistent (101, 136). 
A lack of change in citrate synthase activity with vitamin C supplementation suggests 
that the observed change in insulin sensitivity was independent of skeletal muscle 
mitochondrial content.  Mitochondrial content and insulin sensitivity were also not 
likely influenced by a change in physical activity of participants (97), since a crude 
measure of usual physical energy expenditure (a 7-day recall adapted from the 
Australian National Nutrition Survey) found no significant difference in physical 
activity between vitamin C and placebo treatments. Overall, these findings suggest 
that the observed change in skeletal muscle insulin sensitivity following vitamin C 
supplementation was likely not a result of altered physical activity or mitochondrial 
content of participants.  
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7.5. Effect of vitamin C supplementation on skeletal muscle SVCT2 levels 
 
Chronic high dose vitamin C supplementation significantly increased SVCT2 protein 
expression in skeletal muscle of people with T2D.  SVCT2 protein expression 
increased approximately two-fold post vitamin C supplementation when compared 
with placebo. It was originally hypothesised that skeletal muscle SVCT2 protein 
expression would decrease following vitamin C supplementation in response to 
increased intramuscular vitamin C content and/or decreased skeletal muscle 
oxidative stress.  This hypothesis was based on studies in various human non-muscle 
cell types indicating that SVCT2 expression is inversely regulated by intracellular 
ascorbic acid concentration (259, 262).  Moreover, SVCT2 was found to be redox-
sensitive in skeletal muscle cells (236).  In particular, treatment of C2C12 myotubes 
with the antioxidant lipoic acid decreased, while treatment with H2O2 increased, both 
SVCT2 mRNA and protein levels (236). Thus, it could be argued that interventions 
which aim to increase vitamin C concentrations and/or decrease oxidative stress in 
tissues would decrease tissue SVCT2 expression and thus attenuate vitamin C 
accumulation in accordance with intracellular vitamin C content and/or redox status.  
In mice who are capable of producing vitamin C endogenously, oral vitamin C 
supplementation is largely ineffective at increasing tissue vitamin C concentrations 
to high levels due to strict regulatory control exerted by SVCT transporters (294). 
However, as our current findings suggest, this situation could be different in humans, 
who unlike mice are incapable of producing vitamin C endogenously. The current 
findings, coupled with findings in healthy humans (Chapter 2 on page 71), suggest 
that SVCT2 expression is augmented in skeletal muscle by high dose vitamin C 
supplementation despite the prevailing tissue vitamin C concentration. It is possible 
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that SVCT2 expression responds differently to high dose vitamin C supplementation 
in different tissues as a function of relative tissue vitamin C concentration (294, 312). 
On a gram per wet weight basis, skeletal muscle vitamin C concentrations are 
relatively low compared with many other human tissues (221). Thus, SVCT2 transport 
capacity might not be nearly as saturated by ascorbic acid in skeletal muscle as it 
might be in other human tissues such as the adrenal glands, brain and eye lens after 
high dose vitamin C supplementation. 
The present study did not investigate transport activity of SVCT2. Studies 
investigating ascorbic acid transport into cells and tissues have typically used 
radiolabelled ascorbic acid such as [14C] ascorbic acid to trace its uptake in vitro and 
in vivo e.g. (229, 368, 369). These studies have rarely been undertaken in humans 
however (219, 370). Recent in vitro studies investigated SVCT2 expression in C2C12 
mouse cells using time-dependent and concentration-dependent experiments (236, 
260). These studies observed a matching of ascorbic acid transport with total protein 
and gene expression levels of SVCT2, such that increased and decreased SVCT2 
expression was associated with increased and decreased ascorbic acid transport 
respectively (236, 260). Thus, total SVCT2 protein expression appears to be a good 
indicator of SVCT2 transporter activity in skeletal muscle. Nonetheless, it is possible 
that additional post translational or cellular redistribution regulation of SVCT2 
occurred (371). For instance, SVCT2 has been shown to undergo translocation from 
the cytosol to the plasma membrane in response to extracellular ascorbic acid in 
cultured striatal rat neuronal cells (372) and in response to prostaglandin E2 in 
MC3T3-3T preosteoblastic mouse cells (368). Furthermore, a dominant negative 
short SVCT2 isoform has been identified in a large number of human cell types (345). 
This short SVCT2 isoform can act to decrease normal SVCT2 transport activity via 
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protein-protein interactions in human kidney 293T cells (345). Therefore, further 
investigations of SVCT2 expression should additionally focus on levels of SVCT2 in 
membrane versus cytosolic fractions, and on the relative expression levels of the 
normal SVCT2 isoform versus the short SVCT2 isoform. 
The present study did not measure changes in expression levels of the DHA 
transporters GLUT1 and GLUT4 (266, 270) in skeletal muscle.  Given the non-
specificity of these transporters for DHA, the significance of changes in their 
expression in response to vitamin C supplementation without evaluation of their DHA 
transport activities is unclear in people with T2D. Moreover, the physiological 
significance of GLUT transport of DHA in cellular vitamin C accumulation is uncertain 
(266). 
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7.6. Effect of vitamin C supplementation on skeletal muscle NOS levels 
 
In this study, vitamin C supplementation was found to significantly increase total 
eNOS protein abundance in insulin-stimulated skeletal muscle of people with T2D. 
Skeletal muscle and adipose tissue eNOS protein abundance has been found to be 
decreased in states of obesity and insulin resistance (373). In particular, eNOS protein 
expression was found to be decreased in skeletal muscle of relatively insulin-
resistant, obese humans when compared with relatively insulin-sensitive, non-obese 
humans (374). In another study, eNOS protein expression was decreased in 
gastrocnemius muscle in association with insulin resistance in male Sprague Dawley 
rats after chronic high-fat, high-sugar feeding (375). Furthermore, co-treatment of 
these high-fat, high-sugar rats with the antioxidant SOD mimetic Tempol was shown 
to improve diet-induced impairments in both glucose uptake and eNOS protein 
expression in skeletal muscle (376). These findings suggest that eNOS expression is 
modulated in association with skeletal muscle insulin sensitivity. However, direct 
effects of insulin sensitizing treatments on eNOS expression in skeletal muscle are 
also possible.  Indeed, anti-diabetic thiazalodinedione drugs have been shown to 
robustly increase gene and protein expression of eNOS in endothelial cells (373). 
Thus, the observed findings of increased eNOS protein abundance in skeletal muscle 
following vitamin C supplementation could be a consequence of improved skeletal 
muscle insulin sensitivity and/or a direct effect of vitamin C on eNOS transcription 
and/or translation.  
eNOS has been localized to mitochondrial, sarcolemmal and vascular endothelial 
sites in skeletal muscle (377). In particular, decreased endothelial eNOS activation 
has been implicated in impaired insulin-stimulated glucose uptake by skeletal muscle 
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(378). eNOS activation was shown to play an important role in enhancing insulin-
stimulated capillary recruitment and insulin delivery to skeletal muscle; thus leading 
to improved glucose uptake by muscle (378).  Unfortunately eNOS activity was not 
specifically investigated in response to vitamin C supplementation in this study. 
Therefore, it is uncertain if the increased eNOS protein levels observed were 
concordant with increased eNOS activity in skeletal muscle. The lack of change 
observed in total NOS activity following vitamin C supplementation would appear to 
suggest that this was not the case.  However, nNOS is the dominant NOS isoform in 
skeletal muscle (379); and a lack of change in total NOS activity following vitamin C 
supplementation might more closely reflect the lack of change in nNOS protein 
abundance than eNOS protein abundance. Indeed, vitamin C supplementation was 
shown to potentiate the effects of L-arginine and BH4 supplementation on total eNOS 
protein expression in skeletal muscle of ischaemic rats without significantly altering 
total calcium-dependent NOS activity (291).  
It needs to be acknowledged that an alteration in NOS protein abundance might not 
fully reflect changes in NOS activity. For example, it is known that both eNOS and 
nNOS undergo post-translational phosphorylation in response to insulin stimulation 
(379). This in turn can affect their activation levels (379). eNOS dimerization is 
another important post-translational mechanism involved in the regulation of eNOS 
activity (380). Additional investigations are therefore required to expand on the 
significance of the change in total eNOS protein given the potential of complex post-
translational regulation of eNOS activity.  
A proposed in vivo function of ascorbic acid is to maintain BH4 in its reduced state 
(288). Impaired BH4 levels due to its oxidation by ONOO- (381) can promote eNOS 
“uncoupling” in endothelial cells through a mechanism that promotes the transfer of 
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electrons to molecular oxygen rather than to arginine (292). This leads to the 
preferential formation of ·O2- rather than NO. BH4 levels in skeletal muscle were not 
measured in this study. Thus, it is uncertain if vitamin C treatment promoted 
increased BH4 levels in skeletal muscle. Additional studies are required to further 
investigate the effects of ascorbic acid on BH4 levels in diabetic skeletal muscle.  
Finally, it should be noted that iNOS protein could not be detected in a selection of 
skeletal muscle samples, despite its previous report in diabetic skeletal muscle (142, 
274). Therefore the effect of vitamin C supplementation on iNOS activity in skeletal 
muscle was not specifically investigated. Given iNOS is not constitutively expressed 
in skeletal muscle (273), the possibility that iNOS contributed to total NOS activity in 
some but not all skeletal muscle samples cannot be ruled out. 
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7.7. Comparison of people with T2D and healthy individuals 
 
It is possible to make some tentative comparisons of vitamin C effects in skeletal 
muscle of people with T2D in the major project and healthy individuals in the study 
outlined in Chapter 2 (on page 71).  However, it needs to be emphasized that 
comparisons are tentative at best when considering, firstly, that the participants in 
the two studies were not matched for subject characteristics; and secondly, that the 
duration of vitamin C supplementation was different between studies.  On the other 
hand, the supplemental regimen of both studies was identical in terms of daily 
dosage and supplement products used.  Furthermore, there was considerable 
overlap in terms of the analytical methods used in sample analyses. Thus, a brief 
discussion is now provided in relation to effects of vitamin C supplementation on 
vitamin C concentration, redox status, and SVCT2 transporter expression in people 
with T2D compared with healthy individuals. 
 
7.7.1. Vitamin C concentrations 
 
There is some evidence to suggest that human blood and rodent liver vitamin C 
concentrations are lower and more oxidized in T2D compared with healthy 
individuals (194, 250, 253). Prior to vitamin C supplementation, skeletal muscle TAA 
concentration was lower in the type 2 diabetic participants of the current study (≈22 
μg/g tissue) when compared with age-matched cadavers with deaths of 
miscellaneous cause (≈30 μg/g tissue) (234); and also healthy males of the study in 
Chapter 2 (≈30 μg/g tissue). However, after vitamin C supplementation, muscle 
concentrations in the people with T2D were comparable with these previous values 
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(≈30 μg/g tissue).  It might therefore be speculated that vitamin C supplementation 
normalised the decreased skeletal muscle vitamin C concentrations in people with 
T2D. Furthermore, considering the significant cross-sectional correlation found in the 
diabetic study between muscle TAA and insulin-stimulated Rd, it might be further 
speculated that a normalization of impaired skeletal muscle vitamin C level was an 
underlying factor in the improvement in Δ Rd found following vitamin C 
supplementation.   
Despite an apparent difference in baseline skeletal muscle vitamin C concentrations 
when comparing between the study in people with T2D and the study in Chapter 2 
(on page 85), there was no obvious difference between the studies in either the 
absolute increase (mean: T2D +7.6 μg/g tissue vs. healthy +8.6 μg/g tissue) or the 
relative increase (mean: T2D +36.0 % vs. healthy +31.1 %) in muscle TAA 
concentrations above baseline following vitamin C supplementation. In contrast to 
skeletal muscle, baseline plasma vitamin C levels were similar in both studies (mean: 
T2D 53.8 μmol/l vs. healthy 61.0 μmol/l). However, the absolute increase (mean: T2D 
+32.2 μmol/l vs. healthy +50.4 μmol/l) and relative increase (mean: T2D +59.4 % vs. 
healthy +95.1 %) in plasma vitamin C concentration above baseline were greater in 
the healthy individuals after vitamin C supplementation. These apparent differences 
in vitamin C status in skeletal muscle versus plasma in people with T2D and healthy 
individuals lends further support to the notion that is is important to assess both 
tissue and plasma levels of vitamin C to establish vitamin C status. 
 
7.7.2. Redox status 
 
Vitamin C supplementation was able to improve skeletal muscle DCFH oxidation in 
people with T2D (albeit only in insulin-stimulated muscle) but had no effect on DCFH 
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oxidation in healthy individuals in Chapter 2 (on page 89).  A lack of effect in healthy 
individuals is perhaps not surprising considering that pathological oxidative stress is 
unlikely to be present. Moreover, if skeletal muscle vitamin C levels are already at 
sufficient levels in healthy individuals, it is unlikely that further enhancement of 
vitamin C concentrations is going to greatly augment its antioxidant effects. 
Previously, antioxidant supplementation was shown to be relatively more effective 
in people with T2D compared with matched healthy individuals. In people with T2D, 
four months of vitamin E supplementation (900 mg/day) was shown to produce 
relatively greater increases in insulin-mediated WBGD and NOGM; and relatively 
greater reductions in plasma ·O2-, HbA1c and oxidative stress than in non-diabetics 
(167). In addition, in elderly people with T2D, an acute infusion of high dose vitamin 
C (0.9 mmol/l) produced a greater relative improvement in WBGD and NOGM; and 
relatively greater reductions in plasma ·O2- and oxidative stress than in non-diabetics 
(168). Finally, eight weeks of high dose antioxidant supplementation (24 mg β 
carotene + 1 g ascorbate + 1000 IU α-tocopherol) was found to decrease LDL-
oxidation and lipid peroxidation markers in men with T2D when compared with 
healthy men (382). Thus, the different findings in people with T2D and healthy 
individuals for DCFH oxidation coupled with these previous findings collectively 
suggest that antioxidant supplementation is of benefit for modulating redox status in 
individuals with oxidative stress. 
The only other common redox-related measure undertaken shown to have different 
outcomes following vitamin C supplementation in people with T2D compared with 
the healthy individuals was total SOD activity. As discussed above, increased SOD 
levels could be a compensatory response to increased levels of ROS in skeletal muscle 
(366). Therefore, a decrease in total SOD activity in people with T2D when compared 
Discussion 
211 
 
with no change in healthy individuals following vitamin C supplementation could 
indirectly indicate an improvement in elevated ROS levels in people with T2D. This 
remains somewhat speculative however, since findings are mixed in relation to 
altered SOD levels in diabetic skeletal muscle (364, 365). Further investigations 
looking more specifically at particular SOD isoform activities and expression levels 
might be required to more thoroughly evaluate the significance of these different 
outcomes with respect to total SOD activity. 
 
7.7.3. SVCT2 protein expression 
 
The finding of increased SVCT2 expression in skeletal muscle of people with T2D 
following high dose vitamin C supplementation supports the earlier novel finding of 
increased SVCT2 protein expression in response to vitamin C supplementation in 
healthy individuals in Chapter 2 (on page 86).  Collectively, findings from the two 
studies provide an original insight into the regulation of ascorbic acid transport in 
skeletal muscle in humans in vivo. Interestingly, in both studies it was hypothesised 
that SVCT2 expression would be decreased in a compensatory manner following 
vitamin C supplemention in response to increased vitamin C concentrations and/or 
improved antioxidant status.  However, none of these hypotheses held true.  Thus, 
further investigations that focus on human in vivo regulation of SVCT2 expression 
could be required to better assess its biological responses to modulation of vitamin 
C levels and oxidative stress than the current in vitro or non-human in vivo models of 
investigation (383). 
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7.8. Safety of high dose oral vitamin C 
 
Vitamin C supplementation only produced short term (1-2 weeks) and minor 
gastrointestinal discomfort in one participant during supplementation. In 
comparison, placebo supplementation produced no adverse events in any 
participants. Gastrointestinal side effects are considered one of the few adverse 
events associated with high dose oral vitamin C supplementation (189). A 
comprehensive battery of renal and hepatic function tests that included estimated 
age-adjusted glomerular filtration rate, urea, creatinine, GGT, ALT, AST (Table 6.2 on 
page 155) and serum electrolytes (data not shown), was undertaken during the study 
in people with T2D, for which vitamin C supplementation produced no detrimental 
effects. Of potential concern during high dose vitamin C supplementation is the 
formation of oxalate from ascorbic acid that could crystallize in the urine, forming 
kidney stones in susceptible individuals (171). No participants reported on this 
adverse event. Some studies have found modestly increased urinary oxalate with 
doses of 1-2 g/day in both stone-forming individuals and non-stone-forming 
individuals (197-200), leading to suggested recommendations of <2 g vitamin C/day 
(197, 198) in individuals who are known stone formers. However, most studies in 
humans with normal renal function have not reported significantly elevated levels of 
urinary oxalate following high dose vitamin C (189, 384). Greater uncertainty exists 
in relation to a safe vitamin C dose that avoids worsening of existing hyperoxaluria 
and an increased risk of kidney stones in individuals with end stage renal disease 
(384). Individuals with kidney disease or impaired renal and/or hepatic function were 
excluded from the study in people with T2D.  
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It has been argued that high dose vitamin C supplementation should be avoided in 
patients with haemochromatosis due to potential toxic pro-oxidant effects 
associated with iron overload (385). It has thus been recommended that individuals 
with haemochromatosis limit intake of vitamin C to 500 mg/day from supplements 
(386).  However, there is a lack of data investigating the safety profile of vitamin C 
supplementation in these potentially susceptible individuals in vivo (189). Moreover, 
empirical evidence for in vivo pro-oxidant effects of high dose oral vitamin C are 
lacking (387). Nonetheless, individuals with haemochromatosis were excluded from 
the study in people with T2D. 
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8.0. CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
The present thesis investigated effects of chronic high dose vitamin C 
supplementation on insulin sensitivity, oxidative stress, vitamin C concentration, NOS 
activity, vitamin C redox state and SVCT2 transporter expression in skeletal muscle of 
people with T2D.  Each key investigation undertaken provides novel insights into in 
vivo biological effects of vitamin C supplementation in people with T2D. A separate 
study in healthy individuals was also undertaken to evaluate effects of a similar dose 
of vitamin C in healthy skeletal muscle. 
Vitamin C supplementation significantly improved insulin-stimulated glucose disposal 
and oxidative stress in skeletal muscle of people with T2D.  The finding of improved 
insulin-stimulated oxidative stress in skeletal muscle is of mechanistic relevance to 
the improved insulin-stimulated glucose disposal in skeletal muscle. Through an 
improvement in ROS/RNS levels in skeletal muscle, insulin- and stress-related 
signalling pathways could have been favourably modulated by chronic vitamin C 
ingestion to enhance insulin-stimulated glucose uptake in muscle. Targetted 
mechanistic studies are now required to further elucidate the specific stress-
signalling pathways and insulin-signalling targets that vitamin C might modulate in 
diabetic skeletal muscle.  
This thesis also reports for the first time that high dose vitamin C supplementation 
significantly increases vitamin C levels in skeletal muscle of people with T2D. High 
dose vitamin C supplementation similarly enhanced vitamin C content of skeletal 
muscle in healthy young individuals. An increased skeletal muscle vitamin C 
concentration following vitamin C supplementation in people with T2D could underly 
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the improvement in insulin-stimulated oxidative stress found in skeletal muscle. The 
increased total ascorbic acid concentrations of skeletal muscle and plasma found 
following vitamin C supplementation in people with T2D was largely accounted for 
by an increased content of reduced ascorbic acid rather than dehydroascorbic acid. 
However, no significant effect of vitamin C supplementation on vitamin C redox 
status in either muscle or plasma was observed. 
High dose vitamin C supplementation significantly increased SVCT2 protein levels in 
both diabetic and healthy human skeletal muscle. These findings were contrary to 
originally hypothesized outcomes, that included the supposition that vitamin C would 
decrease SVCT2 expression in accordance with intracellular ascorbic acid and/or 
tissue oxidation status.  However, there is a paucity of studies that have investigated 
effects of vitamin C supplementation on SVCT2 levels in humans in vivo. Moreover, 
typical human in vitro and non-human in vivo investigations of vitamin C transport 
kinetics could be of limited relevance to the human condition in vivo. Thus, these 
novel findings warrant future research into substrate regulation of SVCT2 in humans 
in vivo. 
NOS activity has previously been found to be impaired in skeletal muscle of people 
with T2D. Mechanistically, vitamin C may play a role in improving NOS levels through 
stabilization of the NOS cofactor, BH4.  Vitamin C supplementation did not change 
total NOS activity in skeletal muscle when compared with placebo, although it 
increased eNOS protein expression.   The implications of the latter finding are unclear 
however, and further investigations into the direct (or indirect) modulation of NO 
metabolism by vitamin C are required. In particular, the effects of vitamin C 
supplementation on levels of BH4, eNOS activity and eNOS enzyme phosphorylation 
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status are required to better understand the significance of these findings and how 
they might relate to the improvement in insulin sensitivity observed. 
Several factors implicate the applicability of these findings to the clinical field of T2D 
treatment. Vitamin C supplements were well tolerated by participants, thus offering 
further evidence of the safety of high dose vitamin C intake. In addition, use of an 
over-the-counter vitamin C supplement with a daily dosage equivalent to both the 
prudent upper limit of intake in Australia and a common recommended intake with 
vitamin C supplements was used in the current investigations. This suggests that such 
a supplementation regimen could be a practical approach to improving skeletal 
muscle insulin resistance. Furthermore, vitamin C supplementation was delivered as 
an add-on therapy to usual medically prescribed diabetes treatments in the people 
with T2D. This suggests that vitamin C supplementation could potentially serve as an 
effective complimentary approach to treating skeletal muscle insulin resistance 
within the domain of mainstream medical prescriptions for T2D.  
Overall, these findings provide a biological basis for undertaking a larger clinical trial 
in people with T2D that is focussed on improving measures of glycaemic control with 
long-term, high dose oral vitamin C supplementation. Moreover, these findings 
provide evidence for the potential application of high dose ascorbic acid as a safe 
adjunct therapy in the treatment of skeletal muscle insulin resistance in people with 
T2D.  
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Appendix 10.1. Summary of individual characteristics of participants and screened individuals 
Table 10. 1. Summary data for participants and screenees involved in clinical trial 
 
Participant Final Status
Reason for 
Withdrawal
no. N (Gender) Age height weight BMI Fat-free mass Body fat
Glucose 
uptake
Duration of 
Diabetes
Diabetes 
treatment
Other 
medications
Principal 
ethnicity SBP DBP AA TAA GLUCOSE HBA1C TOTAL C LDL-C HDL-C TRIGS Urea Creatinine Urate GGT AST ALT
Completed or 
withdrawn
m/f years m kg kg/m2 kg % mg/kg FFM/min years mmHg mmHg umol/L umol/L mmol/L % mmol/L mmol/L mmol/L mmol/L mmol/L umol/L mmol/L U/L U/L U/L
1 f 66.9 1.57 74.5 30.2 42.7 43.2 4.87 1 met BP, CHOL, OA, P C 150 85 47.2 51.2 7.1 6.7 5.7 2.6 1.5 3.4 8.8 60.0 0.34 118.0 33.0 39.0 Completed
2 m 62.8 1.76 92.8 30.0 64.9 30.9 2.72 5 met, sulf BP, CHOL, U, P C 140 85 42.7 46.9 9.0 7.1 3.0 1.6 0.9 1.1 7.8 75.0 0.27 21.0 21.0 22.0 Completed
3 m 54.7 1.85 102.7 30.0 68.0 34.9 3.02 6 met, sulf G C 125 80 60.8 65.7 10.3 7.8 5.8 3.3 1.5 2.2 6.2 78.0 0.29 7.0 17.0 28.0 withdrawn Medication changes
4 m 55.2 1.68 88.6 31.4 55.9 37.5 3.53 1 met BP, U, AP A 132 88 49.4 54.1 6.7 6.5 5.0 3.0 0.9 2.4 8.6 97.0 0.45 19.0 17.0 20.0 withdrawn Family circumstance
5 m 40.0 1.72 83.6 28.3 57.2 32.5 1.84 3 diet - A 112 78 34.4 39.8 12.6 9.4 5.8 3.9 0.9 2.2 4.8 80.0 0.30 28.0 17.0 36.0 withdrawn Personal reason
6 m 40.3 1.78 92.6 29.2 64.7 30.2 4.13 2.5 met, dpp-4 - A 135 100 62.1 65.9 8.6 7.6 4.9 3.1 1.0 1.7 4.7 83.0 0.40 28.0 29.0 51.0 Completed
7 m 57.6 1.75 103.6 33.8 67.6 35.3 4.15 5.5 sulf CHOL, P C 130 75 40.4 44.4 8.2 7.7 4.8 2.4 1.1 2.8 4.2 83.0 0.31 51.0 20.0 26.0 withdrawn Moved interstate
8 m 67.3 1.64 75.4 28.0 53.9 28.8 4.57 20 met, sulf BP, GD, AP C 150 85 48.9 53.7 9.4 8.5 5.2 2.2 0.9 4.5 6.6 90.0 0.35 53.0 36.0 68.0 withdrawn Medication change
9 m 68.7 1.72 95.9 32.4 55.3 44 5.35 3 met, dpp-4 BP, CHOL, AT C 150 72 19.6 22.8 9.7 7.4 4.7 2.9 1.3 1.2 6.3 82.0 0.33 69.0 21.0 32.0 Completed
10 m 58.2 1.7 108.5 37.5 69.1 36.6 1.99 2 met, dpp-4 BP, CHOL, AP C 160 85 42.9 45.6 10.9 8.0 4.1 2.0 1.2 2.0 7.0 93.0 0.39 48.0 28.0 54.0 Completed
11 m 57.8 1.77 88.3 28.2 57.5 34.8 2.31 10 met, sulf CHOL C 115 80 51.0 54.7 8.4 7.4 3.2 1.4 1.2 1.3 4.2 72.0 0.31 26.0 23.0 32.0 Completed
12 m 62 1.65 73 26.8 53.1 29.5 3.43 3 met, dpp-4 CHOL C 125 85 50.8 53.3 11.2 7.4 4.1 1.2 2.2 1.6 8.2 78.0 0.21 35.0 18.0 25.0 withdrawn Medication changes
13 m 61 1.72 88.9 30.1 60.8 32.9 3.47 5 met, dpp-4 BP, CHOL, AF, AL C 140 75 36.3 39.4 12.7 7.7 3.2 1.7 0.9 1.3 4.8 93.0 0.22 28.0 17.0 26.0 Completed
Mean (n=13) 13 (12m, 1f) 57.9 1.72 89.9 30.5 59.3 34.7 3.49 5.2 11 met, 5 sulf 10C/3A 135.7 82.5 45.1 49.0 9.6 7.6 4.6 2.4 1.2 2.1 6.3 81.8 0.32 40.8 22.8 35.3 n=7
SEM 2.5 0.02 3.1 0.8 2.1 1.3 0.31 1.4 5 dpp-4, 1 diet 4.0 2.0 3.1 3.2 0.5 0.2 0.3 0.2 0.1 0.3 0.5 2.8 0.02 7.9 1.8 4.0 completed
Additionally screened participants
14 m 54 1.76 86 27.8 4.5 met A 125 75 48.9 49.7 7.2 7.0 3.5 1.8 1.1 1.3
15 f 50 N/A N/A N/A 1 met A 145 100 52.5 52.2 8.1 7.1 5.0 2.9 1.4 1.6
16 f 62 1.52 93 40.3 10 met C 120 80 54.1 57.6 7.5 7.4 4.5 2.3 1.7 1.2
17 m 41 1.65 84 30.9 16 met, sulf A 160 96 54.0 56.8 12.8 10.8 5.3 2.8 1.1 3.0
18 m 65 1.77 75 23.9 23 met C 150 75 41.5 43.7 6.8 6.3 4.1 2.6 1.1 0.8
19 m 51 1.86 99 28.6 0.2 diet C 110 80 40.8 43.3 6.6 6.5 5.0 3.2 1.2 1.4
20 m 43 N/A N/A N/A 10 sulf  A 120 80 49.2 51.5 13.3 9.7 5.1 2.8 1.5 1.7
21 m 56 1.75 70 22.9 0.5 diet C 125 84 60.6 62.9 7.1 6.2 5.5 3.6 1.2 1.6
22 f 61 1.63 75 28.2 1.5 met C 140 90 65.7 68.0 7.1 6.2 4.7 * 1.1 4.7
23 m 65 1.73 106.5 35.6 22 met, sulf C 145 88 44.6 46.1 9.3 7.6 4.2 1.8 1.4 2.2
24 m 45 1.65 67 24.6 0.5 diet A 120 85 44.6 45.9 5.5 5.8 3.9 2.4 1.1 0.8
25 f 48 1.63 58.0 21.8 1 diet C 135 95 74.2 78.9 6.3 6.3 4.0 1.1 2.8 0.3
Mean (n=25) 25 (20m/5f) 55.7 1.71 86.2 29.6 6.3 19 met, 8 sulf, 17C/8A 134.4 84.0 48.7 51.8 8.9 7.4 4.6 2.4 1.3 1.9
SEM 1.8 0.02 2.8 0.9 1.4 5 dpp-4, 5 diet 2.9 1.5 2.2 2.3 0.5 0.2 0.2 0.2 0.1 0.2 * cannot calculate due to excessive TGs
KEY
met - metformin AP - aspirin A - Asian/Pacific Islander
sulf - sulfonylurea AT- asthma C - Caucasian
dpp - dpp-4 inhibitor BP - blood pressure
diet - diet-controlled CHOL - cholesterol
G - glaucoma
OA - osteoarthritis
P - psychoactive
U - stomach ulcer
GD - gord
AF - atrial fibrillation
AL - allergies
On HRTs, overly obese
General Characteristics Blood Pressure Plasma Vitamin C Glucose Control Lipid Profile (serum) Renal Function (serum) Liver Function (serum)
Reason for non-inclusion
Pulled out, BP high
Pulled out, impaired renal function
HbA1c low
Pulled out
HbA1c low, taking vitamin D
HbA1c high, BP high
HbA1c low
newly diagnosed, HbA1c low
smokes occasionally
HbA1c low, newly diagnosed
HbA1c low, TG high, taking vitamin D
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Appendix 10.2. Diet and physical activity self-reports 
 
7-day diet checklist & 
Physical activity recall 
 
1.  The following diet checklist is to be completed at the end 
of each day for seven (7) consecutive days. There are three 
pages for each day to be completed.   An example day’s 
completion is provided at the beginning of the booklet.   
                                                                                                                                                        
2.  Please tick (   ) the appropriate serving size box that best 
approximates your intake (refer to the reference serving size 
guides and photographs attached).   
                                                                                                                                                     
3.  If you consume a listed item more than once during the 
day or if you consume an amount exceeding the largest serving 
size indicated, add an extra tick to the appropriate box in the 
same row.       
                                                                                                                                          
4.  Where indicated, please also list the type and brand name 
of the food item.  Also, where indicated, please note whether the 
food item consumed was fresh, canned or packaged (including 
frozen), or if it was a take-away food item.                                                                 
 
5.  If you do not consume a listed item, do not tick a box for 
that item.            
 
6.  If you would like to explain your intake of a listed food 
item in more detail, some extra space is provided at the end of 
each day.                       
 
7.   At the end of day 7 only, please complete the attached 
physical activity questionnaire. This questionnaire relates to 
physical activity over the previous week.                                                                    
DAY:           Monday                                     DATE: _30 _/ 05 _/ 11__ 
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Food Category         
Serving size: Small  Med  Large  XL Small Medium Large 
Beverages, cereals, meat (indicate type & brand 
name if known) 
Reference serving sizes 
Fruit juice, fruit drink 
(indicate if freshly 
prepared) 
   
 1/2 cup or 
125ml 
1 cup or 
250ml 
1½ cup or 
375ml 
Type:      Orange Juice                 Brand:        Berri 
 
Extra-large (XL) serve: 2 cups or 500ml 
Vegetable juice, 
tomato juice 
(indicate if freshly 
prepared) 
   
 1/2 cup or 
125ml 
1 cup or 
250ml 
1½ cup or 
375ml 
Type:      Carrot Juice                   Brand:        
                                                           
                                                     Freshly prepared 
Extra-large (XL) serve: 2 cups or 500ml 
Fruit-based smoothie 
drink or fruit-based 
cordial 
   
 1/2 cup or 
125ml 
1 cup or 
250ml 
1½ cup or 
375ml 
Type:                                            Brand: 
 
Extra-large (XL) serve: 2 cups or 500ml 
Energy drink or 
vitamin-fortified 
supplement drink  
   
 1/2 cup or 
125 ml 
1 cup or 
250ml 
1½ cup or 
375ml 
Type:      Mother energy drink      Brand:        
                                                              Coca cola 
Extra-large (XL) serve: 2 cups or 500ml 
Breakfast cereal  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1/2 cup 
(any 
cereal) 
1 cup (any 
cereal) 
1½ cups 
(any 
cereal) Type:      Cornflakes                     Brand:             
                                                    Kellogg’s 
Pie with fruit or 
vegetables 
 
   
1/2 slice 
pie (about 
50g) 
1 slice pie 
(about 
100g) 
2 slices pie  
(or 1 
individual 
pie) 
Type:   Berri and Apple pie          Brand:        
                                                    Sara-Lee 
 
Organ meats & pâté  
(including liver, kidney, 
heart, brain) 
   
1/3 cup 
meat 
cooked or 4 
tablespoons 
pâté 
2/3 cup 
cooked 
meat or 
2/3 cups 
pâté 
1 cup 
cooked 
meat or  
1 cup pâté 
Type:       Lamb liver            
FRUITS (indicate fresh “FS” or 
canned/packaged “CP”  
beside the food item) 
 
Apple or Pear           
(small <8cm dia;  
large >8cm dia) 
   
1/2 piece 
or 1/2 cup 
1 small or  
1 cup 
chopped 
1 large or 
1½ cups 
chopped  
Orange                    
(small <8cm dia;  
large >8cm dia) 
   
1/2 orange 
or  
5 slices  
1 small or  
8 slices 
1 large or  
1 cup 
sections 
Mandarin                
(small <6cm dia;  
large >6cm dia) 
   
1 small 
 
1 large or  
½ cup 
slices 
2 (any size) 
or  
1 cup slices 
Grapefruit               
(small <11cm dia;  
large >11cm dia) 
   
1/2 small 
or ½ cup 
1 small, 
1/2  large, 
or 1 cup 
1 large or  
1½ cups 
DAY:           Monday                                     DATE: _30 _/ 05 _/ 11__ 
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Food Category         
Serving size: 
Small  Med Large   
 
Small Medium Large 
 
Guava (any type)    
  
1 common 
or 1/2 cup 
 
2 common 
or 1 cup 
 
3 common 
or 1 ½ cup 
Kiwi Fruit 
   
1 kiwi fruit 
or 1/2 cup 
2 kiwi fruit 
or 1 cup 
3 kiwi fruit 
or  
1 ½ cup 
Mango 
   
1/2 mango 
or 1/2 cup 
sliced 
1 mango 
or 1 cup 
sliced 
1 ½ mango 
or 1½ cup 
sliced 
Paw-paw              
    
1/2 cup 
diced or 
1/4 fruit 
1 cup 
diced or 
1/2 fruit  
1½ cup 
diced or 
3/4 fruit 
Pineapple      
(thin slice: <2.4cm thick;  
thick slice: >2.4cm thick) 
   
1/2 cup 
diced or 1 
thin slice  
1 cup 
diced or 1 
thick slice  
1½ cup 
diced; 1/2 
pineapple 
Banana                
(small <17cm long;  
large >17cm long) 
 
  
1/2 banana 
or 
1/2 cup 
sliced 
1 small 
banana 
1 large or  
1 cup sliced 
Grapes (any type) 
   
1/2 cup 
(about 15 
grapes) 
1 cup 
(about 30 
grapes) 
1½ cups 
Cherries 
   
1/2 cup 
(about 10 
cherries) 
1 cup 
(about 20 
cherries) 
1½ cups 
Strawberries           
(small:<3cm dia;  
large: >3cm dia) 
   
1/2 cup or 
6 small/4 
large  
 1 cup or 
11 small/7 
large  
1½ cups or 
16 small/11 
large  
Other berries           
(indicate type) 
   
1/2 cup 1 cup 1½ cups 
     type: 
Plum or Apricot           
    
1 piece or 
1/3 cup 
sliced 
2 pieces 
or 2/3 cup 
sliced 
3 pieces or 
1 cup sliced 
Peach or Nectarine  
(small <5.5cm dia;  
large >5.5cm dia) 
   
1 small or 
1/2 cup 
sliced 
1 large or 
1 cup 
sliced 
2 small or 
1½ cup 
sliced 
Rockmelon    
     
1/2 cup 
diced or 2 
slices 
1 cup 
diced or 
1/4 melon 
1½ cup 
diced  
Watermelon                  
    
1/2 cup 
diced 
1 cup 
diced 
1½ cups or 
1/16th 
melon 
Honey-dew melon   
    
1/2 cup 
diced  
1 cup 
diced 
1½ cup 
diced or 
1/4 melon 
Fruit salad     
(combination of fruits) 
   
1/2 cup 
diced  
1 cup 
diced  
1½ cup 
diced  
List any other fruits consumed e.g. lychees, lemon, quince, tangelo, custard apple, passionfruit, 
rambutan etc.  
(indicate type, amount & if fresh or canned/packaged) 
 
2 passionfruit, FS   
1/2 custard apple, FS 
 
 
FS 
FS 
DAY:           Monday                                     DATE: _30 _/ 05 _/ 11__ 
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Food Category         
Serving size: 
Small  Med Large   Small Medium Large 
VEGETABLES (indicate if freshly prepared - 
“FS” or if canned/ packaged/takeaway 
products -“CP”)  
 
 
 
 
 
FS 
 
 
 
 
 
 
 
 
 
 
 
 
CP 
 
 
 
 
 
CP 
 
 
 
 
 
 
FS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FS 
 
 
 
 
 
 
 
 
 
 
FS 
 
Green/mixed salad 
(including lettuce, 
tomato, onion etc.)  
in a sandwich/as a side 
salad/with a meal 
   1/2 cup 1 cup 2 cups 
Stir-fried or mixed 
vegetables 
   
1/4 cup 1/2 cup 1 cup 
Coleslaw or potato 
salad 
   
1/4 cup 1/2 cup 1 cup 
Mixed dish: 
casserole, stew, curry 
or stir-fry with 
vegetables; 
ratatouille; paella etc. 
   1/2 cup 1 cup 2 cups 
type: Chicken curry with mixed vegetables 
 
 
Soup with vegetables     1/2 cup 1 cup 2 cups 
type:               Pumpkin 
 
 
VEGETABLES (excluding their use in the 
above dishes) 
 
Potatoes       
(small potato: 4-6cm dia;  
medium: 6-8cm dia;  
large: 8-11cm dia)  
   
1 small 
potato or 
1/2 cup 
1 med 
potato or 
3/4 cup 
1 large 
potato or 1 
cup 
 Were they boiled, baked or mashed?                 
                                                            Mashed    
 
Hot potato 
chips/gems/wedges 
   
1/2 cup 3/4 cup 1 cup 
 Were they homemade, cooked from frozen or 
takeaway? 
 
Potato crisps (any 
flavor)    
1/2 cup 
(15g) 
1 cup 
(30g) 
50g packet 
Pumpkin    1/4 cup 1/2 cup 1 cup 
 Was it boiled, baked or mashed?  
Sweet potato             1/4 cup 1/2 cup 1 cup 
 Was it boiled, baked, fried or mashed? 
 
 
Green peas or green 
beans 
   
1/4 cup 1/2 cup 1 cup 
Snow Peas    1/4 cup 1/2 cup 1 cup 
Silverbeet or spinach    1/4 cup 1/2 cup 1 cup 
Broccoli    1/4 cup 1/2 cup 1 cup 
Cauliflower or 
broccoflower 
   
1/4 cup 1/2 cup 1 cup 
Brussels sprout    2 sprouts  4 sprouts  8 sprouts  
Cabbage (all types)    1/4 cup 1/2 cup 1 cup 
Carrots    1/4 cup 1/2 cup 1 cup 
Swede or Turnip    1/4 cup 1/2 cup 1 cup 
DAY:           Monday                                     DATE: _30 _/ 05 _/ 11__ 
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Food Category      
Serving size: Small Med Large 
  
Small 
 
Medium 
 
Large 
 
Zucchini                
(small <16cm long;   
large >16cm long) 
   
  
1/2 small 
or 1/4 cup 
 
1 small or 
1/2 cup 
 
2/3 large or  
1 cup 
chopped 
Squash         
   
1 ½ button 
or ¼ cup 
3 button 
or 1/2 cup 
6 button 
squash or 1 
cup 
Capsicum (any colour)    
    
1/4 cup or 
1/4 
capsicum 
1/2 cup or 
½ 
capsicum 
1 cup 
chopped or 
1 capsicum 
Sweetcorn/corn on 
cob  
(small cob <8cm long;  
med cob 13cm;  
large cob >20cm long) 
   
small cob 
or 
1/4 cup 
med cob 
or 1/2 cup 
large cob 
or 
1 cup 
Tomatoes      
(small tomato <6cm dia;  
large tomato>6cm dia)    
1/2 small 
or  
3 thin slices 
1 small or 
1/2 cup 
1 large 
tomato  
1 cup 
chopped 
Cherry Tomato 
   
2 tomatoes 
or 1/4 cup 
5 
tomatoes 
or 1/2 cup 
9 tomatoes 
or  
1 cup 
Parsley 
   
5 sprigs or 
1 
tablespoon 
10 sprigs 
or 2 
tablespoon 
20 sprigs or 
3 
tablespoons 
Avocado 
   
1/4 cup or 
4 slices 
1/2 cup or 
1/2 
avocado 
1 cup or 1 
avocado 
Lettuce (any type)    1/2 cup 1 cup 2 cups
Cucumber (any type)  
   
1/4 cup or  
3-4 slices 
1/2 cup 
chopped 
1 cup 
chopped or 
1/2 whole 
Chilies (any type)     
(small: 5cm long;  
medium: 11cm long) 
   
4 small chili 
or 1/4 cup 
2 med chili 
or 1/2 cup 
1 cup chili 
Onions (any type) 
 
   4 thin slices or 1/4 cup 
1/2 cup 
chopped 
1 cup 
chopped 
Other beans  
(indicate type) 
   
1/4 cup 1/2 cup 1 cup 
           Type: 
 
 
List other vegetables consumed e.g. Okra, watercress, leeks, shallots, choko, asparagus, artichoke, 
radish, alfalfa sprouts 
(indicate type, amount & if fresh, frozen, canned, cooked or raw): 
 
 
 
Additional notes you have on your intake of the foods above:                                                                                
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
DAY:                                                      DATE: _          /          /           _ 
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Physical activity recall 
 
 
A. DURING THE LAST WEEK how many times did you walk continuously, for at least 
10 minutes, for recreation/exercise or to get to or from places?               times 
 
What do you estimate was the total time that you spent walking in this way?                  
______________mins 
 
 
B. DURING THE LAST WEEK how many times did you do any vigorous physical 
activity which made you breathe harder or puff and pant? (e.g. jogging, cycling, 
aerobics, competitive tennis, etc.)                  times 
 
What do you estimate was the total time that you spent doing this vigorous 
physical activity?                   mins 
 
 
C. DURING THE LAST WEEK how many times did you do any other more moderate 
physical activity that you haven’t already mentioned? (e.g. gentle swimming, social 
tennis, golf)                  times 
 
What do you estimate was the total time that you spent doing these 
moderate physical activities?                   mins 
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Photographs of sample serving sizes 
Beverages: 
Juice/Fruit drink: 
 
         small serve (125ml)                   medium serve (250ml)               large serve (375ml) 
 
                                             
  small serve (125ml popper)        medium serve (250ml popper)    extra-large serve (500ml) 
 
 
 
Energy drink/vitamin fortified drinks 
                                         
small serve (1-2 small “shots”)             medium serve (250ml drinks) 
 
 
                       
Large energy drinks (approx.375ml)                     Extra-large energy drink (approx.500ml)             
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Cereals: 
 
Breakfast cereal 
 
       small serve (1/2 cup)                   medium serve (1 cup)                 large serve (1 ½ cup) 
 
 
       small serve (1/2 cup)                    medium serve (1 cup)                 large serve (1 ½ cup) 
 
Pie 
 
   small serve (about 50g)          medium serve (about 100g)             large serve (about 200g)     
 
 
Organ Meats: 
 
Liver 
 
       small serve (1/3 cup)                      medium serve (2/3 cup)                large serve (1 cup) 
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Fruit (examples): 
 
 
Rockmelon 
 
small serve (1/2 cup)       medium serve (1 cup or ¼ melon)          large serve (1 ½ cup) 
 
 
Pineapple 
 
small serve (1/2 cup)                 medium serve (1 cup)                    large serve (1 ½ cup) 
 
 
Grapes 
 
small serve (1/2 cup)                  medium serve (1 cup)                     large serve (1 ½ cup) 
 
 
Fruit salad 
 
          small serve (1/2 cup)                medium serve (1 cup)               large serve (1 ½ cup) 
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Small fruit serve examples: 
 
      1 apricot       1 kiwi fruit                   1 small mandarin 
 
 
 
Medium fruit serve examples: 
 
 
               1 small apple                                      1 small orange                         1 cup cherries 
 
                   
      1 large peach or nectarine                          1 small pear                                         1 mango 
 
 
Large fruit serve examples: 
 
 
                 3 plums               11 large strawberries       1 large banana (about 20cm long) 
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Vegetables (examples): 
 
 
Boiled broccoli 
  
                  small serve (1/4 cup)                 medium serve (1/2 cup)                       large serve (1 cup) 
 
 
Boiled pumpkin 
 
             small serve (1/4 cup)                         medium serve (1/2 cup)                   large serve (1 cup) 
 
 
Green Beans 
 
small serve (1/4 cup)                        medium serve (1/2 cup)                  large serve (1 cup) 
 
 
Mixed cooked vegetables 
 
              small serve (1/4 cup)                    medium serve (1/2 cup)                      large serve (1 cup) 
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Corn 
 
 1 small cob or ½ med cob (8cm)   medium serve: 1 med cob (13cm)  large serve: 1 large cob (20cm) 
 
 
Boiled Swede 
 
      small serve (1/4 cup chopped)   medium serve (1/2 cup chopped)    large serve (1 cup chopped) 
 
 
Onions 
 
         small serve (1/4 cup diced)     medium serve (1/2 cup diced)             large serve (1 cup diced) 
 
 
Tomatoes 
 
    small serve (1/4 cup chopped)   medium serve (1/2 cup chopped)        large serve (1 cup chopped) 
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Mixed salad (including lettuce, tomatoes, onion etc.) 
 
          small serve (1/2 cup)                       medium serve (1 cup)                        large serve (2 cups) 
 
 
Parsley (on small plate) 
 
     small serve (5g or 5 sprigs)        medium serve (10g or 10 sprigs)        large serve (20g or 20 sprigs) 
 
 
Vegetable soup 
                       
               small serve (1/2 cup)                  medium serve (1 cup)                       large serve (2 cups) 
 
 
Stew with vegetables 
 
        small serve (1/2 cup)                       medium serve (1 cup)                           large serve (2 cups) 
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Boiled potato 
 
 1 small potato (or about 90g)    1 medium potato (or about 120g)    1 large potato (or about 180g) 
 
 
Mashed potato 
  
            small serve (1/2 cup)                 medium serve (3/4 cup)                           large serve (1 cup) 
 
 
Hot potato chips 
 
           small serve (1/2 cup)                     medium serve (3/4 cup)                           large serve (1 cup) 
 
 
Baked potato 
 
       small serve: 1 small potato     medium serve: 1 medium potato       large serve: 1 large potato 
 
(some photographs from (388))
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Appendix 10.3. Calculations of glucose metabolic measurements from 
GC/MS-derived data and indirect calorimetry 
 
Rate of glucose appearance, Ra (μmol.kg FFM-1.min-1) =  
[Eb/Ep(t)-1]Ib – p*V*G(t)[dEp(t)/dt]/Ep(t) + Evar*Ivar(t)/Ep(t) 
Rate of glucose disappearance, Rd (μmol.kg.FFM-1.min-1) =  
[Eb/Ep(t)-Eb/100]Ib – p*V*G(t)[dEp(t)/dt]/Ep(t) + Evar*Ivar(t)/Ep(t) – p*V*dG(t)/dt 
where 
Eb = enrichment of basal continuous 6, 6-D2 glucose in moles per cent excess 
Ep(t) = plasma MPE, as average of two consecutive samples 
Evar = MPE of glucose infusate 
Ib = continuous tracer infusion rate (μmol.kg-1.min-1)  
(Note: Ib = 0.22 μmol.kg-1.min-1 in this study) 
P = pool fraction assumed to be 0.65 
V = glucose space assumed to be 25% of body weight 
G(t) = plasma glucose (μmol.l-1), as average of two consecutive samples 
Ivar = exogenous glucose infusion rate (μmol.kg-1.min-1) 
Rate of glucose disappearance/plasma insulin, Rd/I (l.kg.FFM-1.min-1) =  
 Rd/plasma insulin (in μmol.l-1) 
Metabolic clearance rate, MCR (ml.kg·FFM-1.min-1) = 
 Rd/plasma glucose (in μmol.ml-1) 
Endogenous glucose production rate, EGP (μmol.kg·FFM-1.min-1) = 
 Ra – glucose infusion rate (in μmol.kg·FFM-1.min-1) 
Non-oxidative glucose metabolism, NOGM (μmol.kg·FFM-1.min-1) =  
 Rd – carbohydrate oxidation rate (in μmol.kg.FFM-1.min-1) 
Carbohydrate oxidation rate (g.min-1) =  
4.55*VCO2 - 3.21*VO2 – 2.87*N (where N is assumed to be 0.009 g.min-1)  
Fat oxidation rate (g.min-1) =  
 1.67*VO2 – 1.67*VCO2 – 1.92*N (where N is assumed to be 0.009 g.min-1) 
(Calculations above are from (323), (326) & (327)) 
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Appendix 10.4. Optimization of GSH/GSSG assay 
 
 
Figure 10. 1. Protein optimization of muscle GSH assay 
An optimal range of protein concentration was determined as 0.0625-0.5 mg/ml, 
with a concentration of 0.125mg/ml used in assays 
 
Figure 10. 2. Protein optimization of muscle GSSG assay 
An optimal range of protein concentration was determined as 0.5-1.0 mg/ml, with a 
concentration of 0.6mg/ml used in assays 
 
 
 
 
 
 
 
Table 10. 2. Muscle GSH 
optimization 
Protein 
concentration 
(mg/ml) 
Concentration 
GSH (μmol/l) 
5 0.37 
1 3.25 
0.5 2.18 
0.25 1.27 
0.125 0.69 
0.0625 0.37 
Table 10. 3. Muscle GSSG 
optimization 
Protein 
concentration 
(mg/ml) 
Concentration 
GSSG (μmol/l) 
5 0.63 
2 2.12 
1 1.23 
0.5 0.59 
0.25 0.36 
0.125 0.24 
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Figure 10. 3. Control samples run on skeletal muscle GSH and GSSG assay plates  
Demonstration of linearity of sample protein concentration in assays for (A) GSH and 
(B) GSSG in skeletal muscle. Data are n=1. 
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Appendix 10.5. Optimization of SOD assay 
 
 
Figure 10. 4. Lysis buffer optimization for SOD assay in skeletal muscle 
A comparison of SOD activity for samples homogenized in different lysis buffers. CS 
buffer contained 0.175 mol/l KCl and 2 mmol/l EDTA (pH 7.4). SOD buffer contained 
100 mmol/l NaH2PO4 (pH 7.0) with 1 mmol/l EDTA and 0.5 % Triton-X100. WB buffer 
contained 50 mmol/l Tris (pH 7.5), 1 mmol/l EDTA, 10 % vol/vol Glycerol, 1 % vol/vol 
Triton X, 50 mmol/l NaF, 5 mmol/l NaPP, 1 mmol/l DTT, 1 mmol/l PMSF, and 5 μl/ml 
protease inhibitor cocktail (#P8340, Sigma-Aldrich). Data are mean ± SEM; *and # 
indicate significantly different to unlabelled bars using a one-way repeated measures 
ANOVA (n=4). The SOD buffer produced the highest SOD activity and was chosen as 
the sample lysis buffer. 
 
 
Figure 10. 5. Control samples run on skeletal muscle SOD assay plate  
Demonstration of linearity of sample protein concentration used in SOD assay (0.2 
mg/ml). Data are n=1. 
